id	sid	tid	token	lemma	pos
dpc-2137	1	1	dermatology	dermatology	NOUN
dpc-2137	1	2	:	:	PUNCT
dpc-2137	1	3	practical	practical	ADJ
dpc-2137	1	4	and	and	CCONJ
dpc-2137	1	5	conceptual	conceptual	ADJ
dpc-2137	1	6	cutaneous	cutaneous	ADJ
dpc-2137	1	7	squamous	squamous	ADJ
dpc-2137	1	8	cell	cell	NOUN
dpc-2137	1	9	carcinoma	carcinoma	NOUN
dpc-2137	1	10	:	:	PUNCT
dpc-2137	1	11	an	an	DET
dpc-2137	1	12	update	update	NOUN
dpc-2137	1	13	on	on	ADP
dpc-2137	1	14	diagnosis	diagnosis	NOUN
dpc-2137	1	15	and	and	CCONJ
dpc-2137	1	16	treatment	treatment	NOUN
dpc-2137	1	17	table	table	NOUN
dpc-2137	1	18	of	of	ADP
dpc-2137	1	19	contents	content	NOUN
dpc-2137	1	20	risk	risk	NOUN
dpc-2137	1	21	factors	factor	NOUN
dpc-2137	1	22	and	and	CCONJ
dpc-2137	1	23	diagnosis	diagnosis	NOUN
dpc-2137	1	24	of	of	ADP
dpc-2137	1	25	advanced	advanced	ADJ
dpc-2137	1	26	cutaneous	cutaneous	ADJ
dpc-2137	1	27	squamous	squamous	ADJ
dpc-2137	1	28	cell	cell	NOUN
dpc-2137	1	29	carcinoma	carcinoma	NOUN
dpc-2137	1	30	gabriella	gabriella	PROPN
dpc-2137	1	31	brancaccio	brancaccio	PROPN
dpc-2137	1	32	,	,	PUNCT
dpc-2137	1	33	giulia	giulia	PROPN
dpc-2137	1	34	briatico	briatico	PROPN
dpc-2137	1	35	,	,	PUNCT
dpc-2137	1	36	cristina	cristina	PROPN
dpc-2137	1	37	pellegrini	pellegrini	PROPN
dpc-2137	1	38	,	,	PUNCT
dpc-2137	1	39	tea	tea	NOUN
dpc-2137	1	40	rocco	rocco	NOUN
dpc-2137	1	41	,	,	PUNCT
dpc-2137	1	42	elvira	elvira	PROPN
dpc-2137	1	43	moscarella	moscarella	PROPN
dpc-2137	1	44	,	,	PUNCT
dpc-2137	1	45	maria	maria	PROPN
dpc-2137	1	46	concetta	concetta	PROPN
dpc-2137	1	47	fargnoli	fargnoli	VERB
dpc-2137	1	48	surgery	surgery	NOUN
dpc-2137	1	49	for	for	ADP
dpc-2137	1	50	cutaneous	cutaneous	ADJ
dpc-2137	1	51	squamous	squamous	ADJ
dpc-2137	1	52	cell	cell	NOUN
dpc-2137	1	53	carcinoma	carcinoma	NOUN
dpc-2137	1	54	and	and	CCONJ
dpc-2137	1	55	its	its	PRON
dpc-2137	1	56	limits	limit	NOUN
dpc-2137	1	57	in	in	ADP
dpc-2137	1	58	advanced	advanced	ADJ
dpc-2137	1	59	disease	disease	NOUN
dpc-2137	1	60	david	david	PROPN
dpc-2137	1	61	moreno	moreno	PROPN
dpc-2137	1	62	-	-	PUNCT
dpc-2137	1	63	ramírez	ramírez	PROPN
dpc-2137	1	64	,	,	PUNCT
dpc-2137	1	65	francisca	francisca	PROPN
dpc-2137	1	66	silva	silva	PROPN
dpc-2137	1	67	-	-	PUNCT
dpc-2137	1	68	clavería	clavería	PROPN
dpc-2137	1	69	,	,	PUNCT
dpc-2137	1	70	almudena	almudena	PROPN
dpc-2137	1	71	fernández	fernández	PROPN
dpc-2137	1	72	-	-	PUNCT
dpc-2137	1	73	orland	orland	PROPN
dpc-2137	1	74	,	,	PUNCT
dpc-2137	1	75	noemí	noemí	PROPN
dpc-2137	1	76	eiris	eiris	PROPN
dpc-2137	1	77	,	,	PUNCT
dpc-2137	1	78	andrés	andrés	PROPN
dpc-2137	1	79	ruiz	ruiz	PROPN
dpc-2137	1	80	de	de	PROPN
dpc-2137	1	81	casas	casas	PROPN
dpc-2137	1	82	,	,	PUNCT
dpc-2137	1	83	lara	lara	PROPN
dpc-2137	1	84	ferrándiz	ferrándiz	PROPN
dpc-2137	1	85	radiotherapy	radiotherapy	PROPN
dpc-2137	1	86	in	in	ADP
dpc-2137	1	87	the	the	DET
dpc-2137	1	88	adjuvant	adjuvant	NOUN
dpc-2137	1	89	and	and	CCONJ
dpc-2137	1	90	advanced	advanced	ADJ
dpc-2137	1	91	setting	setting	NOUN
dpc-2137	1	92	of	of	ADP
dpc-2137	1	93	cscc	cscc	ADJ
dpc-2137	1	94	paolo	paolo	PROPN
dpc-2137	1	95	muto	muto	PROPN
dpc-2137	1	96	and	and	CCONJ
dpc-2137	1	97	francesco	francesco	PROPN
dpc-2137	1	98	pastore	pastore	PROPN
dpc-2137	1	99	immunotherapy	immunotherapy	NOUN
dpc-2137	1	100	and	and	CCONJ
dpc-2137	1	101	systemic	systemic	ADJ
dpc-2137	1	102	treatment	treatment	NOUN
dpc-2137	1	103	of	of	ADP
dpc-2137	1	104	cutaneous	cutaneous	ADJ
dpc-2137	1	105	squamous	squamous	ADJ
dpc-2137	1	106	cell	cell	NOUN
dpc-2137	1	107	carcinoma	carcinoma	NOUN
dpc-2137	1	108	nader	nader	VERB
dpc-2137	1	109	aboul	aboul	NOUN
dpc-2137	1	110	-	-	PUNCT
dpc-2137	1	111	fettouh	fettouh	PROPN
dpc-2137	1	112	,	,	PUNCT
dpc-2137	1	113	daniel	daniel	PROPN
dpc-2137	1	114	morse	morse	PROPN
dpc-2137	1	115	,	,	PUNCT
dpc-2137	1	116	jigar	jigar	PROPN
dpc-2137	1	117	patel	patel	PROPN
dpc-2137	1	118	,	,	PUNCT
dpc-2137	1	119	michael	michael	PROPN
dpc-2137	1	120	r.	r.	PROPN
dpc-2137	1	121	migden	migden	PROPN
dpc-2137	1	122	treatment	treatment	NOUN
dpc-2137	1	123	of	of	ADP
dpc-2137	1	124	cutaneous	cutaneous	ADJ
dpc-2137	1	125	squamous	squamous	ADJ
dpc-2137	1	126	cell	cell	NOUN
dpc-2137	1	127	carcinoma	carcinoma	NOUN
dpc-2137	1	128	with	with	ADP
dpc-2137	1	129	immune	immune	ADJ
dpc-2137	1	130	checkpoint	checkpoint	NOUN
dpc-2137	1	131	inhibitors	inhibitor	NOUN
dpc-2137	1	132	in	in	ADP
dpc-2137	1	133	special	special	ADJ
dpc-2137	1	134	populations	population	NOUN
dpc-2137	1	135	paolo	paolo	PROPN
dpc-2137	1	136	bossi	bossi	PROPN
dpc-2137	1	137	,	,	PUNCT
dpc-2137	1	138	luigi	luigi	PROPN
dpc-2137	1	139	lorini	lorini	PROPN
dpc-2137	1	140	mattioli	mattioli	PROPN
dpc-2137	1	141	1885	1885	NUM
dpc-2137	1	142	www.mattioli1885.com	www.mattioli1885.com	NOUN
dpc-2137	1	143	chief	chief	ADJ
dpc-2137	1	144	editor	editor	NOUN
dpc-2137	1	145	prof	prof	NOUN
dpc-2137	1	146	.	.	PUNCT
dpc-2137	2	1	giuseppe	giuseppe	PROPN
dpc-2137	2	2	argenziano	argenziano	PROPN
dpc-2137	2	3	,	,	PUNCT
dpc-2137	2	4	md	md	PROPN
dpc-2137	2	5	dermatology	dermatology	NOUN
dpc-2137	2	6	unit	unit	NOUN
dpc-2137	2	7	,	,	PUNCT
dpc-2137	2	8	university	university	PROPN
dpc-2137	2	9	of	of	ADP
dpc-2137	2	10	campania	campania	PROPN
dpc-2137	2	11	luigi	luigi	PROPN
dpc-2137	2	12	vanvitelli	vanvitelli	PROPN
dpc-2137	2	13	,	,	PUNCT
dpc-2137	2	14	naples	naples	PROPN
dpc-2137	2	15	,	,	PUNCT
dpc-2137	2	16	italy	italy	PROPN
dpc-2137	2	17	guest	guest	PROPN
dpc-2137	2	18	editors	editors	PROPN
dpc-2137	2	19	prof	prof	PROPN
dpc-2137	2	20	.	.	PUNCT
dpc-2137	3	1	luc	luc	PROPN
dpc-2137	3	2	thomas	thomas	PROPN
dpc-2137	3	3	,	,	PUNCT
dpc-2137	3	4	md	md	PROPN
dpc-2137	3	5	,	,	PUNCT
dpc-2137	3	6	phd	phd	NOUN
dpc-2137	3	7	full	full	ADJ
dpc-2137	3	8	professor	professor	NOUN
dpc-2137	3	9	and	and	CCONJ
dpc-2137	3	10	vice	vice	NOUN
dpc-2137	3	11	-	-	NOUN
dpc-2137	3	12	chair	chair	NOUN
dpc-2137	3	13	,	,	PUNCT
dpc-2137	3	14	department	department	NOUN
dpc-2137	3	15	of	of	ADP
dpc-2137	3	16	dermatology	dermatology	NOUN
dpc-2137	3	17	,	,	PUNCT
dpc-2137	3	18	lyon	lyon	PROPN
dpc-2137	3	19	cancer	cancer	PROPN
dpc-2137	3	20	research	research	PROPN
dpc-2137	3	21	center	center	PROPN
dpc-2137	3	22	,	,	PUNCT
dpc-2137	3	23	lyon	lyon	PROPN
dpc-2137	3	24	1	1	NUM
dpc-2137	3	25	university	university	NOUN
dpc-2137	3	26	,	,	PUNCT
dpc-2137	3	27	centre	centre	PROPN
dpc-2137	3	28	hospitalier	hospitalier	PROPN
dpc-2137	3	29	lyon	lyon	PROPN
dpc-2137	3	30	sud	sud	PROPN
dpc-2137	3	31	,	,	PUNCT
dpc-2137	3	32	france	france	PROPN
dpc-2137	3	33	.	.	PUNCT
dpc-2137	4	1	prof	prof	PROPN
dpc-2137	4	2	.	.	PUNCT
dpc-2137	5	1	ketty	ketty	PROPN
dpc-2137	5	2	peris	peris	PROPN
dpc-2137	5	3	,	,	PUNCT
dpc-2137	5	4	md	md	PROPN
dpc-2137	5	5	full	full	ADJ
dpc-2137	5	6	professor	professor	NOUN
dpc-2137	5	7	of	of	ADP
dpc-2137	5	8	dermatology	dermatology	NOUN
dpc-2137	5	9	,	,	PUNCT
dpc-2137	5	10	chief	chief	NOUN
dpc-2137	5	11	of	of	ADP
dpc-2137	5	12	the	the	DET
dpc-2137	5	13	complex	complex	ADJ
dpc-2137	5	14	operative	operative	ADJ
dpc-2137	5	15	unit	unit	NOUN
dpc-2137	5	16	of	of	ADP
dpc-2137	5	17	dermatology	dermatology	NOUN
dpc-2137	5	18	director	director	NOUN
dpc-2137	5	19	of	of	ADP
dpc-2137	5	20	the	the	DET
dpc-2137	5	21	dermatology	dermatology	NOUN
dpc-2137	5	22	and	and	CCONJ
dpc-2137	5	23	venereology	venereology	NOUN
dpc-2137	5	24	postgraduate	postgraduate	PROPN
dpc-2137	5	25	school	school	PROPN
dpc-2137	5	26	catholic	catholic	PROPN
dpc-2137	5	27	university	university	PROPN
dpc-2137	5	28	of	of	ADP
dpc-2137	5	29	rome	rome	PROPN
dpc-2137	5	30	fondazione	fondazione	PROPN
dpc-2137	5	31	policlinico	policlinico	PROPN
dpc-2137	5	32	universitario	universitario	PROPN
dpc-2137	5	33	agostino	agostino	PROPN
dpc-2137	5	34	gemelli	gemelli	PROPN
dpc-2137	5	35	irccs	irccs	PROPN
dpc-2137	5	36	rome	rome	PROPN
dpc-2137	5	37	,	,	PUNCT
dpc-2137	5	38	italy	italy	PROPN
dpc-2137	5	39	.	.	PUNCT
dpc-2137	6	1	dermatology	dermatology	PROPN
dpc-2137	6	2	practical	practical	ADJ
dpc-2137	6	3	&	&	CCONJ
dpc-2137	6	4	conceptual	conceptual	ADJ
dpc-2137	6	5	review	review	NOUN
dpc-2137	6	6	|	|	ADV
dpc-2137	6	7	dermatol	dermatol	ADJ
dpc-2137	6	8	pract	pract	NOUN
dpc-2137	6	9	concept	concept	NOUN
dpc-2137	6	10	.	.	PUNCT
dpc-2137	7	1	2021:11(s2):e2021170s	2021:11(s2):e2021170s	NUM
dpc-2137	7	2	1	1	NUM
dpc-2137	7	3	treatment	treatment	NOUN
dpc-2137	7	4	of	of	ADP
dpc-2137	7	5	cutaneous	cutaneous	ADJ
dpc-2137	7	6	squamous	squamous	ADJ
dpc-2137	7	7	cell	cell	NOUN
dpc-2137	7	8	carcinoma	carcinoma	NOUN
dpc-2137	7	9	with	with	ADP
dpc-2137	7	10	immune	immune	ADJ
dpc-2137	7	11	checkpoint	checkpoint	NOUN
dpc-2137	7	12	inhibitors	inhibitor	NOUN
dpc-2137	7	13	in	in	ADP
dpc-2137	7	14	special	special	ADJ
dpc-2137	7	15	populations	population	NOUN
dpc-2137	7	16	paolo	paolo	NOUN
dpc-2137	7	17	bossi1	bossi1	PROPN
dpc-2137	7	18	,	,	PUNCT
dpc-2137	7	19	luigi	luigi	PROPN
dpc-2137	7	20	lorini1	lorini1	PROPN
dpc-2137	7	21	1	1	NUM
dpc-2137	7	22	medical	medical	ADJ
dpc-2137	7	23	oncology	oncology	NOUN
dpc-2137	7	24	unit	unit	NOUN
dpc-2137	7	25	,	,	PUNCT
dpc-2137	7	26	department	department	NOUN
dpc-2137	7	27	of	of	ADP
dpc-2137	7	28	medical	medical	ADJ
dpc-2137	7	29	and	and	CCONJ
dpc-2137	7	30	surgical	surgical	ADJ
dpc-2137	7	31	specialties	specialty	NOUN
dpc-2137	7	32	,	,	PUNCT
dpc-2137	7	33	radiological	radiological	ADJ
dpc-2137	7	34	sciences	science	NOUN
dpc-2137	7	35	and	and	CCONJ
dpc-2137	7	36	public	public	ADJ
dpc-2137	7	37	health	health	NOUN
dpc-2137	7	38	,	,	PUNCT
dpc-2137	7	39	asst	asst	PROPN
dpc-2137	7	40	spedali	spedali	PROPN
dpc-2137	7	41	civili	civili	PROPN
dpc-2137	7	42	of	of	ADP
dpc-2137	7	43	brescia	brescia	PROPN
dpc-2137	7	44	,	,	PUNCT
dpc-2137	7	45	university	university	NOUN
dpc-2137	7	46	of	of	ADP
dpc-2137	7	47	brescia	brescia	PROPN
dpc-2137	7	48	,	,	PUNCT
dpc-2137	7	49	brescia	brescia	PROPN
dpc-2137	7	50	,	,	PUNCT
dpc-2137	7	51	italy	italy	PROPN
dpc-2137	7	52	.	.	PUNCT
dpc-2137	8	1	key	key	ADJ
dpc-2137	8	2	words	word	NOUN
dpc-2137	8	3	:	:	PUNCT
dpc-2137	8	4	cutaneous	cutaneous	ADJ
dpc-2137	8	5	squamous	squamous	ADJ
dpc-2137	8	6	cell	cell	NOUN
dpc-2137	8	7	carcinoma	carcinoma	NOUN
dpc-2137	8	8	,	,	PUNCT
dpc-2137	8	9	special	special	ADJ
dpc-2137	8	10	population	population	NOUN
dpc-2137	8	11	,	,	PUNCT
dpc-2137	8	12	auto	auto	NOUN
dpc-2137	8	13	-	-	PUNCT
dpc-2137	8	14	immune	immune	ADJ
dpc-2137	8	15	disease	disease	NOUN
dpc-2137	8	16	,	,	PUNCT
dpc-2137	8	17	immunosuppression	immunosuppression	NOUN
dpc-2137	8	18	,	,	PUNCT
dpc-2137	8	19	immunodepression	immunodepression	NOUN
dpc-2137	8	20	citation	citation	NOUN
dpc-2137	8	21	:	:	PUNCT
dpc-2137	8	22	bossi	bossi	PROPN
dpc-2137	8	23	p	p	PROPN
dpc-2137	8	24	,	,	PUNCT
dpc-2137	8	25	lorini	lorini	PROPN
dpc-2137	8	26	l.	l.	PROPN
dpc-2137	8	27	treatment	treatment	NOUN
dpc-2137	8	28	of	of	ADP
dpc-2137	8	29	cutaneous	cutaneous	ADJ
dpc-2137	8	30	squamous	squamous	ADJ
dpc-2137	8	31	cell	cell	NOUN
dpc-2137	8	32	carcinoma	carcinoma	NOUN
dpc-2137	8	33	with	with	ADP
dpc-2137	8	34	immune	immune	ADJ
dpc-2137	8	35	checkpoint	checkpoint	NOUN
dpc-2137	8	36	inhibitors	inhibitor	NOUN
dpc-2137	8	37	in	in	ADP
dpc-2137	8	38	special	special	ADJ
dpc-2137	8	39	populations	population	NOUN
dpc-2137	8	40	.	.	PUNCT
dpc-2137	9	1	dermatol	dermatol	NOUN
dpc-2137	9	2	pract	pract	PROPN
dpc-2137	9	3	concept	concept	NOUN
dpc-2137	9	4	.	.	PUNCT
dpc-2137	10	1	2021:11(s2):e2021170s	2021:11(s2):e2021170s	X
dpc-2137	10	2	.	.	X
dpc-2137	11	1	doi	doi	NOUN
dpc-2137	11	2	:	:	PUNCT
dpc-2137	11	3	https://doi.org/10.5826/dpc.11s2a170s	https://doi.org/10.5826/dpc.11s2a170s	PROPN
dpc-2137	11	4	accepted	accept	VERB
dpc-2137	11	5	:	:	PUNCT
dpc-2137	11	6	september	september	PROPN
dpc-2137	11	7	25	25	NUM
dpc-2137	11	8	,	,	PUNCT
dpc-2137	11	9	2021	2021	NUM
dpc-2137	11	10	;	;	PUNCT
dpc-2137	11	11	published	publish	VERB
dpc-2137	11	12	:	:	PUNCT
dpc-2137	11	13	november	november	PROPN
dpc-2137	11	14	,	,	PUNCT
dpc-2137	11	15	2021	2021	NUM
dpc-2137	11	16	copyright	copyright	NOUN
dpc-2137	11	17	:	:	PUNCT
dpc-2137	11	18	©	©	PROPN
dpc-2137	11	19	2021	2021	NUM
dpc-2137	11	20	bossi	bossi	NOUN
dpc-2137	11	21	and	and	CCONJ
dpc-2137	11	22	lorini	lorini	PROPN
dpc-2137	11	23	.	.	PUNCT
dpc-2137	12	1	this	this	PRON
dpc-2137	12	2	is	be	AUX
dpc-2137	12	3	an	an	DET
dpc-2137	12	4	open	open	ADJ
dpc-2137	12	5	-	-	PUNCT
dpc-2137	12	6	access	access	NOUN
dpc-2137	12	7	article	article	NOUN
dpc-2137	12	8	distributed	distribute	VERB
dpc-2137	12	9	under	under	ADP
dpc-2137	12	10	the	the	DET
dpc-2137	12	11	terms	term	NOUN
dpc-2137	12	12	of	of	ADP
dpc-2137	12	13	the	the	DET
dpc-2137	12	14	creative	creative	ADJ
dpc-2137	12	15	commons	common	NOUN
dpc-2137	12	16	attribution	attribution	NOUN
dpc-2137	12	17	license	license	NOUN
dpc-2137	12	18	by	by	ADP
dpc-2137	12	19	-	-	PUNCT
dpc-2137	12	20	nc-4.0	nc-4.0	NOUN
dpc-2137	12	21	,	,	PUNCT
dpc-2137	12	22	which	which	PRON
dpc-2137	12	23	permits	permit	VERB
dpc-2137	12	24	unrestricted	unrestricted	ADJ
dpc-2137	12	25	noncommercial	noncommercial	ADJ
dpc-2137	12	26	use	use	NOUN
dpc-2137	12	27	,	,	PUNCT
dpc-2137	12	28	distribution	distribution	NOUN
dpc-2137	12	29	,	,	PUNCT
dpc-2137	12	30	and	and	CCONJ
dpc-2137	12	31	reproduction	reproduction	NOUN
dpc-2137	12	32	in	in	ADP
dpc-2137	12	33	any	any	DET
dpc-2137	12	34	medium	medium	NOUN
dpc-2137	12	35	,	,	PUNCT
dpc-2137	12	36	provided	provide	VERB
dpc-2137	12	37	the	the	DET
dpc-2137	12	38	original	original	ADJ
dpc-2137	12	39	authors	author	NOUN
dpc-2137	12	40	and	and	CCONJ
dpc-2137	12	41	source	source	NOUN
dpc-2137	12	42	are	be	AUX
dpc-2137	12	43	credited	credit	VERB
dpc-2137	12	44	.	.	PUNCT
dpc-2137	13	1	funding	funding	NOUN
dpc-2137	13	2	:	:	PUNCT
dpc-2137	13	3	none	none	NOUN
dpc-2137	13	4	.	.	PUNCT
dpc-2137	14	1	competing	compete	VERB
dpc-2137	14	2	interests	interest	NOUN
dpc-2137	14	3	:	:	PUNCT
dpc-2137	14	4	pb	pb	PRON
dpc-2137	14	5	participated	participate	VERB
dpc-2137	14	6	in	in	ADP
dpc-2137	14	7	advisory	advisory	ADJ
dpc-2137	14	8	boards	board	NOUN
dpc-2137	14	9	or	or	CCONJ
dpc-2137	14	10	received	receive	VERB
dpc-2137	14	11	conference	conference	NOUN
dpc-2137	14	12	honoraria	honorarium	NOUN
dpc-2137	14	13	from	from	ADP
dpc-2137	14	14	merck	merck	PROPN
dpc-2137	14	15	,	,	PUNCT
dpc-2137	14	16	sanofi	sanofi	NOUN
dpc-2137	14	17	-	-	PUNCT
dpc-2137	14	18	regeneron	regeneron	PROPN
dpc-2137	14	19	,	,	PUNCT
dpc-2137	14	20	merck	merck	PROPN
dpc-2137	14	21	sharp	sharp	PROPN
dpc-2137	14	22	&	&	CCONJ
dpc-2137	14	23	dohme	dohme	PROPN
dpc-2137	14	24	,	,	PUNCT
dpc-2137	14	25	sun	sun	PROPN
dpc-2137	14	26	pharma	pharma	PROPN
dpc-2137	14	27	,	,	PUNCT
dpc-2137	14	28	angelini	angelini	PROPN
dpc-2137	14	29	,	,	PUNCT
dpc-2137	14	30	molteni	molteni	NOUN
dpc-2137	14	31	,	,	PUNCT
dpc-2137	14	32	bristol	bristol	PROPN
dpc-2137	14	33	-	-	PUNCT
dpc-2137	14	34	myers	myers	PROPN
dpc-2137	14	35	squibb	squibb	PROPN
dpc-2137	14	36	,	,	PUNCT
dpc-2137	14	37	gsk	gsk	PROPN
dpc-2137	14	38	.	.	PUNCT
dpc-2137	15	1	authorship	authorship	NOUN
dpc-2137	15	2	:	:	PUNCT
dpc-2137	15	3	both	both	DET
dpc-2137	15	4	authors	author	NOUN
dpc-2137	15	5	have	have	AUX
dpc-2137	15	6	contributed	contribute	VERB
dpc-2137	15	7	significantly	significantly	ADV
dpc-2137	15	8	to	to	ADP
dpc-2137	15	9	this	this	DET
dpc-2137	15	10	publication	publication	NOUN
dpc-2137	15	11	.	.	PUNCT
dpc-2137	16	1	corresponding	correspond	VERB
dpc-2137	16	2	author	author	NOUN
dpc-2137	16	3	:	:	PUNCT
dpc-2137	16	4	paolo	paolo	PROPN
dpc-2137	16	5	bossi	bossi	PROPN
dpc-2137	16	6	,	,	PUNCT
dpc-2137	16	7	md	md	PROPN
dpc-2137	16	8	.	.	PROPN
dpc-2137	16	9	medical	medical	ADJ
dpc-2137	16	10	oncology	oncology	NOUN
dpc-2137	16	11	unit	unit	NOUN
dpc-2137	16	12	,	,	PUNCT
dpc-2137	16	13	department	department	NOUN
dpc-2137	16	14	of	of	ADP
dpc-2137	16	15	medical	medical	ADJ
dpc-2137	16	16	and	and	CCONJ
dpc-2137	16	17	surgical	surgical	ADJ
dpc-2137	16	18	specialties	specialty	NOUN
dpc-2137	16	19	,	,	PUNCT
dpc-2137	16	20	radiological	radiological	ADJ
dpc-2137	16	21	sciences	science	NOUN
dpc-2137	16	22	and	and	CCONJ
dpc-2137	16	23	public	public	ADJ
dpc-2137	16	24	health	health	NOUN
dpc-2137	16	25	,	,	PUNCT
dpc-2137	16	26	asst	asst	PROPN
dpc-2137	16	27	spedali	spedali	PROPN
dpc-2137	16	28	civili	civili	PROPN
dpc-2137	16	29	of	of	ADP
dpc-2137	16	30	brescia	brescia	PROPN
dpc-2137	16	31	,	,	PUNCT
dpc-2137	16	32	university	university	NOUN
dpc-2137	16	33	of	of	ADP
dpc-2137	16	34	brescia	brescia	PROPN
dpc-2137	16	35	,	,	PUNCT
dpc-2137	16	36	brescia	brescia	PROPN
dpc-2137	16	37	,	,	PUNCT
dpc-2137	16	38	italy	italy	PROPN
dpc-2137	16	39	.	.	PUNCT
dpc-2137	17	1	email	email	NOUN
dpc-2137	17	2	:	:	PUNCT
dpc-2137	17	3	paolo.bossi@unibs.it	paolo.bossi@unibs.it	NOUN
dpc-2137	17	4	this	this	DET
dpc-2137	17	5	article	article	NOUN
dpc-2137	17	6	is	be	AUX
dpc-2137	17	7	part	part	NOUN
dpc-2137	17	8	of	of	ADP
dpc-2137	17	9	the	the	DET
dpc-2137	17	10	dpc	dpc	PROPN
dpc-2137	17	11	journal	journal	PROPN
dpc-2137	17	12	special	special	ADJ
dpc-2137	17	13	issue	issue	NOUN
dpc-2137	17	14	cutaneous	cutaneous	ADJ
dpc-2137	17	15	squamous	squamous	ADJ
dpc-2137	17	16	cell	cell	NOUN
dpc-2137	17	17	carcinoma	carcinoma	NOUN
dpc-2137	17	18	:	:	PUNCT
dpc-2137	17	19	an	an	DET
dpc-2137	17	20	update	update	NOUN
dpc-2137	17	21	on	on	ADP
dpc-2137	17	22	diagnosis	diagnosis	NOUN
dpc-2137	17	23	and	and	CCONJ
dpc-2137	17	24	treatment	treatment	NOUN
dpc-2137	17	25	guest	guest	NOUN
dpc-2137	17	26	editors	editor	NOUN
dpc-2137	17	27	prof	prof	PROPN
dpc-2137	17	28	.	.	PUNCT
dpc-2137	18	1	luc	luc	PROPN
dpc-2137	18	2	thomas	thomas	PROPN
dpc-2137	18	3	,	,	PUNCT
dpc-2137	18	4	md	md	PROPN
dpc-2137	18	5	,	,	PUNCT
dpc-2137	18	6	phd	phd	NOUN
dpc-2137	18	7	full	full	ADJ
dpc-2137	18	8	professor	professor	NOUN
dpc-2137	18	9	and	and	CCONJ
dpc-2137	18	10	vice	vice	NOUN
dpc-2137	18	11	-	-	NOUN
dpc-2137	18	12	chair	chair	NOUN
dpc-2137	18	13	,	,	PUNCT
dpc-2137	18	14	department	department	NOUN
dpc-2137	18	15	of	of	ADP
dpc-2137	18	16	dermatology	dermatology	NOUN
dpc-2137	18	17	,	,	PUNCT
dpc-2137	18	18	lyon	lyon	PROPN
dpc-2137	18	19	cancer	cancer	PROPN
dpc-2137	18	20	research	research	PROPN
dpc-2137	18	21	center	center	PROPN
dpc-2137	18	22	,	,	PUNCT
dpc-2137	18	23	lyon	lyon	PROPN
dpc-2137	18	24	1	1	NUM
dpc-2137	18	25	university	university	NOUN
dpc-2137	18	26	,	,	PUNCT
dpc-2137	18	27	centre	centre	PROPN
dpc-2137	18	28	hospitalier	hospitalier	PROPN
dpc-2137	18	29	lyon	lyon	PROPN
dpc-2137	18	30	sud	sud	PROPN
dpc-2137	18	31	,	,	PUNCT
dpc-2137	18	32	france	france	PROPN
dpc-2137	18	33	.	.	PUNCT
dpc-2137	19	1	prof	prof	PROPN
dpc-2137	19	2	.	.	PUNCT
dpc-2137	20	1	ketty	ketty	PROPN
dpc-2137	20	2	peris	peris	PROPN
dpc-2137	20	3	,	,	PUNCT
dpc-2137	20	4	md	md	PROPN
dpc-2137	20	5	full	full	ADJ
dpc-2137	20	6	professor	professor	NOUN
dpc-2137	20	7	of	of	ADP
dpc-2137	20	8	dermatology	dermatology	NOUN
dpc-2137	20	9	,	,	PUNCT
dpc-2137	20	10	chief	chief	NOUN
dpc-2137	20	11	of	of	ADP
dpc-2137	20	12	the	the	DET
dpc-2137	20	13	complex	complex	ADJ
dpc-2137	20	14	operative	operative	ADJ
dpc-2137	20	15	unit	unit	NOUN
dpc-2137	20	16	of	of	ADP
dpc-2137	20	17	dermatology	dermatology	NOUN
dpc-2137	20	18	director	director	NOUN
dpc-2137	20	19	of	of	ADP
dpc-2137	20	20	the	the	DET
dpc-2137	20	21	dermatology	dermatology	NOUN
dpc-2137	20	22	and	and	CCONJ
dpc-2137	20	23	venereology	venereology	NOUN
dpc-2137	20	24	postgraduate	postgraduate	PROPN
dpc-2137	20	25	school	school	PROPN
dpc-2137	20	26	catholic	catholic	PROPN
dpc-2137	20	27	university	university	PROPN
dpc-2137	20	28	of	of	ADP
dpc-2137	20	29	rome	rome	PROPN
dpc-2137	20	30	fondazione	fondazione	PROPN
dpc-2137	20	31	policlinico	policlinico	PROPN
dpc-2137	20	32	universitario	universitario	PROPN
dpc-2137	20	33	agostino	agostino	PROPN
dpc-2137	20	34	gemelli	gemelli	PROPN
dpc-2137	20	35	irccs	irccs	PROPN
dpc-2137	20	36	rome	rome	PROPN
dpc-2137	20	37	,	,	PUNCT
dpc-2137	20	38	italy	italy	PROPN
dpc-2137	20	39	cutaneous	cutaneous	ADJ
dpc-2137	20	40	squamous	squamous	ADJ
dpc-2137	20	41	cell	cell	NOUN
dpc-2137	20	42	carcinoma	carcinoma	NOUN
dpc-2137	20	43	(	(	PUNCT
dpc-2137	20	44	cscc	cscc	ADJ
dpc-2137	20	45	)	)	PUNCT
dpc-2137	20	46	may	may	AUX
dpc-2137	20	47	develop	develop	VERB
dpc-2137	20	48	in	in	ADP
dpc-2137	20	49	patients	patient	NOUN
dpc-2137	20	50	with	with	ADP
dpc-2137	20	51	dysregulated	dysregulated	ADJ
dpc-2137	20	52	immune	immune	ADJ
dpc-2137	20	53	activation	activation	NOUN
dpc-2137	20	54	(	(	PUNCT
dpc-2137	20	55	pre	pre	ADJ
dpc-2137	20	56	-	-	ADJ
dpc-2137	20	57	existing	existing	ADJ
dpc-2137	20	58	autoimmune	autoimmune	ADJ
dpc-2137	20	59	diseases	disease	NOUN
dpc-2137	20	60	or	or	CCONJ
dpc-2137	20	61	immunosuppression	immunosuppression	NOUN
dpc-2137	20	62	due	due	ADJ
dpc-2137	20	63	to	to	ADP
dpc-2137	20	64	hematopoietic	hematopoietic	ADJ
dpc-2137	20	65	/	/	SYM
dpc-2137	20	66	solid	solid	ADJ
dpc-2137	20	67	organ	organ	NOUN
dpc-2137	20	68	transplant	transplant	NOUN
dpc-2137	20	69	recipients	recipient	NOUN
dpc-2137	20	70	)	)	PUNCT
dpc-2137	20	71	,	,	PUNCT
dpc-2137	20	72	patients	patient	NOUN
dpc-2137	20	73	with	with	ADP
dpc-2137	20	74	a	a	DET
dpc-2137	20	75	compromised	compromise	VERB
dpc-2137	20	76	immune	immune	ADJ
dpc-2137	20	77	function	function	NOUN
dpc-2137	20	78	(	(	PUNCT
dpc-2137	20	79	long	long	ADJ
dpc-2137	20	80	-	-	PUNCT
dpc-2137	20	81	term	term	NOUN
dpc-2137	20	82	immunosuppression	immunosuppression	NOUN
dpc-2137	20	83	)	)	PUNCT
dpc-2137	20	84	,	,	PUNCT
dpc-2137	20	85	and	and	CCONJ
dpc-2137	20	86	patients	patient	NOUN
dpc-2137	20	87	carrying	carry	VERB
dpc-2137	20	88	chronic	chronic	ADJ
dpc-2137	20	89	viral	viral	ADJ
dpc-2137	20	90	infections	infection	NOUN
dpc-2137	20	91	,	,	PUNCT
dpc-2137	20	92	or	or	CCONJ
dpc-2137	20	93	those	those	PRON
dpc-2137	20	94	affected	affect	VERB
dpc-2137	20	95	by	by	ADP
dpc-2137	20	96	lymphoproliferative	lymphoproliferative	ADJ
dpc-2137	20	97	diseases	disease	NOUN
dpc-2137	20	98	.	.	PUNCT
dpc-2137	21	1	it	it	PRON
dpc-2137	21	2	should	should	AUX
dpc-2137	21	3	be	be	AUX
dpc-2137	21	4	also	also	ADV
dpc-2137	21	5	considered	consider	VERB
dpc-2137	21	6	that	that	SCONJ
dpc-2137	21	7	patients	patient	NOUN
dpc-2137	21	8	presenting	present	VERB
dpc-2137	21	9	with	with	ADP
dpc-2137	21	10	immunosuppression	immunosuppression	NOUN
dpc-2137	21	11	have	have	VERB
dpc-2137	21	12	a	a	DET
dpc-2137	21	13	high	high	ADJ
dpc-2137	21	14	incidence	incidence	NOUN
dpc-2137	21	15	of	of	ADP
dpc-2137	21	16	cscc	cscc	ADJ
dpc-2137	21	17	(	(	PUNCT
dpc-2137	21	18	65–250	65–250	NUM
dpc-2137	21	19	-	-	PUNCT
dpc-2137	21	20	times	time	NOUN
dpc-2137	21	21	higher	high	ADJ
dpc-2137	21	22	than	than	ADP
dpc-2137	21	23	general	general	ADJ
dpc-2137	21	24	population	population	NOUN
dpc-2137	21	25	)	)	PUNCT
dpc-2137	21	26	,	,	PUNCT
dpc-2137	21	27	highlighting	highlight	VERB
dpc-2137	21	28	the	the	DET
dpc-2137	21	29	central	central	ADJ
dpc-2137	21	30	role	role	NOUN
dpc-2137	21	31	played	play	VERB
dpc-2137	21	32	by	by	ADP
dpc-2137	21	33	the	the	DET
dpc-2137	21	34	immune	immune	ADJ
dpc-2137	21	35	system	system	NOUN
dpc-2137	21	36	in	in	ADP
dpc-2137	21	37	the	the	DET
dpc-2137	21	38	development	development	NOUN
dpc-2137	21	39	of	of	ADP
dpc-2137	21	40	cscc	cscc	NOUN
dpc-2137	21	41	.	.	PUNCT
dpc-2137	22	1	all	all	DET
dpc-2137	22	2	these	these	DET
dpc-2137	22	3	cases	case	NOUN
dpc-2137	22	4	must	must	AUX
dpc-2137	22	5	be	be	AUX
dpc-2137	22	6	considered	consider	VERB
dpc-2137	22	7	as	as	ADP
dpc-2137	22	8	“	"	PUNCT
dpc-2137	22	9	special	special	ADJ
dpc-2137	22	10	populations	population	NOUN
dpc-2137	22	11	”	"	PUNCT
dpc-2137	22	12	abstract	abstract	ADJ
dpc-2137	22	13	2	2	NUM
dpc-2137	22	14	review	review	NOUN
dpc-2137	22	15	|	|	ADV
dpc-2137	22	16	dermatol	dermatol	ADJ
dpc-2137	22	17	pract	pract	NOUN
dpc-2137	22	18	concept	concept	NOUN
dpc-2137	22	19	.	.	PUNCT
dpc-2137	23	1	2021:11(s2):e2021170s	2021:11(s2):e2021170s	NUM
dpc-2137	23	2	introduction	introduction	NOUN
dpc-2137	23	3	cutaneous	cutaneous	ADJ
dpc-2137	23	4	squamous	squamous	ADJ
dpc-2137	23	5	cell	cell	NOUN
dpc-2137	23	6	carcinoma	carcinoma	NOUN
dpc-2137	23	7	(	(	PUNCT
dpc-2137	23	8	cscc	cscc	ADJ
dpc-2137	23	9	)	)	PUNCT
dpc-2137	23	10	is	be	AUX
dpc-2137	23	11	the	the	DET
dpc-2137	23	12	second	second	ADJ
dpc-2137	23	13	most	most	ADV
dpc-2137	23	14	common	common	ADJ
dpc-2137	23	15	non	non	ADJ
dpc-2137	23	16	-	-	ADJ
dpc-2137	23	17	melanoma	melanoma	ADJ
dpc-2137	23	18	skin	skin	NOUN
dpc-2137	23	19	cancer	cancer	NOUN
dpc-2137	23	20	,	,	PUNCT
dpc-2137	23	21	accounting	account	VERB
dpc-2137	23	22	for	for	ADP
dpc-2137	23	23	20	20	NUM
dpc-2137	23	24	%	%	NOUN
dpc-2137	23	25	of	of	ADP
dpc-2137	23	26	skin	skin	NOUN
dpc-2137	23	27	cancers	cancer	NOUN
dpc-2137	23	28	[	[	X
dpc-2137	23	29	1	1	NUM
dpc-2137	23	30	]	]	PUNCT
dpc-2137	23	31	.	.	PUNCT
dpc-2137	24	1	incidence	incidence	NOUN
dpc-2137	24	2	rates	rate	NOUN
dpc-2137	24	3	change	change	VERB
dpc-2137	24	4	according	accord	VERB
dpc-2137	24	5	to	to	ADP
dpc-2137	24	6	skin	skin	NOUN
dpc-2137	24	7	phenotype	phenotype	NOUN
dpc-2137	24	8	,	,	PUNCT
dpc-2137	24	9	gender	gender	NOUN
dpc-2137	24	10	(	(	PUNCT
dpc-2137	24	11	highest	high	ADJ
dpc-2137	24	12	risk	risk	NOUN
dpc-2137	24	13	for	for	ADP
dpc-2137	24	14	men	man	NOUN
dpc-2137	24	15	compared	compare	VERB
dpc-2137	24	16	with	with	ADP
dpc-2137	24	17	women	woman	NOUN
dpc-2137	24	18	)	)	PUNCT
dpc-2137	24	19	,	,	PUNCT
dpc-2137	24	20	and	and	CCONJ
dpc-2137	24	21	geographic	geographic	ADJ
dpc-2137	24	22	areas	area	NOUN
dpc-2137	24	23	:	:	PUNCT
dpc-2137	24	24	in	in	ADP
dpc-2137	24	25	north	north	PROPN
dpc-2137	24	26	america	america	PROPN
dpc-2137	24	27	,	,	PUNCT
dpc-2137	24	28	the	the	DET
dpc-2137	24	29	incidence	incidence	NOUN
dpc-2137	24	30	changes	change	VERB
dpc-2137	24	31	between	between	ADP
dpc-2137	24	32	canada	canada	PROPN
dpc-2137	24	33	(	(	PUNCT
dpc-2137	24	34	60/100,000	60/100,000	NUM
dpc-2137	24	35	inhabitants	inhabitant	NOUN
dpc-2137	24	36	)	)	PUNCT
dpc-2137	24	37	and	and	CCONJ
dpc-2137	24	38	arizona	arizona	PROPN
dpc-2137	24	39	(	(	PUNCT
dpc-2137	24	40	usa	usa	PROPN
dpc-2137	24	41	)	)	PUNCT
dpc-2137	24	42	(	(	PUNCT
dpc-2137	24	43	290/100,000	290/100,000	NUM
dpc-2137	24	44	inhabitants	inhabitant	NOUN
dpc-2137	24	45	)	)	PUNCT
dpc-2137	24	46	;	;	PUNCT
dpc-2137	24	47	in	in	ADP
dpc-2137	24	48	europe	europe	PROPN
dpc-2137	24	49	,	,	PUNCT
dpc-2137	24	50	age	age	NOUN
dpc-2137	24	51	-	-	PUNCT
dpc-2137	24	52	standardized	standardize	VERB
dpc-2137	24	53	incidence	incidence	NOUN
dpc-2137	24	54	is	be	AUX
dpc-2137	24	55	9–96/100,000	9–96/100,000	NUM
dpc-2137	24	56	inhabitants	inhabitant	NOUN
dpc-2137	24	57	for	for	ADP
dpc-2137	24	58	males	male	NOUN
dpc-2137	24	59	and	and	CCONJ
dpc-2137	24	60	5–68/100,000	5–68/100,000	NUM
dpc-2137	24	61	inhabitants	inhabitant	NOUN
dpc-2137	24	62	for	for	ADP
dpc-2137	24	63	females	female	NOUN
dpc-2137	24	64	;	;	PUNCT
dpc-2137	24	65	and	and	CCONJ
dpc-2137	24	66	in	in	ADP
dpc-2137	24	67	australia	australia	PROPN
dpc-2137	24	68	,	,	PUNCT
dpc-2137	24	69	the	the	DET
dpc-2137	24	70	incidence	incidence	NOUN
dpc-2137	24	71	reported	report	VERB
dpc-2137	24	72	is	be	AUX
dpc-2137	24	73	387/100,000	387/100,000	NUM
dpc-2137	24	74	inhabitants	inhabitant	NOUN
dpc-2137	24	75	[	[	X
dpc-2137	24	76	2	2	NUM
dpc-2137	24	77	]	]	PUNCT
dpc-2137	24	78	.	.	PUNCT
dpc-2137	25	1	mortality	mortality	NOUN
dpc-2137	25	2	rates	rate	NOUN
dpc-2137	25	3	for	for	ADP
dpc-2137	25	4	cscc	cscc	ADJ
dpc-2137	25	5	are	be	AUX
dpc-2137	25	6	not	not	PART
dpc-2137	25	7	always	always	ADV
dpc-2137	25	8	well	well	ADV
dpc-2137	25	9	documented	document	VERB
dpc-2137	25	10	;	;	PUNCT
dpc-2137	25	11	however	however	ADV
dpc-2137	25	12	,	,	PUNCT
dpc-2137	25	13	5	5	NUM
dpc-2137	25	14	-	-	PUNCT
dpc-2137	25	15	year	year	NOUN
dpc-2137	25	16	survival	survival	NOUN
dpc-2137	25	17	rate	rate	NOUN
dpc-2137	25	18	is	be	AUX
dpc-2137	25	19	estimated	estimate	VERB
dpc-2137	25	20	to	to	PART
dpc-2137	25	21	be	be	AUX
dpc-2137	25	22	ranging	range	VERB
dpc-2137	25	23	from	from	ADP
dpc-2137	25	24	88	88	NUM
dpc-2137	25	25	%	%	NOUN
dpc-2137	25	26	for	for	ADP
dpc-2137	25	27	localized	localized	ADJ
dpc-2137	25	28	disease	disease	NOUN
dpc-2137	25	29	,	,	PUNCT
dpc-2137	25	30	to	to	ADP
dpc-2137	25	31	50	50	NUM
dpc-2137	25	32	%	%	NOUN
dpc-2137	25	33	for	for	ADP
dpc-2137	25	34	metastatic	metastatic	ADJ
dpc-2137	25	35	disease	disease	NOUN
dpc-2137	25	36	[	[	X
dpc-2137	25	37	3,4	3,4	NUM
dpc-2137	25	38	]	]	PUNCT
dpc-2137	25	39	.	.	PUNCT
dpc-2137	26	1	most	most	ADJ
dpc-2137	26	2	csccs	csccs	PROPN
dpc-2137	26	3	are	be	AUX
dpc-2137	26	4	diagnosed	diagnose	VERB
dpc-2137	26	5	in	in	ADP
dpc-2137	26	6	the	the	DET
dpc-2137	26	7	early	early	ADJ
dpc-2137	26	8	stage	stage	NOUN
dpc-2137	26	9	and	and	CCONJ
dpc-2137	26	10	are	be	AUX
dpc-2137	26	11	eligible	eligible	ADJ
dpc-2137	26	12	for	for	ADP
dpc-2137	26	13	curative	curative	ADJ
dpc-2137	26	14	treatment	treatment	NOUN
dpc-2137	26	15	(	(	PUNCT
dpc-2137	26	16	more	more	ADJ
dpc-2137	26	17	than	than	ADP
dpc-2137	26	18	90	90	NUM
dpc-2137	26	19	%	%	NOUN
dpc-2137	26	20	of	of	ADP
dpc-2137	26	21	cases	case	NOUN
dpc-2137	26	22	)	)	PUNCT
dpc-2137	26	23	,	,	PUNCT
dpc-2137	26	24	however	however	ADV
dpc-2137	26	25	,	,	PUNCT
dpc-2137	26	26	up	up	ADP
dpc-2137	26	27	to	to	PART
dpc-2137	26	28	5	5	NUM
dpc-2137	26	29	%	%	NOUN
dpc-2137	26	30	of	of	ADP
dpc-2137	26	31	cases	case	NOUN
dpc-2137	26	32	may	may	AUX
dpc-2137	26	33	present	present	VERB
dpc-2137	26	34	with	with	ADP
dpc-2137	26	35	a	a	DET
dpc-2137	26	36	non	non	ADJ
dpc-2137	26	37	-	-	ADJ
dpc-2137	26	38	resectable	resectable	ADJ
dpc-2137	26	39	disease	disease	NOUN
dpc-2137	26	40	[	[	X
dpc-2137	26	41	5	5	NUM
dpc-2137	26	42	]	]	PUNCT
dpc-2137	26	43	and	and	CCONJ
dpc-2137	26	44	other	other	ADJ
dpc-2137	26	45	cases	case	NOUN
dpc-2137	26	46	may	may	AUX
dpc-2137	26	47	not	not	PART
dpc-2137	26	48	be	be	AUX
dpc-2137	26	49	eligible	eligible	ADJ
dpc-2137	26	50	for	for	ADP
dpc-2137	26	51	surgery	surgery	NOUN
dpc-2137	26	52	due	due	ADP
dpc-2137	26	53	to	to	ADP
dpc-2137	26	54	comorbidities	comorbiditie	NOUN
dpc-2137	26	55	.	.	PUNCT
dpc-2137	27	1	immune	immune	ADJ
dpc-2137	27	2	checkpoint	checkpoint	NOUN
dpc-2137	27	3	inhibitors	inhibitor	NOUN
dpc-2137	27	4	(	(	PUNCT
dpc-2137	27	5	icis	icis	NOUN
dpc-2137	27	6	)	)	PUNCT
dpc-2137	27	7	offer	offer	VERB
dpc-2137	27	8	new	new	ADJ
dpc-2137	27	9	therapeutic	therapeutic	ADJ
dpc-2137	27	10	perspectives	perspective	NOUN
dpc-2137	27	11	to	to	PART
dpc-2137	27	12	cscc	cscc	VERB
dpc-2137	27	13	not	not	PART
dpc-2137	27	14	amenable	amenable	ADJ
dpc-2137	27	15	to	to	ADP
dpc-2137	27	16	locoregional	locoregional	ADJ
dpc-2137	27	17	treatments	treatment	NOUN
dpc-2137	27	18	,	,	PUNCT
dpc-2137	27	19	achieving	achieve	VERB
dpc-2137	27	20	response	response	NOUN
dpc-2137	27	21	rates	rate	NOUN
dpc-2137	27	22	in	in	ADP
dpc-2137	27	23	up	up	ADP
dpc-2137	27	24	to	to	PART
dpc-2137	27	25	50	50	NUM
dpc-2137	27	26	%	%	NOUN
dpc-2137	27	27	of	of	ADP
dpc-2137	27	28	cases	case	NOUN
dpc-2137	27	29	and	and	CCONJ
dpc-2137	27	30	providing	provide	VERB
dpc-2137	27	31	benefits	benefit	NOUN
dpc-2137	27	32	to	to	ADP
dpc-2137	27	33	a	a	DET
dpc-2137	27	34	subgroup	subgroup	NOUN
dpc-2137	27	35	with	with	ADP
dpc-2137	27	36	durable	durable	ADJ
dpc-2137	27	37	disease	disease	NOUN
dpc-2137	27	38	control	control	NOUN
dpc-2137	28	1	[	[	X
dpc-2137	28	2	6	6	NUM
dpc-2137	28	3	]	]	PUNCT
dpc-2137	28	4	.	.	PUNCT
dpc-2137	29	1	despite	despite	SCONJ
dpc-2137	29	2	general	general	ADJ
dpc-2137	29	3	good	good	ADJ
dpc-2137	29	4	tolerability	tolerability	NOUN
dpc-2137	29	5	,	,	PUNCT
dpc-2137	29	6	immunotherapy	immunotherapy	NOUN
dpc-2137	29	7	could	could	AUX
dpc-2137	29	8	be	be	AUX
dpc-2137	29	9	rarely	rarely	ADV
dpc-2137	29	10	associated	associate	VERB
dpc-2137	29	11	with	with	ADP
dpc-2137	29	12	severe	severe	ADJ
dpc-2137	29	13	immune	immune	NOUN
dpc-2137	29	14	-	-	PUNCT
dpc-2137	29	15	related	relate	VERB
dpc-2137	29	16	adverse	adverse	ADJ
dpc-2137	29	17	events	event	NOUN
dpc-2137	29	18	(	(	PUNCT
dpc-2137	29	19	iraes	iraes	NOUN
dpc-2137	29	20	)	)	PUNCT
dpc-2137	29	21	,	,	PUNCT
dpc-2137	29	22	due	due	ADP
dpc-2137	29	23	to	to	ADP
dpc-2137	29	24	uncontrolled	uncontrolled	ADJ
dpc-2137	29	25	activation	activation	NOUN
dpc-2137	29	26	of	of	ADP
dpc-2137	29	27	the	the	DET
dpc-2137	29	28	immune	immune	ADJ
dpc-2137	29	29	system	system	NOUN
dpc-2137	29	30	.	.	PUNCT
dpc-2137	30	1	in	in	ADP
dpc-2137	30	2	this	this	DET
dpc-2137	30	3	regard	regard	NOUN
dpc-2137	30	4	,	,	PUNCT
dpc-2137	30	5	immunotherapy	immunotherapy	NOUN
dpc-2137	30	6	safety	safety	NOUN
dpc-2137	30	7	profile	profile	NOUN
dpc-2137	30	8	should	should	AUX
dpc-2137	30	9	also	also	ADV
dpc-2137	30	10	be	be	AUX
dpc-2137	30	11	studied	study	VERB
dpc-2137	30	12	in	in	ADP
dpc-2137	30	13	“	"	PUNCT
dpc-2137	30	14	special	special	ADJ
dpc-2137	30	15	populations	population	NOUN
dpc-2137	30	16	”	"	PUNCT
dpc-2137	30	17	,	,	PUNCT
dpc-2137	30	18	ie	ie	X
dpc-2137	30	19	,	,	PUNCT
dpc-2137	30	20	the	the	DET
dpc-2137	30	21	patients	patient	NOUN
dpc-2137	30	22	whose	whose	DET
dpc-2137	30	23	comorbidities	comorbiditie	NOUN
dpc-2137	30	24	or	or	CCONJ
dpc-2137	30	25	frailties	frailty	NOUN
dpc-2137	30	26	excluded	exclude	VERB
dpc-2137	30	27	them	they	PRON
dpc-2137	30	28	from	from	ADP
dpc-2137	30	29	clinical	clinical	ADJ
dpc-2137	30	30	trials	trial	NOUN
dpc-2137	30	31	that	that	PRON
dpc-2137	30	32	led	lead	VERB
dpc-2137	30	33	to	to	ADP
dpc-2137	30	34	the	the	DET
dpc-2137	30	35	approval	approval	NOUN
dpc-2137	30	36	of	of	ADP
dpc-2137	30	37	icis	icis	PROPN
dpc-2137	30	38	.	.	PUNCT
dpc-2137	31	1	special	special	ADJ
dpc-2137	31	2	populations	population	NOUN
dpc-2137	31	3	include	include	VERB
dpc-2137	31	4	patients	patient	NOUN
dpc-2137	31	5	with	with	ADP
dpc-2137	31	6	dysregulated	dysregulated	ADJ
dpc-2137	31	7	immune	immune	ADJ
dpc-2137	31	8	activation	activation	NOUN
dpc-2137	31	9	(	(	PUNCT
dpc-2137	31	10	pre	pre	ADJ
dpc-2137	31	11	-	-	ADJ
dpc-2137	31	12	existing	existing	ADJ
dpc-2137	31	13	autoimmune	autoimmune	ADJ
dpc-2137	31	14	diseases	disease	NOUN
dpc-2137	31	15	or	or	CCONJ
dpc-2137	31	16	immunosuppression	immunosuppression	NOUN
dpc-2137	31	17	due	due	ADJ
dpc-2137	31	18	to	to	ADP
dpc-2137	31	19	hematopoietic	hematopoietic	ADJ
dpc-2137	31	20	/	/	SYM
dpc-2137	31	21	solid	solid	ADJ
dpc-2137	31	22	organ	organ	NOUN
dpc-2137	31	23	transplant	transplant	NOUN
dpc-2137	31	24	recipients	recipient	NOUN
dpc-2137	31	25	)	)	PUNCT
dpc-2137	31	26	,	,	PUNCT
dpc-2137	31	27	patients	patient	NOUN
dpc-2137	31	28	with	with	ADP
dpc-2137	31	29	a	a	DET
dpc-2137	31	30	compromised	compromise	VERB
dpc-2137	31	31	immune	immune	ADJ
dpc-2137	31	32	function	function	NOUN
dpc-2137	31	33	(	(	PUNCT
dpc-2137	31	34	long	long	ADJ
dpc-2137	31	35	-	-	PUNCT
dpc-2137	31	36	term	term	NOUN
dpc-2137	31	37	immunosuppression	immunosuppression	NOUN
dpc-2137	31	38	)	)	PUNCT
dpc-2137	31	39	,	,	PUNCT
dpc-2137	31	40	patients	patient	NOUN
dpc-2137	31	41	with	with	ADP
dpc-2137	31	42	chronic	chronic	ADJ
dpc-2137	31	43	viral	viral	ADJ
dpc-2137	31	44	infections	infection	NOUN
dpc-2137	31	45	,	,	PUNCT
dpc-2137	31	46	or	or	CCONJ
dpc-2137	31	47	those	those	PRON
dpc-2137	31	48	affected	affect	VERB
dpc-2137	31	49	by	by	ADP
dpc-2137	31	50	lymphoproliferative	lymphoproliferative	ADJ
dpc-2137	31	51	diseases	disease	NOUN
dpc-2137	31	52	in	in	ADP
dpc-2137	31	53	which	which	PRON
dpc-2137	31	54	the	the	DET
dpc-2137	31	55	safety	safety	NOUN
dpc-2137	31	56	of	of	ADP
dpc-2137	31	57	icis	icis	NOUN
dpc-2137	31	58	is	be	AUX
dpc-2137	31	59	not	not	PART
dpc-2137	31	60	well	well	ADV
dpc-2137	31	61	studied	study	VERB
dpc-2137	31	62	.	.	PUNCT
dpc-2137	32	1	“	"	PUNCT
dpc-2137	32	2	special	special	ADJ
dpc-2137	32	3	population	population	NOUN
dpc-2137	32	4	”	"	PUNCT
dpc-2137	32	5	in	in	ADP
dpc-2137	32	6	immunotherapy	immunotherapy	NOUN
dpc-2137	32	7	treatment	treatment	NOUN
dpc-2137	32	8	patients	patient	NOUN
dpc-2137	32	9	receiving	receive	VERB
dpc-2137	32	10	solid	solid	ADJ
dpc-2137	32	11	organ	organ	NOUN
dpc-2137	32	12	transplantation	transplantation	NOUN
dpc-2137	32	13	(	(	PUNCT
dpc-2137	32	14	sot	sot	ADJ
dpc-2137	32	15	)	)	PUNCT
dpc-2137	32	16	or	or	CCONJ
dpc-2137	32	17	hematopoietic	hematopoietic	ADJ
dpc-2137	32	18	stem	stem	NOUN
dpc-2137	32	19	cell	cell	NOUN
dpc-2137	32	20	transplant	transplant	NOUN
dpc-2137	32	21	(	(	PUNCT
dpc-2137	32	22	hsct	hsct	PROPN
dpc-2137	32	23	)	)	PUNCT
dpc-2137	32	24	require	require	VERB
dpc-2137	32	25	modulation	modulation	NOUN
dpc-2137	32	26	of	of	ADP
dpc-2137	32	27	the	the	DET
dpc-2137	32	28	immune	immune	ADJ
dpc-2137	32	29	system	system	NOUN
dpc-2137	32	30	to	to	PART
dpc-2137	32	31	maintain	maintain	VERB
dpc-2137	32	32	allograft	allograft	NOUN
dpc-2137	32	33	tolerance	tolerance	NOUN
dpc-2137	32	34	and	and	CCONJ
dpc-2137	32	35	avoid	avoid	VERB
dpc-2137	32	36	rejection	rejection	NOUN
dpc-2137	32	37	,	,	PUNCT
dpc-2137	32	38	and	and	CCONJ
dpc-2137	32	39	graft	graft	NOUN
dpc-2137	32	40	versus	versus	ADP
dpc-2137	32	41	host	host	NOUN
dpc-2137	32	42	disease	disease	NOUN
dpc-2137	32	43	(	(	PUNCT
dpc-2137	32	44	gvhd	gvhd	PROPN
dpc-2137	32	45	)	)	PUNCT
dpc-2137	32	46	.	.	PUNCT
dpc-2137	33	1	preclinical	preclinical	ADJ
dpc-2137	33	2	data	datum	NOUN
dpc-2137	33	3	showed	show	VERB
dpc-2137	33	4	that	that	SCONJ
dpc-2137	33	5	the	the	DET
dpc-2137	33	6	pd-1	pd-1	NOUN
dpc-2137	33	7	/	/	SYM
dpc-2137	33	8	pd	pd	ADJ
dpc-2137	33	9	-	-	PUNCT
dpc-2137	33	10	l1	l1	PROPN
dpc-2137	33	11	axis	axis	NOUN
dpc-2137	33	12	has	have	VERB
dpc-2137	33	13	an	an	DET
dpc-2137	33	14	important	important	ADJ
dpc-2137	33	15	role	role	NOUN
dpc-2137	33	16	in	in	ADP
dpc-2137	33	17	maintaining	maintain	VERB
dpc-2137	33	18	tolerance	tolerance	NOUN
dpc-2137	33	19	,	,	PUNCT
dpc-2137	33	20	even	even	ADV
dpc-2137	33	21	if	if	SCONJ
dpc-2137	33	22	not	not	PART
dpc-2137	33	23	well	well	ADV
dpc-2137	33	24	understood	understand	VERB
dpc-2137	33	25	.	.	PUNCT
dpc-2137	34	1	pd-1	pd-1	ADP
dpc-2137	34	2	/	/	SYM
dpc-2137	34	3	pd	pd	ADJ
dpc-2137	34	4	-	-	PUNCT
dpc-2137	34	5	l1	l1	PROPN
dpc-2137	34	6	axis	axis	NOUN
dpc-2137	34	7	is	be	AUX
dpc-2137	34	8	required	require	VERB
dpc-2137	34	9	for	for	ADP
dpc-2137	34	10	the	the	DET
dpc-2137	34	11	maintenance	maintenance	NOUN
dpc-2137	34	12	of	of	ADP
dpc-2137	34	13	t	t	NOUN
dpc-2137	34	14	-	-	PUNCT
dpc-2137	34	15	cell	cell	NOUN
dpc-2137	34	16	tolerance	tolerance	NOUN
dpc-2137	34	17	to	to	PART
dpc-2137	34	18	prevent	prevent	VERB
dpc-2137	34	19	alloimmunity	alloimmunity	NOUN
dpc-2137	34	20	following	follow	VERB
dpc-2137	34	21	hsct	hsct	NOUN
dpc-2137	34	22	,	,	PUNCT
dpc-2137	34	23	and	and	CCONJ
dpc-2137	34	24	reduces	reduce	VERB
dpc-2137	34	25	the	the	DET
dpc-2137	34	26	risk	risk	NOUN
dpc-2137	34	27	of	of	ADP
dpc-2137	34	28	gvhd	gvhd	NOUN
dpc-2137	34	29	[	[	X
dpc-2137	34	30	7	7	NUM
dpc-2137	34	31	]	]	PUNCT
dpc-2137	34	32	.	.	PUNCT
dpc-2137	35	1	as	as	SCONJ
dpc-2137	35	2	the	the	DET
dpc-2137	35	3	intervention	intervention	NOUN
dpc-2137	35	4	with	with	ADP
dpc-2137	35	5	icis	icis	PROPN
dpc-2137	35	6	migh	migh	AUX
dpc-2137	35	7	induce	induce	VERB
dpc-2137	35	8	alteration	alteration	NOUN
dpc-2137	35	9	in	in	ADP
dpc-2137	35	10	the	the	DET
dpc-2137	35	11	mechanism	mechanism	NOUN
dpc-2137	35	12	of	of	ADP
dpc-2137	35	13	t	t	NOUN
dpc-2137	35	14	-	-	PUNCT
dpc-2137	35	15	cell	cell	NOUN
dpc-2137	35	16	exhaustion	exhaustion	NOUN
dpc-2137	35	17	,	,	PUNCT
dpc-2137	35	18	thus	thus	ADV
dpc-2137	35	19	reinvigorating	reinvigorate	VERB
dpc-2137	35	20	immune	immune	ADJ
dpc-2137	35	21	response	response	NOUN
dpc-2137	35	22	,	,	PUNCT
dpc-2137	35	23	icis	icis	PROPN
dpc-2137	35	24	could	could	AUX
dpc-2137	35	25	be	be	AUX
dpc-2137	35	26	also	also	ADV
dpc-2137	35	27	responsible	responsible	ADJ
dpc-2137	35	28	for	for	ADP
dpc-2137	35	29	organ	organ	NOUN
dpc-2137	35	30	rejection	rejection	NOUN
dpc-2137	35	31	[	[	X
dpc-2137	35	32	8,9	8,9	NUM
dpc-2137	35	33	]	]	X
dpc-2137	35	34	;	;	PUNCT
dpc-2137	35	35	as	as	SCONJ
dpc-2137	35	36	a	a	DET
dpc-2137	35	37	consequence	consequence	NOUN
dpc-2137	35	38	sot	sot	ADJ
dpc-2137	35	39	recipients	recipient	NOUN
dpc-2137	35	40	were	be	AUX
dpc-2137	35	41	usually	usually	ADV
dpc-2137	35	42	excluded	exclude	VERB
dpc-2137	35	43	from	from	ADP
dpc-2137	35	44	main	main	ADJ
dpc-2137	35	45	ici	ici	NOUN
dpc-2137	35	46	clinical	clinical	ADJ
dpc-2137	35	47	trials	trial	NOUN
dpc-2137	35	48	.	.	PUNCT
dpc-2137	36	1	data	datum	NOUN
dpc-2137	36	2	in	in	ADP
dpc-2137	36	3	literature	literature	NOUN
dpc-2137	36	4	regarding	regard	VERB
dpc-2137	36	5	the	the	DET
dpc-2137	36	6	use	use	NOUN
dpc-2137	36	7	of	of	ADP
dpc-2137	36	8	icis	icis	NOUN
dpc-2137	36	9	in	in	ADP
dpc-2137	36	10	this	this	DET
dpc-2137	36	11	population	population	NOUN
dpc-2137	36	12	are	be	AUX
dpc-2137	36	13	related	relate	VERB
dpc-2137	36	14	to	to	ADP
dpc-2137	36	15	case	case	NOUN
dpc-2137	36	16	series	series	NOUN
dpc-2137	36	17	and	and	CCONJ
dpc-2137	36	18	case	case	NOUN
dpc-2137	36	19	reports	report	VERB
dpc-2137	36	20	.	.	PUNCT
dpc-2137	37	1	rejection	rejection	NOUN
dpc-2137	37	2	rates	rate	NOUN
dpc-2137	37	3	in	in	ADP
dpc-2137	37	4	patients	patient	NOUN
dpc-2137	37	5	receiving	receive	VERB
dpc-2137	37	6	icis	icis	NOUN
dpc-2137	37	7	are	be	AUX
dpc-2137	37	8	reported	report	VERB
dpc-2137	37	9	in	in	ADP
dpc-2137	37	10	36	36	NUM
dpc-2137	37	11	%	%	NOUN
dpc-2137	37	12	and	and	CCONJ
dpc-2137	37	13	54	54	NUM
dpc-2137	37	14	%	%	NOUN
dpc-2137	37	15	of	of	ADP
dpc-2137	37	16	liver	liver	NOUN
dpc-2137	37	17	and	and	CCONJ
dpc-2137	37	18	kidney	kidney	NOUN
dpc-2137	37	19	transplantation	transplantation	NOUN
dpc-2137	37	20	,	,	PUNCT
dpc-2137	37	21	respectively	respectively	ADV
dpc-2137	37	22	[	[	X
dpc-2137	37	23	10	10	NUM
dpc-2137	37	24	]	]	PUNCT
dpc-2137	37	25	.	.	PUNCT
dpc-2137	38	1	recently	recently	ADV
dpc-2137	38	2	,	,	PUNCT
dpc-2137	38	3	19	19	NUM
dpc-2137	38	4	patients	patient	NOUN
dpc-2137	38	5	receiving	receive	VERB
dpc-2137	38	6	liver	liver	NOUN
dpc-2137	38	7	transplant	transplant	NOUN
dpc-2137	38	8	and	and	CCONJ
dpc-2137	38	9	29	29	NUM
dpc-2137	38	10	patients	patient	NOUN
dpc-2137	38	11	receiving	receive	VERB
dpc-2137	38	12	kidney	kidney	NOUN
dpc-2137	38	13	transplant	transplant	NOUN
dpc-2137	38	14	were	be	AUX
dpc-2137	38	15	treated	treat	VERB
dpc-2137	38	16	with	with	ADP
dpc-2137	38	17	icis	icis	PROPN
dpc-2137	38	18	,	,	PUNCT
dpc-2137	38	19	showing	show	VERB
dpc-2137	38	20	a	a	DET
dpc-2137	38	21	disease	disease	NOUN
dpc-2137	38	22	control	control	NOUN
dpc-2137	38	23	rate	rate	NOUN
dpc-2137	38	24	of	of	ADP
dpc-2137	38	25	35	35	NUM
dpc-2137	38	26	%	%	NOUN
dpc-2137	38	27	and	and	CCONJ
dpc-2137	38	28	an	an	DET
dpc-2137	38	29	organ	organ	NOUN
dpc-2137	38	30	rejection	rejection	NOUN
dpc-2137	38	31	rate	rate	NOUN
dpc-2137	38	32	of	of	ADP
dpc-2137	38	33	37	37	NUM
dpc-2137	38	34	%	%	NOUN
dpc-2137	38	35	and	and	CCONJ
dpc-2137	38	36	45	45	NUM
dpc-2137	38	37	%	%	NOUN
dpc-2137	38	38	for	for	ADP
dpc-2137	38	39	liver	liver	NOUN
dpc-2137	38	40	and	and	CCONJ
dpc-2137	38	41	kidney	kidney	NOUN
dpc-2137	38	42	transplantation	transplantation	NOUN
dpc-2137	38	43	,	,	PUNCT
dpc-2137	38	44	respectively	respectively	ADV
dpc-2137	38	45	[	[	X
dpc-2137	38	46	11	11	NUM
dpc-2137	38	47	]	]	PUNCT
dpc-2137	38	48	.	.	PUNCT
dpc-2137	39	1	a	a	DET
dpc-2137	39	2	literature	literature	NOUN
dpc-2137	39	3	search	search	NOUN
dpc-2137	39	4	and	and	CCONJ
dpc-2137	39	5	review	review	NOUN
dpc-2137	39	6	of	of	ADP
dpc-2137	39	7	27	27	NUM
dpc-2137	39	8	articles	article	NOUN
dpc-2137	39	9	reported	report	VERB
dpc-2137	39	10	a	a	DET
dpc-2137	39	11	40	40	NUM
dpc-2137	39	12	%	%	NOUN
dpc-2137	39	13	rate	rate	NOUN
dpc-2137	39	14	of	of	ADP
dpc-2137	39	15	allograft	allograft	NOUN
dpc-2137	39	16	rejection	rejection	NOUN
dpc-2137	39	17	in	in	ADP
dpc-2137	39	18	renal	renal	ADJ
dpc-2137	39	19	transplant	transplant	NOUN
dpc-2137	39	20	recipients	recipient	NOUN
dpc-2137	39	21	treated	treat	VERB
dpc-2137	39	22	with	with	ADP
dpc-2137	39	23	icis	icis	NOUN
dpc-2137	39	24	for	for	ADP
dpc-2137	39	25	advanced	advanced	ADJ
dpc-2137	39	26	solid	solid	ADJ
dpc-2137	39	27	cancers	cancer	NOUN
dpc-2137	39	28	(	(	PUNCT
dpc-2137	39	29	mainly	mainly	ADV
dpc-2137	39	30	melanoma	melanoma	NOUN
dpc-2137	39	31	)	)	PUNCT
dpc-2137	39	32	;	;	PUNCT
dpc-2137	39	33	17	17	NUM
dpc-2137	39	34	%	%	NOUN
dpc-2137	39	35	of	of	ADP
dpc-2137	39	36	these	these	DET
dpc-2137	39	37	patients	patient	NOUN
dpc-2137	39	38	achieved	achieve	VERB
dpc-2137	39	39	a	a	DET
dpc-2137	39	40	partial	partial	ADJ
dpc-2137	39	41	response	response	NOUN
dpc-2137	39	42	to	to	ADP
dpc-2137	39	43	immunotherapy	immunotherapy	NOUN
dpc-2137	39	44	[	[	X
dpc-2137	39	45	12	12	NUM
dpc-2137	39	46	]	]	PUNCT
dpc-2137	39	47	.	.	PUNCT
dpc-2137	40	1	a	a	DET
dpc-2137	40	2	large	large	ADJ
dpc-2137	40	3	systematic	systematic	ADJ
dpc-2137	40	4	review	review	NOUN
dpc-2137	40	5	on	on	ADP
dpc-2137	40	6	sot	sot	ADJ
dpc-2137	40	7	recipients	recipient	NOUN
dpc-2137	40	8	undergoing	undergo	VERB
dpc-2137	40	9	icis	icis	PROPN
dpc-2137	40	10	due	due	ADP
dpc-2137	40	11	to	to	ADP
dpc-2137	40	12	advanced	advanced	ADJ
dpc-2137	40	13	solid	solid	ADJ
dpc-2137	40	14	cancer	cancer	NOUN
dpc-2137	40	15	confirmed	confirm	VERB
dpc-2137	40	16	the	the	DET
dpc-2137	40	17	rejection	rejection	NOUN
dpc-2137	40	18	rate	rate	NOUN
dpc-2137	40	19	of	of	ADP
dpc-2137	40	20	approximately	approximately	ADV
dpc-2137	40	21	40	40	NUM
dpc-2137	40	22	%	%	NOUN
dpc-2137	40	23	,	,	PUNCT
dpc-2137	40	24	similar	similar	ADJ
dpc-2137	40	25	across	across	ADP
dpc-2137	40	26	the	the	DET
dpc-2137	40	27	type	type	NOUN
dpc-2137	40	28	of	of	ADP
dpc-2137	40	29	icis	icis	NOUN
dpc-2137	40	30	and	and	CCONJ
dpc-2137	40	31	primary	primary	ADJ
dpc-2137	40	32	tumor	tumor	NOUN
dpc-2137	40	33	histology	histology	NOUN
dpc-2137	40	34	[	[	X
dpc-2137	40	35	13	13	NUM
dpc-2137	40	36	]	]	PUNCT
dpc-2137	40	37	.	.	PUNCT
dpc-2137	41	1	an	an	DET
dpc-2137	41	2	important	important	ADJ
dpc-2137	41	3	issue	issue	NOUN
dpc-2137	41	4	is	be	AUX
dpc-2137	41	5	how	how	SCONJ
dpc-2137	41	6	to	to	PART
dpc-2137	41	7	reduce	reduce	VERB
dpc-2137	41	8	risk	risk	NOUN
dpc-2137	41	9	of	of	ADP
dpc-2137	41	10	organ	organ	NOUN
dpc-2137	41	11	rejection	rejection	NOUN
dpc-2137	41	12	without	without	ADP
dpc-2137	41	13	affecting	affect	VERB
dpc-2137	41	14	immunotherapy	immunotherapy	NOUN
dpc-2137	41	15	efficacy	efficacy	NOUN
dpc-2137	41	16	:	:	PUNCT
dpc-2137	41	17	lowering	lower	VERB
dpc-2137	41	18	or	or	CCONJ
dpc-2137	41	19	withdrawing	withdraw	VERB
dpc-2137	41	20	immunosuppressive	immunosuppressive	ADJ
dpc-2137	41	21	regimens	regimen	NOUN
dpc-2137	41	22	is	be	AUX
dpc-2137	41	23	possible	possible	ADJ
dpc-2137	41	24	,	,	PUNCT
dpc-2137	41	25	however	however	ADV
dpc-2137	41	26	this	this	PRON
dpc-2137	41	27	needs	need	VERB
dpc-2137	41	28	to	to	PART
dpc-2137	41	29	be	be	AUX
dpc-2137	41	30	discussed	discuss	VERB
dpc-2137	41	31	in	in	ADP
dpc-2137	41	32	multidisciplinary	multidisciplinary	ADJ
dpc-2137	41	33	tumor	tumor	NOUN
dpc-2137	41	34	board	board	NOUN
dpc-2137	41	35	[	[	X
dpc-2137	41	36	14,15	14,15	NUM
dpc-2137	41	37	]	]	PUNCT
dpc-2137	41	38	.	.	PUNCT
dpc-2137	42	1	intriguingly	intriguingly	ADV
dpc-2137	42	2	,	,	PUNCT
dpc-2137	42	3	immune	immune	ADJ
dpc-2137	42	4	-	-	PUNCT
dpc-2137	42	5	suppressive	suppressive	NOUN
dpc-2137	42	6	agents	agent	NOUN
dpc-2137	42	7	used	use	VERB
dpc-2137	42	8	in	in	ADP
dpc-2137	42	9	combination	combination	NOUN
dpc-2137	42	10	with	with	ADP
dpc-2137	42	11	corticosteroids	corticosteroid	NOUN
dpc-2137	42	12	could	could	AUX
dpc-2137	42	13	modulate	modulate	VERB
dpc-2137	42	14	the	the	DET
dpc-2137	42	15	risk	risk	NOUN
dpc-2137	42	16	of	of	ADP
dpc-2137	42	17	organ	organ	NOUN
dpc-2137	42	18	rejection	rejection	NOUN
dpc-2137	42	19	.	.	PUNCT
dpc-2137	43	1	it	it	PRON
dpc-2137	43	2	seems	seem	VERB
dpc-2137	43	3	that	that	SCONJ
dpc-2137	43	4	the	the	DET
dpc-2137	43	5	use	use	NOUN
dpc-2137	43	6	of	of	ADP
dpc-2137	43	7	mtor	mtor	NOUN
dpc-2137	43	8	inhibitors	inhibitor	NOUN
dpc-2137	43	9	,	,	PUNCT
dpc-2137	43	10	instead	instead	ADV
dpc-2137	43	11	of	of	ADP
dpc-2137	43	12	calcineurin	calcineurin	ADJ
dpc-2137	43	13	inhibitors	inhibitor	NOUN
dpc-2137	43	14	,	,	PUNCT
dpc-2137	43	15	could	could	AUX
dpc-2137	43	16	be	be	AUX
dpc-2137	43	17	an	an	DET
dpc-2137	43	18	option	option	NOUN
dpc-2137	43	19	for	for	ADP
dpc-2137	43	20	sot	sot	ADJ
dpc-2137	43	21	recipients	recipient	NOUN
dpc-2137	43	22	with	with	ADP
dpc-2137	43	23	cancer	cancer	NOUN
dpc-2137	43	24	for	for	ADP
dpc-2137	43	25	treatment	treatment	NOUN
dpc-2137	43	26	with	with	ADP
dpc-2137	43	27	immune	immune	ADJ
dpc-2137	43	28	checkpoint	checkpoint	NOUN
dpc-2137	43	29	inhibitors	inhibitor	NOUN
dpc-2137	43	30	(	(	PUNCT
dpc-2137	43	31	icis	icis	NOUN
dpc-2137	43	32	)	)	PUNCT
dpc-2137	43	33	,	,	PUNCT
dpc-2137	43	34	as	as	SCONJ
dpc-2137	43	35	the	the	DET
dpc-2137	43	36	safety	safety	NOUN
dpc-2137	43	37	and	and	CCONJ
dpc-2137	43	38	activity	activity	NOUN
dpc-2137	43	39	of	of	ADP
dpc-2137	43	40	these	these	DET
dpc-2137	43	41	drugs	drug	NOUN
dpc-2137	43	42	have	have	AUX
dpc-2137	43	43	not	not	PART
dpc-2137	43	44	been	be	AUX
dpc-2137	43	45	studied	study	VERB
dpc-2137	43	46	on	on	ADP
dpc-2137	43	47	these	these	DET
dpc-2137	43	48	specific	specific	ADJ
dpc-2137	43	49	cases	case	NOUN
dpc-2137	43	50	,	,	PUNCT
dpc-2137	43	51	since	since	SCONJ
dpc-2137	43	52	these	these	DET
dpc-2137	43	53	patients	patient	NOUN
dpc-2137	43	54	were	be	AUX
dpc-2137	43	55	excluded	exclude	VERB
dpc-2137	43	56	from	from	ADP
dpc-2137	43	57	clinical	clinical	ADJ
dpc-2137	43	58	trials	trial	NOUN
dpc-2137	43	59	leading	lead	VERB
dpc-2137	43	60	to	to	ADP
dpc-2137	43	61	approval	approval	NOUN
dpc-2137	43	62	of	of	ADP
dpc-2137	43	63	icis	icis	PROPN
dpc-2137	43	64	.	.	PUNCT
dpc-2137	44	1	it	it	PRON
dpc-2137	44	2	is	be	AUX
dpc-2137	44	3	therefore	therefore	ADV
dpc-2137	44	4	important	important	ADJ
dpc-2137	44	5	to	to	PART
dpc-2137	44	6	gain	gain	VERB
dpc-2137	44	7	as	as	ADV
dpc-2137	44	8	much	much	ADJ
dpc-2137	44	9	information	information	NOUN
dpc-2137	44	10	as	as	ADP
dpc-2137	44	11	possible	possible	ADJ
dpc-2137	44	12	from	from	ADP
dpc-2137	44	13	the	the	DET
dpc-2137	44	14	analysis	analysis	NOUN
dpc-2137	44	15	of	of	ADP
dpc-2137	44	16	real	real	ADJ
dpc-2137	44	17	-	-	PUNCT
dpc-2137	44	18	life	life	NOUN
dpc-2137	44	19	data	datum	NOUN
dpc-2137	44	20	,	,	PUNCT
dpc-2137	44	21	to	to	PART
dpc-2137	44	22	derive	derive	VERB
dpc-2137	44	23	an	an	DET
dpc-2137	44	24	indication	indication	NOUN
dpc-2137	44	25	to	to	PART
dpc-2137	44	26	be	be	AUX
dpc-2137	44	27	adopted	adopt	VERB
dpc-2137	44	28	in	in	ADP
dpc-2137	44	29	everyday	everyday	ADJ
dpc-2137	44	30	clinical	clinical	ADJ
dpc-2137	44	31	setting	setting	NOUN
dpc-2137	44	32	.	.	PUNCT
dpc-2137	45	1	moreover	moreover	ADV
dpc-2137	45	2	,	,	PUNCT
dpc-2137	45	3	therapeutic	therapeutic	ADJ
dpc-2137	45	4	alternatives	alternative	NOUN
dpc-2137	45	5	other	other	ADJ
dpc-2137	45	6	than	than	ADP
dpc-2137	45	7	icis	icis	PROPN
dpc-2137	45	8	are	be	AUX
dpc-2137	45	9	scarce	scarce	ADJ
dpc-2137	45	10	,	,	PUNCT
dpc-2137	45	11	mainly	mainly	ADV
dpc-2137	45	12	consisting	consist	VERB
dpc-2137	45	13	in	in	ADP
dpc-2137	45	14	chemotherapy	chemotherapy	NOUN
dpc-2137	45	15	and	and	CCONJ
dpc-2137	45	16	anti	anti	ADJ
dpc-2137	45	17	-	-	ADJ
dpc-2137	45	18	egfr	egfr	ADJ
dpc-2137	45	19	agents	agent	NOUN
dpc-2137	45	20	,	,	PUNCT
dpc-2137	45	21	whose	whose	DET
dpc-2137	45	22	activity	activity	NOUN
dpc-2137	45	23	is	be	AUX
dpc-2137	45	24	lower	low	ADJ
dpc-2137	45	25	than	than	ADP
dpc-2137	45	26	immunotherapy	immunotherapy	NOUN
dpc-2137	45	27	and	and	CCONJ
dpc-2137	45	28	whose	whose	DET
dpc-2137	45	29	toxicity	toxicity	NOUN
dpc-2137	45	30	(	(	PUNCT
dpc-2137	45	31	particularly	particularly	ADV
dpc-2137	45	32	with	with	ADP
dpc-2137	45	33	chemotherapy	chemotherapy	NOUN
dpc-2137	45	34	)	)	PUNCT
dpc-2137	45	35	are	be	AUX
dpc-2137	45	36	not	not	PART
dpc-2137	45	37	sustainable	sustainable	ADJ
dpc-2137	45	38	by	by	ADP
dpc-2137	45	39	this	this	DET
dpc-2137	45	40	frail	frail	ADJ
dpc-2137	45	41	population	population	NOUN
dpc-2137	45	42	.	.	PUNCT
dpc-2137	46	1	here	here	ADV
dpc-2137	46	2	,	,	PUNCT
dpc-2137	46	3	we	we	PRON
dpc-2137	46	4	describe	describe	VERB
dpc-2137	46	5	the	the	DET
dpc-2137	46	6	current	current	ADJ
dpc-2137	46	7	evidence	evidence	NOUN
dpc-2137	46	8	of	of	ADP
dpc-2137	46	9	treatment	treatment	NOUN
dpc-2137	46	10	with	with	ADP
dpc-2137	46	11	icis	icis	NOUN
dpc-2137	46	12	in	in	ADP
dpc-2137	46	13	special	special	ADJ
dpc-2137	46	14	populations	population	NOUN
dpc-2137	46	15	and	and	CCONJ
dpc-2137	46	16	conclude	conclude	VERB
dpc-2137	46	17	that	that	SCONJ
dpc-2137	46	18	it	it	PRON
dpc-2137	46	19	is	be	AUX
dpc-2137	46	20	necessary	necessary	ADJ
dpc-2137	46	21	to	to	PART
dpc-2137	46	22	find	find	VERB
dpc-2137	46	23	a	a	DET
dpc-2137	46	24	balance	balance	NOUN
dpc-2137	46	25	between	between	ADP
dpc-2137	46	26	treatment	treatment	NOUN
dpc-2137	46	27	risks	risk	NOUN
dpc-2137	46	28	(	(	PUNCT
dpc-2137	46	29	toxicities	toxicity	NOUN
dpc-2137	46	30	)	)	PUNCT
dpc-2137	46	31	and	and	CCONJ
dpc-2137	46	32	benefits	benefit	NOUN
dpc-2137	46	33	(	(	PUNCT
dpc-2137	46	34	efficacy	efficacy	NOUN
dpc-2137	46	35	)	)	PUNCT
dpc-2137	46	36	,	,	PUNCT
dpc-2137	46	37	as	as	ADV
dpc-2137	46	38	well	well	ADV
dpc-2137	46	39	as	as	ADP
dpc-2137	46	40	engaging	engage	VERB
dpc-2137	46	41	a	a	DET
dpc-2137	46	42	multidisciplinary	multidisciplinary	ADJ
dpc-2137	46	43	team	team	NOUN
dpc-2137	46	44	of	of	ADP
dpc-2137	46	45	experts	expert	NOUN
dpc-2137	46	46	to	to	PART
dpc-2137	46	47	thoroughly	thoroughly	ADV
dpc-2137	46	48	manage	manage	VERB
dpc-2137	46	49	and	and	CCONJ
dpc-2137	46	50	treat	treat	VERB
dpc-2137	46	51	these	these	DET
dpc-2137	46	52	patients	patient	NOUN
dpc-2137	46	53	.	.	PUNCT
dpc-2137	47	1	review	review	VERB
dpc-2137	47	2	|	|	ADV
dpc-2137	47	3	dermatol	dermatol	ADJ
dpc-2137	47	4	pract	pract	NOUN
dpc-2137	47	5	concept	concept	NOUN
dpc-2137	47	6	.	.	PUNCT
dpc-2137	48	1	2021:11(s2):e2021170s	2021:11(s2):e2021170s	NUM
dpc-2137	48	2	3	3	NUM
dpc-2137	48	3	requiring	require	VERB
dpc-2137	48	4	ici	ici	NOUN
dpc-2137	48	5	treatment	treatment	NOUN
dpc-2137	48	6	,	,	PUNCT
dpc-2137	48	7	due	due	ADP
dpc-2137	48	8	to	to	ADP
dpc-2137	48	9	the	the	DET
dpc-2137	48	10	reduction	reduction	NOUN
dpc-2137	48	11	of	of	ADP
dpc-2137	48	12	the	the	DET
dpc-2137	48	13	risk	risk	NOUN
dpc-2137	48	14	to	to	PART
dpc-2137	48	15	develop	develop	VERB
dpc-2137	48	16	organ	organ	NOUN
dpc-2137	48	17	rejection	rejection	NOUN
dpc-2137	48	18	,	,	PUNCT
dpc-2137	48	19	combined	combine	VERB
dpc-2137	48	20	with	with	ADP
dpc-2137	48	21	the	the	DET
dpc-2137	48	22	known	know	VERB
dpc-2137	48	23	antitumor	antitumor	NOUN
dpc-2137	48	24	activity	activity	NOUN
dpc-2137	48	25	[	[	X
dpc-2137	48	26	16,17	16,17	NUM
dpc-2137	48	27	]	]	PUNCT
dpc-2137	48	28	.	.	PUNCT
dpc-2137	49	1	icis	icis	PROPN
dpc-2137	49	2	are	be	AUX
dpc-2137	49	3	currently	currently	ADV
dpc-2137	49	4	used	use	VERB
dpc-2137	49	5	in	in	ADP
dpc-2137	49	6	hematological	hematological	ADJ
dpc-2137	49	7	diseases	disease	NOUN
dpc-2137	49	8	as	as	ADP
dpc-2137	49	9	salvage	salvage	NOUN
dpc-2137	49	10	therapies	therapy	NOUN
dpc-2137	49	11	in	in	ADP
dpc-2137	49	12	patients	patient	NOUN
dpc-2137	49	13	affected	affect	VERB
dpc-2137	49	14	by	by	ADP
dpc-2137	49	15	hodgkin	hodgkin	PROPN
dpc-2137	49	16	lymphoma	lymphoma	NOUN
dpc-2137	49	17	,	,	PUNCT
dpc-2137	49	18	while	while	SCONJ
dpc-2137	49	19	there	there	PRON
dpc-2137	49	20	is	be	VERB
dpc-2137	49	21	limited	limited	ADJ
dpc-2137	49	22	evidence	evidence	NOUN
dpc-2137	49	23	of	of	ADP
dpc-2137	49	24	their	their	PRON
dpc-2137	49	25	use	use	NOUN
dpc-2137	49	26	in	in	ADP
dpc-2137	49	27	other	other	ADJ
dpc-2137	49	28	types	type	NOUN
dpc-2137	49	29	of	of	ADP
dpc-2137	49	30	lymphoma	lymphoma	NOUN
dpc-2137	49	31	and	and	CCONJ
dpc-2137	49	32	lymphoproliferative	lymphoproliferative	ADJ
dpc-2137	49	33	disease	disease	NOUN
dpc-2137	50	1	[	[	X
dpc-2137	50	2	18	18	NUM
dpc-2137	50	3	]	]	PUNCT
dpc-2137	50	4	.	.	PUNCT
dpc-2137	51	1	patients	patient	NOUN
dpc-2137	51	2	who	who	PRON
dpc-2137	51	3	need	need	VERB
dpc-2137	51	4	icis	icis	NOUN
dpc-2137	51	5	treatment	treatment	NOUN
dpc-2137	51	6	for	for	ADP
dpc-2137	51	7	solid	solid	ADJ
dpc-2137	51	8	cancer	cancer	NOUN
dpc-2137	51	9	with	with	ADP
dpc-2137	51	10	a	a	DET
dpc-2137	51	11	history	history	NOUN
dpc-2137	51	12	of	of	ADP
dpc-2137	51	13	hematological	hematological	ADJ
dpc-2137	51	14	disease	disease	NOUN
dpc-2137	51	15	could	could	AUX
dpc-2137	51	16	have	have	AUX
dpc-2137	51	17	previously	previously	ADV
dpc-2137	51	18	received	receive	VERB
dpc-2137	51	19	an	an	DET
dpc-2137	51	20	immunotherapy	immunotherapy	NOUN
dpc-2137	51	21	treatment	treatment	NOUN
dpc-2137	51	22	or	or	CCONJ
dpc-2137	51	23	could	could	AUX
dpc-2137	51	24	have	have	AUX
dpc-2137	51	25	also	also	ADV
dpc-2137	51	26	received	receive	VERB
dpc-2137	51	27	an	an	DET
dpc-2137	51	28	autogenic	autogenic	ADJ
dpc-2137	51	29	/	/	SYM
dpc-2137	51	30	allogenic	allogenic	ADJ
dpc-2137	51	31	transplant	transplant	NOUN
dpc-2137	51	32	.	.	PUNCT
dpc-2137	52	1	if	if	SCONJ
dpc-2137	52	2	treatment	treatment	NOUN
dpc-2137	52	3	with	with	ADP
dpc-2137	52	4	icis	icis	NOUN
dpc-2137	52	5	was	be	AUX
dpc-2137	52	6	well	well	ADV
dpc-2137	52	7	tolerated	tolerate	VERB
dpc-2137	52	8	by	by	ADP
dpc-2137	52	9	hematological	hematological	ADJ
dpc-2137	52	10	patients	patient	NOUN
dpc-2137	52	11	,	,	PUNCT
dpc-2137	52	12	further	far	ADV
dpc-2137	52	13	retreatment	retreatment	ADJ
dpc-2137	52	14	with	with	ADP
dpc-2137	52	15	icis	icis	PROPN
dpc-2137	52	16	is	be	AUX
dpc-2137	52	17	not	not	PART
dpc-2137	52	18	contraindicated	contraindicate	VERB
dpc-2137	52	19	[	[	X
dpc-2137	52	20	8	8	NUM
dpc-2137	52	21	]	]	PUNCT
dpc-2137	52	22	.	.	PUNCT
dpc-2137	53	1	on	on	ADP
dpc-2137	53	2	the	the	DET
dpc-2137	53	3	other	other	ADJ
dpc-2137	53	4	hand	hand	NOUN
dpc-2137	53	5	,	,	PUNCT
dpc-2137	53	6	patients	patient	NOUN
dpc-2137	53	7	who	who	PRON
dpc-2137	53	8	previously	previously	ADV
dpc-2137	53	9	received	receive	VERB
dpc-2137	53	10	an	an	DET
dpc-2137	53	11	allogeneic	allogeneic	ADJ
dpc-2137	53	12	transplant	transplant	NOUN
dpc-2137	53	13	due	due	ADP
dpc-2137	53	14	to	to	ADP
dpc-2137	53	15	hematological	hematological	ADJ
dpc-2137	53	16	diseases	disease	NOUN
dpc-2137	53	17	need	need	VERB
dpc-2137	53	18	to	to	PART
dpc-2137	53	19	be	be	AUX
dpc-2137	53	20	carefully	carefully	ADV
dpc-2137	53	21	evaluated	evaluate	VERB
dpc-2137	53	22	:	:	PUNCT
dpc-2137	53	23	icis	icis	PROPN
dpc-2137	53	24	treatment	treatment	NOUN
dpc-2137	53	25	increases	increase	VERB
dpc-2137	53	26	the	the	DET
dpc-2137	53	27	risk	risk	NOUN
dpc-2137	53	28	of	of	ADP
dpc-2137	53	29	gvhd	gvhd	NOUN
dpc-2137	53	30	;	;	PUNCT
dpc-2137	53	31	intriguingly	intriguingly	ADV
dpc-2137	53	32	antictla-4	antictla-4	VERB
dpc-2137	53	33	ipilimumab	ipilimumab	NOUN
dpc-2137	53	34	appears	appear	VERB
dpc-2137	53	35	to	to	PART
dpc-2137	53	36	have	have	VERB
dpc-2137	53	37	higher	high	ADJ
dpc-2137	53	38	safety	safety	NOUN
dpc-2137	53	39	in	in	ADP
dpc-2137	53	40	this	this	DET
dpc-2137	53	41	setting	setting	NOUN
dpc-2137	53	42	[	[	X
dpc-2137	53	43	19–21	19–21	NUM
dpc-2137	53	44	]	]	PUNCT
dpc-2137	53	45	.	.	PUNCT
dpc-2137	54	1	well	well	ADV
dpc-2137	54	2	-	-	PUNCT
dpc-2137	54	3	known	know	VERB
dpc-2137	54	4	risk	risk	NOUN
dpc-2137	54	5	factors	factor	NOUN
dpc-2137	54	6	that	that	PRON
dpc-2137	54	7	increase	increase	VERB
dpc-2137	54	8	the	the	DET
dpc-2137	54	9	risk	risk	NOUN
dpc-2137	54	10	of	of	ADP
dpc-2137	54	11	gvhd	gvhd	NOUN
dpc-2137	54	12	during	during	ADP
dpc-2137	54	13	icis	icis	PROPN
dpc-2137	54	14	treatment	treatment	NOUN
dpc-2137	54	15	are	be	AUX
dpc-2137	54	16	:	:	PUNCT
dpc-2137	54	17	a	a	DET
dpc-2137	54	18	previous	previous	ADJ
dpc-2137	54	19	gvhd	gvhd	NOUN
dpc-2137	54	20	,	,	PUNCT
dpc-2137	54	21	the	the	DET
dpc-2137	54	22	status	status	NOUN
dpc-2137	54	23	of	of	ADP
dpc-2137	54	24	chronic	chronic	ADJ
dpc-2137	54	25	gvhd	gvhd	NOUN
dpc-2137	54	26	,	,	PUNCT
dpc-2137	54	27	and	and	CCONJ
dpc-2137	54	28	previous	previous	ADJ
dpc-2137	54	29	toxicities	toxicity	NOUN
dpc-2137	54	30	[	[	X
dpc-2137	54	31	8	8	NUM
dpc-2137	54	32	]	]	PUNCT
dpc-2137	54	33	.	.	PUNCT
dpc-2137	55	1	another	another	DET
dpc-2137	55	2	group	group	NOUN
dpc-2137	55	3	of	of	ADP
dpc-2137	55	4	patients	patient	NOUN
dpc-2137	55	5	at	at	ADP
dpc-2137	55	6	higher	high	ADJ
dpc-2137	55	7	risk	risk	NOUN
dpc-2137	55	8	of	of	ADP
dpc-2137	55	9	toxicities	toxicity	NOUN
dpc-2137	55	10	by	by	ADP
dpc-2137	55	11	immunotherapy	immunotherapy	NOUN
dpc-2137	55	12	are	be	AUX
dpc-2137	55	13	those	those	PRON
dpc-2137	55	14	suffering	suffer	VERB
dpc-2137	55	15	from	from	ADP
dpc-2137	55	16	autoimmune	autoimmune	ADJ
dpc-2137	55	17	diseases	disease	NOUN
dpc-2137	55	18	.	.	PUNCT
dpc-2137	56	1	in	in	ADP
dpc-2137	56	2	these	these	DET
dpc-2137	56	3	cases	case	NOUN
dpc-2137	56	4	,	,	PUNCT
dpc-2137	56	5	further	further	ADJ
dpc-2137	56	6	immune	immune	ADJ
dpc-2137	56	7	stimulation	stimulation	NOUN
dpc-2137	56	8	could	could	AUX
dpc-2137	56	9	lead	lead	VERB
dpc-2137	56	10	to	to	ADP
dpc-2137	56	11	a	a	DET
dpc-2137	56	12	possible	possible	ADJ
dpc-2137	56	13	flare	flare	NOUN
dpc-2137	56	14	in	in	ADP
dpc-2137	56	15	immune	immune	ADJ
dpc-2137	56	16	activation	activation	NOUN
dpc-2137	56	17	,	,	PUNCT
dpc-2137	56	18	with	with	ADP
dpc-2137	56	19	clinical	clinical	ADJ
dpc-2137	56	20	consequences	consequence	NOUN
dpc-2137	56	21	.	.	PUNCT
dpc-2137	57	1	therefore	therefore	ADV
dpc-2137	57	2	,	,	PUNCT
dpc-2137	57	3	patients	patient	NOUN
dpc-2137	57	4	affected	affect	VERB
dpc-2137	57	5	by	by	ADP
dpc-2137	57	6	autoimmune	autoimmune	ADJ
dpc-2137	57	7	diseases	disease	NOUN
dpc-2137	57	8	,	,	PUNCT
dpc-2137	57	9	even	even	ADV
dpc-2137	57	10	if	if	SCONJ
dpc-2137	57	11	silent	silent	ADJ
dpc-2137	57	12	,	,	PUNCT
dpc-2137	57	13	are	be	AUX
dpc-2137	57	14	usually	usually	ADV
dpc-2137	57	15	excluded	exclude	VERB
dpc-2137	57	16	from	from	ADP
dpc-2137	57	17	clinical	clinical	ADJ
dpc-2137	57	18	trials	trial	NOUN
dpc-2137	57	19	with	with	ADP
dpc-2137	57	20	icis	icis	PROPN
dpc-2137	57	21	,	,	PUNCT
dpc-2137	57	22	for	for	ADP
dpc-2137	57	23	fear	fear	NOUN
dpc-2137	57	24	of	of	ADP
dpc-2137	57	25	new	new	ADJ
dpc-2137	57	26	,	,	PUNCT
dpc-2137	57	27	potentially	potentially	ADV
dpc-2137	57	28	life	life	NOUN
dpc-2137	57	29	-	-	PUNCT
dpc-2137	57	30	threatening	threatening	ADJ
dpc-2137	57	31	,	,	PUNCT
dpc-2137	57	32	symptoms	symptom	NOUN
dpc-2137	57	33	’	'	PUNCT
dpc-2137	57	34	appearance	appearance	NOUN
dpc-2137	57	35	.	.	PUNCT
dpc-2137	58	1	preclinical	preclinical	ADJ
dpc-2137	58	2	data	datum	NOUN
dpc-2137	58	3	showed	show	VERB
dpc-2137	58	4	that	that	SCONJ
dpc-2137	58	5	mice	mouse	NOUN
dpc-2137	58	6	deficient	deficient	ADJ
dpc-2137	58	7	for	for	ADP
dpc-2137	58	8	ctla-4	ctla-4	NOUN
dpc-2137	58	9	or	or	CCONJ
dpc-2137	58	10	pd-1	pd-1	ADP
dpc-2137	58	11	/	/	SYM
dpc-2137	58	12	pd	pd	NOUN
dpc-2137	58	13	-	-	PROPN
dpc-2137	58	14	l1	l1	PROPN
dpc-2137	58	15	may	may	AUX
dpc-2137	58	16	develop	develop	VERB
dpc-2137	58	17	serious	serious	ADJ
dpc-2137	58	18	immune	immune	NOUN
dpc-2137	58	19	-	-	PUNCT
dpc-2137	58	20	mediated	mediate	VERB
dpc-2137	58	21	symptoms	symptom	NOUN
dpc-2137	58	22	,	,	PUNCT
dpc-2137	58	23	including	include	VERB
dpc-2137	58	24	one	one	NUM
dpc-2137	58	25	death	death	NOUN
dpc-2137	58	26	due	due	ADP
dpc-2137	58	27	to	to	ADP
dpc-2137	58	28	fulminant	fulminant	ADJ
dpc-2137	58	29	autoimmune	autoimmune	ADJ
dpc-2137	58	30	disease	disease	NOUN
dpc-2137	59	1	[	[	X
dpc-2137	59	2	22	22	NUM
dpc-2137	59	3	]	]	PUNCT
dpc-2137	59	4	.	.	PUNCT
dpc-2137	60	1	however	however	ADV
dpc-2137	60	2	,	,	PUNCT
dpc-2137	60	3	cancer	cancer	NOUN
dpc-2137	60	4	patients	patient	NOUN
dpc-2137	60	5	suffering	suffer	VERB
dpc-2137	60	6	from	from	ADP
dpc-2137	60	7	previous	previous	ADJ
dpc-2137	60	8	autoimmune	autoimmune	ADJ
dpc-2137	60	9	disease	disease	NOUN
dpc-2137	60	10	do	do	AUX
dpc-2137	60	11	not	not	PART
dpc-2137	60	12	represent	represent	VERB
dpc-2137	60	13	a	a	DET
dpc-2137	60	14	small	small	ADJ
dpc-2137	60	15	portion	portion	NOUN
dpc-2137	60	16	of	of	ADP
dpc-2137	60	17	cancer	cancer	NOUN
dpc-2137	60	18	patients	patient	NOUN
dpc-2137	60	19	:	:	PUNCT
dpc-2137	60	20	for	for	ADP
dpc-2137	60	21	instance	instance	NOUN
dpc-2137	60	22	,	,	PUNCT
dpc-2137	60	23	it	it	PRON
dpc-2137	60	24	is	be	AUX
dpc-2137	60	25	estimated	estimate	VERB
dpc-2137	60	26	that	that	SCONJ
dpc-2137	60	27	13	13	NUM
dpc-2137	60	28	%	%	NOUN
dpc-2137	60	29	of	of	ADP
dpc-2137	60	30	lung	lung	NOUN
dpc-2137	60	31	cancer	cancer	NOUN
dpc-2137	60	32	patients	patient	NOUN
dpc-2137	60	33	had	have	VERB
dpc-2137	60	34	a	a	DET
dpc-2137	60	35	positive	positive	ADJ
dpc-2137	60	36	anamnesis	anamnesis	NOUN
dpc-2137	60	37	for	for	ADP
dpc-2137	60	38	autoimmune	autoimmune	ADJ
dpc-2137	60	39	disease	disease	NOUN
dpc-2137	61	1	[	[	X
dpc-2137	61	2	23	23	NUM
dpc-2137	61	3	]	]	PUNCT
dpc-2137	61	4	.	.	PUNCT
dpc-2137	62	1	a	a	DET
dpc-2137	62	2	series	series	NOUN
dpc-2137	62	3	of	of	ADP
dpc-2137	62	4	30	30	NUM
dpc-2137	62	5	patients	patient	NOUN
dpc-2137	62	6	affected	affect	VERB
dpc-2137	62	7	by	by	ADP
dpc-2137	62	8	melanoma	melanoma	NOUN
dpc-2137	62	9	,	,	PUNCT
dpc-2137	62	10	treated	treat	VERB
dpc-2137	62	11	with	with	ADP
dpc-2137	62	12	icis	icis	NOUN
dpc-2137	62	13	and	and	CCONJ
dpc-2137	62	14	with	with	ADP
dpc-2137	62	15	concurrent	concurrent	ADJ
dpc-2137	62	16	diagnosis	diagnosis	NOUN
dpc-2137	62	17	of	of	ADP
dpc-2137	62	18	autoimmune	autoimmune	ADJ
dpc-2137	62	19	disease	disease	NOUN
dpc-2137	62	20	showed	show	VERB
dpc-2137	62	21	that	that	SCONJ
dpc-2137	62	22	27	27	NUM
dpc-2137	62	23	%	%	NOUN
dpc-2137	62	24	of	of	ADP
dpc-2137	62	25	patients	patient	NOUN
dpc-2137	62	26	had	have	VERB
dpc-2137	62	27	exacerbations	exacerbation	NOUN
dpc-2137	62	28	of	of	ADP
dpc-2137	62	29	their	their	PRON
dpc-2137	62	30	autoimmune	autoimmune	ADJ
dpc-2137	62	31	disease	disease	NOUN
dpc-2137	62	32	,	,	PUNCT
dpc-2137	62	33	33	33	NUM
dpc-2137	62	34	%	%	NOUN
dpc-2137	62	35	developed	develop	VERB
dpc-2137	62	36	immune	immune	NOUN
dpc-2137	62	37	-	-	PUNCT
dpc-2137	62	38	related	relate	VERB
dpc-2137	62	39	adverse	adverse	ADJ
dpc-2137	62	40	events	event	NOUN
dpc-2137	62	41	(	(	PUNCT
dpc-2137	62	42	iraes	iraes	NOUN
dpc-2137	62	43	)	)	PUNCT
dpc-2137	62	44	requiring	require	VERB
dpc-2137	62	45	treatment	treatment	NOUN
dpc-2137	62	46	,	,	PUNCT
dpc-2137	62	47	and	and	CCONJ
dpc-2137	62	48	one	one	NUM
dpc-2137	62	49	patient	patient	NOUN
dpc-2137	62	50	with	with	ADP
dpc-2137	62	51	psoriasis	psoriasis	NOUN
dpc-2137	62	52	died	die	VERB
dpc-2137	62	53	of	of	ADP
dpc-2137	62	54	autoimmune	autoimmune	ADJ
dpc-2137	62	55	colitis	colitis	NOUN
dpc-2137	62	56	;	;	PUNCT
dpc-2137	62	57	the	the	DET
dpc-2137	62	58	response	response	NOUN
dpc-2137	62	59	rate	rate	NOUN
dpc-2137	62	60	was	be	AUX
dpc-2137	62	61	comparable	comparable	ADJ
dpc-2137	62	62	with	with	ADP
dpc-2137	62	63	other	other	ADJ
dpc-2137	62	64	ipilimumab	ipilimumab	ADJ
dpc-2137	62	65	clinical	clinical	ADJ
dpc-2137	62	66	trials	trial	NOUN
dpc-2137	62	67	[	[	X
dpc-2137	62	68	24	24	NUM
dpc-2137	62	69	]	]	PUNCT
dpc-2137	62	70	.	.	PUNCT
dpc-2137	63	1	safety	safety	NOUN
dpc-2137	63	2	and	and	CCONJ
dpc-2137	63	3	efficacy	efficacy	NOUN
dpc-2137	63	4	of	of	ADP
dpc-2137	63	5	anti	anti	ADJ
dpc-2137	63	6	-	-	ADJ
dpc-2137	63	7	pd-1	pd-1	ADJ
dpc-2137	63	8	/	/	SYM
dpc-2137	63	9	anti	anti	ADJ
dpc-2137	63	10	-	-	ADJ
dpc-2137	63	11	pd	pd	ADJ
dpc-2137	63	12	-	-	PUNCT
dpc-2137	63	13	l1	l1	PROPN
dpc-2137	63	14	therapy	therapy	NOUN
dpc-2137	63	15	in	in	ADP
dpc-2137	63	16	cancer	cancer	NOUN
dpc-2137	63	17	patients	patient	NOUN
dpc-2137	63	18	affected	affect	VERB
dpc-2137	63	19	by	by	ADP
dpc-2137	63	20	autoimmune	autoimmune	ADJ
dpc-2137	63	21	disorders	disorder	NOUN
dpc-2137	63	22	have	have	AUX
dpc-2137	63	23	been	be	AUX
dpc-2137	63	24	shown	show	VERB
dpc-2137	63	25	in	in	ADP
dpc-2137	63	26	various	various	ADJ
dpc-2137	63	27	series	series	NOUN
dpc-2137	63	28	:	:	PUNCT
dpc-2137	63	29	rates	rate	NOUN
dpc-2137	63	30	of	of	ADP
dpc-2137	63	31	iraes	irae	NOUN
dpc-2137	63	32	and	and	CCONJ
dpc-2137	63	33	autoimmune	autoimmune	ADJ
dpc-2137	63	34	flare	flare	NOUN
dpc-2137	63	35	were	be	AUX
dpc-2137	63	36	consistent	consistent	ADJ
dpc-2137	63	37	,	,	PUNCT
dpc-2137	63	38	ranging	range	VERB
dpc-2137	63	39	from	from	ADP
dpc-2137	63	40	23	23	NUM
dpc-2137	63	41	%	%	NOUN
dpc-2137	63	42	to	to	PART
dpc-2137	63	43	44	44	NUM
dpc-2137	63	44	%	%	NOUN
dpc-2137	63	45	,	,	PUNCT
dpc-2137	63	46	and	and	CCONJ
dpc-2137	63	47	efficacy	efficacy	NOUN
dpc-2137	63	48	did	do	AUX
dpc-2137	63	49	not	not	PART
dpc-2137	63	50	differ	differ	VERB
dpc-2137	63	51	from	from	ADP
dpc-2137	63	52	clinical	clinical	ADJ
dpc-2137	63	53	trials	trial	NOUN
dpc-2137	63	54	in	in	ADP
dpc-2137	63	55	patients	patient	NOUN
dpc-2137	63	56	without	without	ADP
dpc-2137	63	57	autoimmune	autoimmune	ADJ
dpc-2137	63	58	disorders	disorder	NOUN
dpc-2137	63	59	.	.	PUNCT
dpc-2137	64	1	to	to	PART
dpc-2137	64	2	note	note	VERB
dpc-2137	64	3	,	,	PUNCT
dpc-2137	64	4	iraes	irae	NOUN
dpc-2137	64	5	and	and	CCONJ
dpc-2137	64	6	autoimmune	autoimmune	ADJ
dpc-2137	64	7	flares	flare	NOUN
dpc-2137	64	8	responded	respond	VERB
dpc-2137	64	9	well	well	ADV
dpc-2137	64	10	to	to	ADP
dpc-2137	64	11	a	a	DET
dpc-2137	64	12	classic	classic	ADJ
dpc-2137	64	13	therapeutic	therapeutic	ADJ
dpc-2137	64	14	algorithm	algorithm	NOUN
dpc-2137	64	15	[	[	X
dpc-2137	64	16	25–28	25–28	NOUN
dpc-2137	64	17	]	]	PUNCT
dpc-2137	64	18	.	.	PUNCT
dpc-2137	65	1	is	be	AUX
dpc-2137	65	2	important	important	ADJ
dpc-2137	65	3	to	to	PART
dpc-2137	65	4	consider	consider	VERB
dpc-2137	65	5	cancer	cancer	NOUN
dpc-2137	65	6	patients	patient	NOUN
dpc-2137	65	7	with	with	ADP
dpc-2137	65	8	specific	specific	ADJ
dpc-2137	65	9	circulating	circulate	VERB
dpc-2137	65	10	autoimmune	autoimmune	ADJ
dpc-2137	65	11	markers	marker	NOUN
dpc-2137	65	12	or	or	CCONJ
dpc-2137	65	13	antibodies	antibodie	VERB
dpc-2137	65	14	without	without	ADP
dpc-2137	65	15	evidence	evidence	NOUN
dpc-2137	65	16	of	of	ADP
dpc-2137	65	17	autoimmune	autoimmune	ADJ
dpc-2137	65	18	disease	disease	NOUN
dpc-2137	65	19	:	:	PUNCT
dpc-2137	65	20	this	this	DET
dpc-2137	65	21	population	population	NOUN
dpc-2137	65	22	experienced	experience	VERB
dpc-2137	65	23	greater	great	ADJ
dpc-2137	65	24	efficacy	efficacy	NOUN
dpc-2137	65	25	and	and	CCONJ
dpc-2137	65	26	greater	great	ADJ
dpc-2137	65	27	toxicities	toxicity	NOUN
dpc-2137	65	28	from	from	ADP
dpc-2137	65	29	icis	icis	PROPN
dpc-2137	65	30	treatment	treatment	PROPN
dpc-2137	65	31	[	[	X
dpc-2137	65	32	29	29	NUM
dpc-2137	65	33	]	]	PUNCT
dpc-2137	65	34	.	.	PUNCT
dpc-2137	66	1	recently	recently	ADV
dpc-2137	66	2	,	,	PUNCT
dpc-2137	66	3	an	an	DET
dpc-2137	66	4	italian	italian	ADJ
dpc-2137	66	5	series	series	NOUN
dpc-2137	66	6	showed	show	VERB
dpc-2137	66	7	no	no	DET
dpc-2137	66	8	difference	difference	NOUN
dpc-2137	66	9	in	in	ADP
dpc-2137	66	10	grade	grade	NOUN
dpc-2137	66	11	3–4	3–4	NUM
dpc-2137	66	12	iraes	iraes	NOUN
dpc-2137	66	13	among	among	ADP
dpc-2137	66	14	751	751	NUM
dpc-2137	66	15	cancer	cancer	NOUN
dpc-2137	66	16	patients	patient	NOUN
dpc-2137	66	17	treated	treat	VERB
dpc-2137	66	18	with	with	ADP
dpc-2137	66	19	anti	anti	ADJ
dpc-2137	66	20	-	-	ADJ
dpc-2137	66	21	pd-1	pd-1	ADJ
dpc-2137	66	22	agents	agent	NOUN
dpc-2137	66	23	comparing	compare	VERB
dpc-2137	66	24	patients	patient	NOUN
dpc-2137	66	25	with	with	ADP
dpc-2137	66	26	or	or	CCONJ
dpc-2137	66	27	without	without	ADP
dpc-2137	66	28	autoimmune	autoimmune	ADJ
dpc-2137	66	29	disorders	disorder	NOUN
dpc-2137	66	30	[	[	X
dpc-2137	66	31	30	30	NUM
dpc-2137	66	32	]	]	PUNCT
dpc-2137	66	33	.	.	PUNCT
dpc-2137	67	1	chronic	chronic	ADJ
dpc-2137	67	2	immune	immune	ADJ
dpc-2137	67	3	suppression	suppression	NOUN
dpc-2137	67	4	due	due	ADP
dpc-2137	67	5	to	to	ADP
dpc-2137	67	6	treatment	treatment	NOUN
dpc-2137	67	7	of	of	ADP
dpc-2137	67	8	the	the	DET
dpc-2137	67	9	aforementioned	aforementioned	ADJ
dpc-2137	67	10	conditions	condition	NOUN
dpc-2137	67	11	may	may	AUX
dpc-2137	67	12	hind	hind	VERB
dpc-2137	67	13	the	the	DET
dpc-2137	67	14	effects	effect	NOUN
dpc-2137	67	15	of	of	ADP
dpc-2137	67	16	immunotherapy	immunotherapy	NOUN
dpc-2137	67	17	by	by	ADP
dpc-2137	67	18	blocking	block	VERB
dpc-2137	67	19	t	t	NOUN
dpc-2137	67	20	-	-	PUNCT
dpc-2137	67	21	cell	cell	NOUN
dpc-2137	67	22	activity	activity	NOUN
dpc-2137	67	23	.	.	PUNCT
dpc-2137	68	1	patients	patient	NOUN
dpc-2137	68	2	receiving	receive	VERB
dpc-2137	68	3	chronic	chronic	ADJ
dpc-2137	68	4	immunosuppressant	immunosuppressant	ADJ
dpc-2137	68	5	agents	agent	NOUN
dpc-2137	68	6	or	or	CCONJ
dpc-2137	68	7	high	high	ADV
dpc-2137	68	8	-	-	PUNCT
dpc-2137	68	9	dose	dose	VERB
dpc-2137	68	10	steroids	steroid	NOUN
dpc-2137	68	11	are	be	AUX
dpc-2137	68	12	usually	usually	ADV
dpc-2137	68	13	excluded	exclude	VERB
dpc-2137	68	14	from	from	ADP
dpc-2137	68	15	trials	trial	NOUN
dpc-2137	68	16	with	with	ADP
dpc-2137	68	17	icis	icis	PROPN
dpc-2137	68	18	,	,	PUNCT
dpc-2137	68	19	consequently	consequently	ADV
dpc-2137	68	20	,	,	PUNCT
dpc-2137	68	21	data	datum	NOUN
dpc-2137	68	22	in	in	ADP
dpc-2137	68	23	literature	literature	NOUN
dpc-2137	68	24	is	be	AUX
dpc-2137	68	25	limited	limit	VERB
dpc-2137	68	26	.	.	PUNCT
dpc-2137	69	1	experiences	experience	NOUN
dpc-2137	69	2	from	from	ADP
dpc-2137	69	3	ipilimumab	ipilimumab	ADJ
dpc-2137	69	4	trials	trial	NOUN
dpc-2137	69	5	,	,	PUNCT
dpc-2137	69	6	given	give	VERB
dpc-2137	69	7	the	the	DET
dpc-2137	69	8	frequency	frequency	NOUN
dpc-2137	69	9	of	of	ADP
dpc-2137	69	10	primary	primary	ADJ
dpc-2137	69	11	or	or	CCONJ
dpc-2137	69	12	secondary	secondary	ADJ
dpc-2137	69	13	adrenal	adrenal	ADJ
dpc-2137	69	14	insufficiency	insufficiency	NOUN
dpc-2137	69	15	,	,	PUNCT
dpc-2137	69	16	showed	show	VERB
dpc-2137	69	17	that	that	SCONJ
dpc-2137	69	18	a	a	DET
dpc-2137	69	19	physiologic	physiologic	ADJ
dpc-2137	69	20	(	(	PUNCT
dpc-2137	69	21	replacement	replacement	NOUN
dpc-2137	69	22	)	)	PUNCT
dpc-2137	69	23	dose	dose	NOUN
dpc-2137	69	24	of	of	ADP
dpc-2137	69	25	corticosteroids	corticosteroid	NOUN
dpc-2137	69	26	did	do	AUX
dpc-2137	69	27	not	not	PART
dpc-2137	69	28	influence	influence	VERB
dpc-2137	69	29	icis	icis	NOUN
dpc-2137	69	30	activity	activity	NOUN
dpc-2137	69	31	[	[	X
dpc-2137	69	32	31,32	31,32	NUM
dpc-2137	69	33	]	]	PUNCT
dpc-2137	69	34	.	.	PUNCT
dpc-2137	70	1	on	on	ADP
dpc-2137	70	2	the	the	DET
dpc-2137	70	3	other	other	ADJ
dpc-2137	70	4	hand	hand	NOUN
dpc-2137	70	5	,	,	PUNCT
dpc-2137	70	6	patients	patient	NOUN
dpc-2137	70	7	with	with	ADP
dpc-2137	70	8	prior	prior	ADJ
dpc-2137	70	9	autoimmunity	autoimmunity	NOUN
dpc-2137	70	10	receiving	receive	VERB
dpc-2137	70	11	high	high	ADJ
dpc-2137	70	12	-	-	PUNCT
dpc-2137	70	13	dose	dose	NOUN
dpc-2137	70	14	steroids	steroid	NOUN
dpc-2137	70	15	showed	show	VERB
dpc-2137	70	16	less	less	ADJ
dpc-2137	70	17	activity	activity	NOUN
dpc-2137	70	18	of	of	ADP
dpc-2137	70	19	icis	icis	NOUN
dpc-2137	70	20	if	if	SCONJ
dpc-2137	70	21	compared	compare	VERB
dpc-2137	70	22	with	with	ADP
dpc-2137	70	23	patients	patient	NOUN
dpc-2137	70	24	who	who	PRON
dpc-2137	70	25	did	do	AUX
dpc-2137	70	26	not	not	PART
dpc-2137	70	27	need	need	VERB
dpc-2137	70	28	high	high	ADJ
dpc-2137	70	29	-	-	PUNCT
dpc-2137	70	30	dose	dose	NOUN
dpc-2137	70	31	corticosteroids	corticosteroid	NOUN
dpc-2137	70	32	(	(	PUNCT
dpc-2137	70	33	response	response	NOUN
dpc-2137	70	34	rate	rate	NOUN
dpc-2137	70	35	:	:	PUNCT
dpc-2137	70	36	15	15	NUM
dpc-2137	70	37	%	%	NOUN
dpc-2137	70	38	vs	vs	ADP
dpc-2137	70	39	40	40	NUM
dpc-2137	70	40	%	%	NOUN
dpc-2137	70	41	,	,	PUNCT
dpc-2137	70	42	respectively	respectively	ADV
dpc-2137	70	43	)	)	PUNCT
dpc-2137	71	1	[	[	X
dpc-2137	71	2	25	25	NUM
dpc-2137	71	3	]	]	PUNCT
dpc-2137	71	4	.	.	PUNCT
dpc-2137	72	1	a	a	DET
dpc-2137	72	2	study	study	NOUN
dpc-2137	72	3	of	of	ADP
dpc-2137	72	4	ipilimumab	ipilimumab	NOUN
dpc-2137	72	5	in	in	ADP
dpc-2137	72	6	patients	patient	NOUN
dpc-2137	72	7	affected	affect	VERB
dpc-2137	72	8	by	by	ADP
dpc-2137	72	9	metastatic	metastatic	ADJ
dpc-2137	72	10	melanoma	melanoma	NOUN
dpc-2137	72	11	with	with	ADP
dpc-2137	72	12	brain	brain	NOUN
dpc-2137	72	13	metastasis	metastasis	NOUN
dpc-2137	72	14	,	,	PUNCT
dpc-2137	72	15	confirmed	confirm	VERB
dpc-2137	72	16	a	a	DET
dpc-2137	72	17	lower	low	ADJ
dpc-2137	72	18	response	response	NOUN
dpc-2137	72	19	rate	rate	NOUN
dpc-2137	72	20	in	in	ADP
dpc-2137	72	21	patients	patient	NOUN
dpc-2137	72	22	receiving	receive	VERB
dpc-2137	72	23	high	high	ADJ
dpc-2137	72	24	-	-	PUNCT
dpc-2137	72	25	dose	dose	NOUN
dpc-2137	72	26	steroids	steroid	NOUN
dpc-2137	72	27	[	[	X
dpc-2137	72	28	33	33	NUM
dpc-2137	72	29	]	]	PUNCT
dpc-2137	72	30	.	.	PUNCT
dpc-2137	73	1	recently	recently	ADV
dpc-2137	73	2	,	,	PUNCT
dpc-2137	73	3	a	a	DET
dpc-2137	73	4	single	single	ADJ
dpc-2137	73	5	-	-	PUNCT
dpc-2137	73	6	institution	institution	NOUN
dpc-2137	73	7	study	study	NOUN
dpc-2137	73	8	showed	show	VERB
dpc-2137	73	9	that	that	SCONJ
dpc-2137	73	10	the	the	DET
dpc-2137	73	11	early	early	ADJ
dpc-2137	73	12	start	start	NOUN
dpc-2137	73	13	of	of	ADP
dpc-2137	73	14	steroids	steroid	NOUN
dpc-2137	73	15	during	during	ADP
dpc-2137	73	16	immunotherapy	immunotherapy	NOUN
dpc-2137	73	17	could	could	AUX
dpc-2137	73	18	be	be	AUX
dpc-2137	73	19	linked	link	VERB
dpc-2137	73	20	to	to	ADP
dpc-2137	73	21	a	a	DET
dpc-2137	73	22	lower	low	ADJ
dpc-2137	73	23	probability	probability	NOUN
dpc-2137	73	24	of	of	ADP
dpc-2137	73	25	response	response	NOUN
dpc-2137	73	26	and	and	CCONJ
dpc-2137	73	27	lower	low	ADJ
dpc-2137	73	28	survival	survival	NOUN
dpc-2137	74	1	[	[	X
dpc-2137	74	2	34	34	NUM
dpc-2137	74	3	]	]	PUNCT
dpc-2137	74	4	.	.	PUNCT
dpc-2137	75	1	importance	importance	NOUN
dpc-2137	75	2	of	of	ADP
dpc-2137	75	3	considering	consider	VERB
dpc-2137	75	4	“	"	PUNCT
dpc-2137	75	5	special	special	ADJ
dpc-2137	75	6	populations	population	NOUN
dpc-2137	75	7	”	"	PUNCT
dpc-2137	75	8	with	with	ADP
dpc-2137	75	9	cscc	cscc	VERB
dpc-2137	75	10	the	the	DET
dpc-2137	75	11	immune	immune	ADJ
dpc-2137	75	12	suppressed	suppress	VERB
dpc-2137	75	13	population	population	NOUN
dpc-2137	75	14	has	have	VERB
dpc-2137	75	15	an	an	DET
dpc-2137	75	16	incidence	incidence	NOUN
dpc-2137	75	17	of	of	ADP
dpc-2137	75	18	cscc	cscc	NOUN
dpc-2137	75	19	that	that	PRON
dpc-2137	75	20	is	be	AUX
dpc-2137	75	21	65–250	65–250	NUM
dpc-2137	75	22	-	-	PUNCT
dpc-2137	75	23	times	time	NOUN
dpc-2137	75	24	higher	high	ADJ
dpc-2137	75	25	compared	compare	VERB
dpc-2137	75	26	with	with	ADP
dpc-2137	75	27	the	the	DET
dpc-2137	75	28	general	general	ADJ
dpc-2137	75	29	population	population	NOUN
dpc-2137	75	30	.	.	PUNCT
dpc-2137	76	1	this	this	PRON
dpc-2137	76	2	draws	draw	VERB
dpc-2137	76	3	attention	attention	NOUN
dpc-2137	76	4	to	to	ADP
dpc-2137	76	5	the	the	DET
dpc-2137	76	6	central	central	ADJ
dpc-2137	76	7	role	role	NOUN
dpc-2137	76	8	played	play	VERB
dpc-2137	76	9	by	by	ADP
dpc-2137	76	10	the	the	DET
dpc-2137	76	11	immune	immune	ADJ
dpc-2137	76	12	system	system	NOUN
dpc-2137	76	13	in	in	ADP
dpc-2137	76	14	the	the	DET
dpc-2137	76	15	development	development	NOUN
dpc-2137	76	16	of	of	ADP
dpc-2137	76	17	cscc	cscc	NOUN
dpc-2137	76	18	[	[	X
dpc-2137	76	19	35	35	NUM
dpc-2137	76	20	]	]	PUNCT
dpc-2137	76	21	.	.	PUNCT
dpc-2137	77	1	immunosuppression	immunosuppression	NOUN
dpc-2137	77	2	could	could	AUX
dpc-2137	77	3	be	be	AUX
dpc-2137	77	4	iatrogenic	iatrogenic	ADJ
dpc-2137	77	5	,	,	PUNCT
dpc-2137	77	6	usually	usually	ADV
dpc-2137	77	7	due	due	ADJ
dpc-2137	77	8	to	to	ADP
dpc-2137	77	9	therapies	therapy	NOUN
dpc-2137	77	10	used	use	VERB
dpc-2137	77	11	for	for	ADP
dpc-2137	77	12	allogenic	allogenic	ADJ
dpc-2137	77	13	organ	organ	NOUN
dpc-2137	77	14	transplants	transplant	NOUN
dpc-2137	77	15	,	,	PUNCT
dpc-2137	77	16	hematological	hematological	ADJ
dpc-2137	77	17	or	or	CCONJ
dpc-2137	77	18	autoimmune	autoimmune	ADJ
dpc-2137	77	19	diseases	disease	NOUN
dpc-2137	77	20	,	,	PUNCT
dpc-2137	77	21	related	relate	VERB
dpc-2137	77	22	to	to	ADP
dpc-2137	77	23	hiv	hiv	PROPN
dpc-2137	77	24	,	,	PUNCT
dpc-2137	77	25	or	or	CCONJ
dpc-2137	77	26	primary	primary	ADJ
dpc-2137	77	27	immunodeficiency	immunodeficiency	NOUN
dpc-2137	77	28	.	.	PUNCT
dpc-2137	78	1	the	the	DET
dpc-2137	78	2	immune	immune	NOUN
dpc-2137	78	3	-	-	PUNCT
dpc-2137	78	4	suppressed	suppress	VERB
dpc-2137	78	5	population	population	NOUN
dpc-2137	78	6	represents	represent	VERB
dpc-2137	78	7	a	a	DET
dpc-2137	78	8	challenging	challenging	ADJ
dpc-2137	78	9	target	target	NOUN
dpc-2137	78	10	in	in	ADP
dpc-2137	78	11	the	the	DET
dpc-2137	78	12	treatment	treatment	NOUN
dpc-2137	78	13	of	of	ADP
dpc-2137	78	14	advanced	advanced	ADJ
dpc-2137	78	15	or	or	CCONJ
dpc-2137	78	16	metastatic	metastatic	ADJ
dpc-2137	78	17	cscc	cscc	NOUN
dpc-2137	78	18	not	not	PART
dpc-2137	78	19	amenable	amenable	ADJ
dpc-2137	78	20	to	to	ADP
dpc-2137	78	21	locoregional	locoregional	ADJ
dpc-2137	78	22	treatment	treatment	NOUN
dpc-2137	78	23	,	,	PUNCT
dpc-2137	78	24	as	as	SCONJ
dpc-2137	78	25	they	they	PRON
dpc-2137	78	26	present	present	VERB
dpc-2137	78	27	with	with	ADP
dpc-2137	78	28	a	a	DET
dpc-2137	78	29	more	more	ADV
dpc-2137	78	30	aggressive	aggressive	ADJ
dpc-2137	78	31	disease	disease	NOUN
dpc-2137	78	32	and	and	CCONJ
dpc-2137	78	33	with	with	ADP
dpc-2137	78	34	a	a	DET
dpc-2137	78	35	higher	high	ADJ
dpc-2137	78	36	risk	risk	NOUN
dpc-2137	78	37	of	of	ADP
dpc-2137	78	38	developing	develop	VERB
dpc-2137	78	39	immune	immune	ADJ
dpc-2137	78	40	related	relate	VERB
dpc-2137	78	41	toxicities	toxicity	NOUN
dpc-2137	78	42	due	due	ADJ
dpc-2137	78	43	to	to	ADP
dpc-2137	78	44	icis	icis	PROPN
dpc-2137	78	45	.	.	PUNCT
dpc-2137	79	1	cscc	cscc	PROPN
dpc-2137	79	2	grows	grow	VERB
dpc-2137	79	3	more	more	ADV
dpc-2137	79	4	rapidly	rapidly	ADV
dpc-2137	79	5	in	in	ADP
dpc-2137	79	6	immunosuppressed	immunosuppressed	ADJ
dpc-2137	79	7	patients	patient	NOUN
dpc-2137	79	8	and	and	CCONJ
dpc-2137	79	9	has	have	VERB
dpc-2137	79	10	a	a	DET
dpc-2137	79	11	higher	high	ADJ
dpc-2137	79	12	tendency	tendency	NOUN
dpc-2137	79	13	to	to	PART
dpc-2137	79	14	develop	develop	VERB
dpc-2137	79	15	local	local	ADJ
dpc-2137	79	16	and	and	CCONJ
dpc-2137	79	17	distance	distance	NOUN
dpc-2137	79	18	recurrences	recurrence	NOUN
dpc-2137	79	19	[	[	X
dpc-2137	79	20	36	36	NUM
dpc-2137	79	21	]	]	PUNCT
dpc-2137	79	22	.	.	PUNCT
dpc-2137	80	1	moreover	moreover	ADV
dpc-2137	80	2	,	,	PUNCT
dpc-2137	80	3	mortality	mortality	NOUN
dpc-2137	80	4	rates	rate	NOUN
dpc-2137	80	5	are	be	AUX
dpc-2137	80	6	higher	high	ADJ
dpc-2137	80	7	for	for	ADP
dpc-2137	80	8	cscc	cscc	ADJ
dpc-2137	80	9	patients	patient	NOUN
dpc-2137	80	10	with	with	ADP
dpc-2137	80	11	a	a	DET
dpc-2137	80	12	history	history	NOUN
dpc-2137	80	13	of	of	ADP
dpc-2137	80	14	sot	sot	ADJ
dpc-2137	80	15	[	[	X
dpc-2137	80	16	37	37	NUM
dpc-2137	80	17	]	]	PUNCT
dpc-2137	80	18	.	.	PUNCT
dpc-2137	81	1	immunotherapy	immunotherapy	NOUN
dpc-2137	81	2	with	with	ADP
dpc-2137	81	3	icis	icis	PROPN
dpc-2137	81	4	anti	anti	PROPN
dpc-2137	81	5	-	-	PROPN
dpc-2137	81	6	pd-1	pd-1	ADJ
dpc-2137	81	7	(	(	PUNCT
dpc-2137	81	8	cemiplimab	cemiplimab	NOUN
dpc-2137	81	9	and	and	CCONJ
dpc-2137	81	10	pembrolizumab	pembrolizumab	NOUN
dpc-2137	81	11	)	)	PUNCT
dpc-2137	81	12	,	,	PUNCT
dpc-2137	81	13	are	be	AUX
dpc-2137	81	14	now	now	ADV
dpc-2137	81	15	recommended	recommend	VERB
dpc-2137	81	16	as	as	ADP
dpc-2137	81	17	first	first	ADJ
dpc-2137	81	18	-	-	PUNCT
dpc-2137	81	19	line	line	NOUN
dpc-2137	81	20	treatment	treatment	NOUN
dpc-2137	81	21	for	for	ADP
dpc-2137	81	22	patients	patient	NOUN
dpc-2137	81	23	with	with	ADP
dpc-2137	81	24	advanced	advanced	ADJ
dpc-2137	81	25	cscc	cscc	NOUN
dpc-2137	81	26	who	who	PRON
dpc-2137	81	27	are	be	AUX
dpc-2137	81	28	not	not	PART
dpc-2137	81	29	eligible	eligible	ADJ
dpc-2137	81	30	for	for	ADP
dpc-2137	81	31	surgery	surgery	NOUN
dpc-2137	81	32	or	or	CCONJ
dpc-2137	81	33	radiotherapy	radiotherapy	NOUN
dpc-2137	81	34	based	base	VERB
dpc-2137	81	35	on	on	ADP
dpc-2137	81	36	results	result	NOUN
dpc-2137	81	37	of	of	ADP
dpc-2137	81	38	phase	phase	NOUN
dpc-2137	81	39	ii	ii	NOUN
dpc-2137	81	40	clinical	clinical	ADJ
dpc-2137	81	41	trials	trial	NOUN
dpc-2137	81	42	[	[	X
dpc-2137	81	43	6,38,39	6,38,39	NOUN
dpc-2137	81	44	]	]	X
dpc-2137	81	45	.	.	PUNCT
dpc-2137	82	1	however	however	ADV
dpc-2137	82	2	,	,	PUNCT
dpc-2137	82	3	patients	patient	NOUN
dpc-2137	82	4	affected	affect	VERB
dpc-2137	82	5	by	by	ADP
dpc-2137	82	6	autoimmune	autoimmune	ADJ
dpc-2137	82	7	disease	disease	NOUN
dpc-2137	82	8	requiring	require	VERB
dpc-2137	82	9	immunosuppressive	immunosuppressive	ADJ
dpc-2137	82	10	agents	agent	NOUN
dpc-2137	82	11	,	,	PUNCT
dpc-2137	82	12	anamnesis	anamnesis	NOUN
dpc-2137	82	13	of	of	ADP
dpc-2137	82	14	prior	prior	ADJ
dpc-2137	82	15	solid	solid	ADJ
dpc-2137	82	16	organ	organ	NOUN
dpc-2137	82	17	transplant	transplant	NOUN
dpc-2137	82	18	,	,	PUNCT
dpc-2137	82	19	active	active	ADJ
dpc-2137	82	20	viral	viral	ADJ
dpc-2137	82	21	infection	infection	NOUN
dpc-2137	82	22	requiring	require	VERB
dpc-2137	82	23	specific	specific	ADJ
dpc-2137	82	24	therapy	therapy	NOUN
dpc-2137	82	25	,	,	PUNCT
dpc-2137	82	26	such	such	ADJ
dpc-2137	82	27	as	as	ADP
dpc-2137	82	28	hiv	hiv	PROPN
dpc-2137	82	29	or	or	CCONJ
dpc-2137	82	30	hepatitis	hepatitis	PROPN
dpc-2137	82	31	b	b	PROPN
dpc-2137	82	32	virus	virus	NOUN
dpc-2137	82	33	or	or	CCONJ
dpc-2137	82	34	hepatitis	hepatitis	PROPN
dpc-2137	82	35	c	c	PROPN
dpc-2137	82	36	virus	virus	NOUN
dpc-2137	82	37	,	,	PUNCT
dpc-2137	82	38	and	and	CCONJ
dpc-2137	82	39	affected	affect	VERB
dpc-2137	82	40	by	by	ADP
dpc-2137	82	41	chronic	chronic	ADJ
dpc-2137	82	42	lymphocytic	lymphocytic	ADJ
dpc-2137	82	43	leukemia	leukemia	NOUN
dpc-2137	82	44	were	be	AUX
dpc-2137	82	45	4	4	NUM
dpc-2137	82	46	review	review	NOUN
dpc-2137	82	47	|	|	ADV
dpc-2137	82	48	dermatol	dermatol	ADJ
dpc-2137	82	49	pract	pract	NOUN
dpc-2137	82	50	concept	concept	NOUN
dpc-2137	82	51	.	.	PUNCT
dpc-2137	83	1	2021:11(s2):e2021170s	2021:11(s2):e2021170s	NUM
dpc-2137	83	2	excluded	exclude	VERB
dpc-2137	83	3	by	by	ADP
dpc-2137	83	4	registration	registration	NOUN
dpc-2137	83	5	drug	drug	NOUN
dpc-2137	83	6	clinical	clinical	ADJ
dpc-2137	83	7	trials	trial	NOUN
dpc-2137	83	8	.	.	PUNCT
dpc-2137	84	1	in	in	ADP
dpc-2137	84	2	addition	addition	NOUN
dpc-2137	84	3	,	,	PUNCT
dpc-2137	84	4	international	international	ADJ
dpc-2137	84	5	guidelines	guideline	NOUN
dpc-2137	84	6	do	do	AUX
dpc-2137	84	7	not	not	PART
dpc-2137	84	8	give	give	VERB
dpc-2137	84	9	specific	specific	ADJ
dpc-2137	84	10	guidance	guidance	NOUN
dpc-2137	84	11	to	to	PART
dpc-2137	84	12	treat	treat	VERB
dpc-2137	84	13	these	these	DET
dpc-2137	84	14	patiens	patien	NOUN
dpc-2137	84	15	.	.	PUNCT
dpc-2137	85	1	therapeutic	therapeutic	ADJ
dpc-2137	85	2	alternatives	alternative	NOUN
dpc-2137	85	3	for	for	ADP
dpc-2137	85	4	those	those	DET
dpc-2137	85	5	populations	population	NOUN
dpc-2137	85	6	who	who	PRON
dpc-2137	85	7	are	be	AUX
dpc-2137	85	8	excluded	exclude	VERB
dpc-2137	85	9	by	by	ADP
dpc-2137	85	10	clinical	clinical	ADJ
dpc-2137	85	11	trials	trial	NOUN
dpc-2137	85	12	with	with	ADP
dpc-2137	85	13	icis	icis	NOUN
dpc-2137	85	14	are	be	AUX
dpc-2137	85	15	scarce	scarce	ADJ
dpc-2137	85	16	,	,	PUNCT
dpc-2137	85	17	possibly	possibly	ADV
dpc-2137	85	18	limited	limit	VERB
dpc-2137	85	19	by	by	ADP
dpc-2137	85	20	less	less	ADJ
dpc-2137	85	21	activity	activity	NOUN
dpc-2137	85	22	and	and	CCONJ
dpc-2137	85	23	more	more	ADJ
dpc-2137	85	24	toxicity	toxicity	NOUN
dpc-2137	85	25	,	,	PUNCT
dpc-2137	85	26	mainly	mainly	ADV
dpc-2137	85	27	based	base	VERB
dpc-2137	85	28	on	on	ADP
dpc-2137	85	29	platinum	platinum	NOUN
dpc-2137	85	30	-	-	PUNCT
dpc-2137	85	31	based	base	VERB
dpc-2137	85	32	chemotherapy	chemotherapy	NOUN
dpc-2137	85	33	and	and	CCONJ
dpc-2137	85	34	antiegfr	antiegfr	NOUN
dpc-2137	85	35	-	-	PUNCT
dpc-2137	85	36	targeted	target	VERB
dpc-2137	85	37	treatment	treatment	NOUN
dpc-2137	85	38	.	.	PUNCT
dpc-2137	86	1	platinum	platinum	NOUN
dpc-2137	86	2	-	-	PUNCT
dpc-2137	86	3	based	base	VERB
dpc-2137	86	4	chemotherapy	chemotherapy	NOUN
dpc-2137	86	5	for	for	ADP
dpc-2137	86	6	advanced	advanced	ADJ
dpc-2137	86	7	cscc	cscc	NOUN
dpc-2137	86	8	showed	show	VERB
dpc-2137	86	9	an	an	DET
dpc-2137	86	10	objective	objective	ADJ
dpc-2137	86	11	response	response	NOUN
dpc-2137	86	12	rate	rate	NOUN
dpc-2137	86	13	of	of	ADP
dpc-2137	86	14	44	44	NUM
dpc-2137	86	15	%	%	NOUN
dpc-2137	86	16	,	,	PUNCT
dpc-2137	86	17	median	median	ADJ
dpc-2137	86	18	progression	progression	NOUN
dpc-2137	86	19	free	free	ADJ
dpc-2137	86	20	survival	survival	NOUN
dpc-2137	86	21	(	(	PUNCT
dpc-2137	86	22	mpfs	mpfs	PROPN
dpc-2137	86	23	)	)	PUNCT
dpc-2137	86	24	and	and	CCONJ
dpc-2137	86	25	median	median	ADJ
dpc-2137	86	26	overall	overall	ADJ
dpc-2137	86	27	survival	survival	NOUN
dpc-2137	86	28	(	(	PUNCT
dpc-2137	86	29	mos	mos	NOUN
dpc-2137	86	30	)	)	PUNCT
dpc-2137	86	31	was	be	AUX
dpc-2137	86	32	5.5	5.5	NUM
dpc-2137	86	33	months	month	NOUN
dpc-2137	86	34	and	and	CCONJ
dpc-2137	86	35	10.9	10.9	NUM
dpc-2137	86	36	months	month	NOUN
dpc-2137	86	37	,	,	PUNCT
dpc-2137	86	38	respectively	respectively	ADV
dpc-2137	86	39	,	,	PUNCT
dpc-2137	86	40	and	and	CCONJ
dpc-2137	86	41	the	the	DET
dpc-2137	86	42	3	3	NUM
dpc-2137	86	43	-	-	PUNCT
dpc-2137	86	44	year	year	NOUN
dpc-2137	86	45	survival	survival	NOUN
dpc-2137	86	46	was	be	AUX
dpc-2137	86	47	22	22	NUM
dpc-2137	86	48	%	%	NOUN
dpc-2137	87	1	[	[	X
dpc-2137	87	2	40	40	NUM
dpc-2137	87	3	]	]	PUNCT
dpc-2137	87	4	.	.	PUNCT
dpc-2137	88	1	cetuximab	cetuximab	NOUN
dpc-2137	88	2	(	(	PUNCT
dpc-2137	88	3	anti	anti	ADJ
dpc-2137	88	4	-	-	ADJ
dpc-2137	88	5	egfr	egfr	ADJ
dpc-2137	88	6	-	-	PUNCT
dpc-2137	88	7	targeted	target	VERB
dpc-2137	88	8	treatment	treatment	NOUN
dpc-2137	88	9	)	)	PUNCT
dpc-2137	88	10	,	,	PUNCT
dpc-2137	88	11	when	when	SCONJ
dpc-2137	88	12	employed	employ	VERB
dpc-2137	88	13	as	as	ADP
dpc-2137	88	14	monotherapy	monotherapy	NOUN
dpc-2137	88	15	,	,	PUNCT
dpc-2137	88	16	showed	show	VERB
dpc-2137	88	17	27.7	27.7	NUM
dpc-2137	88	18	%	%	NOUN
dpc-2137	88	19	of	of	ADP
dpc-2137	88	20	response	response	NOUN
dpc-2137	88	21	rate	rate	NOUN
dpc-2137	88	22	with	with	ADP
dpc-2137	88	23	2	2	NUM
dpc-2137	88	24	complete	complete	ADJ
dpc-2137	88	25	responses	response	NOUN
dpc-2137	88	26	out	out	ADP
dpc-2137	88	27	of	of	ADP
dpc-2137	88	28	36	36	NUM
dpc-2137	88	29	patients	patient	NOUN
dpc-2137	88	30	,	,	PUNCT
dpc-2137	88	31	responses	response	NOUN
dpc-2137	88	32	were	be	AUX
dpc-2137	88	33	rapid	rapid	ADJ
dpc-2137	88	34	,	,	PUNCT
dpc-2137	88	35	and	and	CCONJ
dpc-2137	88	36	61	61	NUM
dpc-2137	88	37	%	%	NOUN
dpc-2137	88	38	of	of	ADP
dpc-2137	88	39	patients	patient	NOUN
dpc-2137	88	40	had	have	VERB
dpc-2137	88	41	serious	serious	ADJ
dpc-2137	88	42	adverse	adverse	ADJ
dpc-2137	88	43	events	event	NOUN
dpc-2137	88	44	(	(	PUNCT
dpc-2137	88	45	grade	grade	NOUN
dpc-2137	88	46	3–4	3–4	NUM
dpc-2137	88	47	)	)	PUNCT
dpc-2137	89	1	[	[	X
dpc-2137	89	2	41	41	NUM
dpc-2137	89	3	]	]	PUNCT
dpc-2137	89	4	.	.	PUNCT
dpc-2137	90	1	within	within	ADP
dpc-2137	90	2	this	this	DET
dpc-2137	90	3	scenario	scenario	NOUN
dpc-2137	90	4	it	it	PRON
dpc-2137	90	5	becomes	become	VERB
dpc-2137	90	6	strikingly	strikingly	ADV
dpc-2137	90	7	important	important	ADJ
dpc-2137	90	8	to	to	PART
dpc-2137	90	9	balance	balance	VERB
dpc-2137	90	10	risks	risk	NOUN
dpc-2137	90	11	(	(	PUNCT
dpc-2137	90	12	toxicities	toxicity	NOUN
dpc-2137	90	13	)	)	PUNCT
dpc-2137	90	14	and	and	CCONJ
dpc-2137	90	15	benefits	benefit	NOUN
dpc-2137	90	16	(	(	PUNCT
dpc-2137	90	17	efficacy	efficacy	NOUN
dpc-2137	90	18	)	)	PUNCT
dpc-2137	90	19	of	of	ADP
dpc-2137	90	20	icis	icis	PROPN
dpc-2137	90	21	,	,	PUNCT
dpc-2137	90	22	when	when	SCONJ
dpc-2137	90	23	managing	manage	VERB
dpc-2137	90	24	treatment	treatment	NOUN
dpc-2137	90	25	for	for	ADP
dpc-2137	90	26	the	the	DET
dpc-2137	90	27	“	"	PUNCT
dpc-2137	90	28	special	special	ADJ
dpc-2137	90	29	population	population	NOUN
dpc-2137	90	30	”	"	PUNCT
dpc-2137	90	31	excluded	exclude	VERB
dpc-2137	90	32	from	from	ADP
dpc-2137	90	33	icis	icis	NOUN
dpc-2137	90	34	in	in	ADP
dpc-2137	90	35	previous	previous	ADJ
dpc-2137	90	36	clinical	clinical	ADJ
dpc-2137	90	37	trials	trial	NOUN
dpc-2137	90	38	.	.	PUNCT
dpc-2137	91	1	immunotherapy	immunotherapy	NOUN
dpc-2137	91	2	in	in	ADP
dpc-2137	91	3	cscc	cscc	ADJ
dpc-2137	91	4	and	and	CCONJ
dpc-2137	91	5	special	special	ADJ
dpc-2137	91	6	patient	patient	NOUN
dpc-2137	91	7	populations	population	NOUN
dpc-2137	91	8	there	there	PRON
dpc-2137	91	9	is	be	VERB
dpc-2137	91	10	a	a	DET
dpc-2137	91	11	lack	lack	NOUN
dpc-2137	91	12	of	of	ADP
dpc-2137	91	13	prospective	prospective	ADJ
dpc-2137	91	14	data	datum	NOUN
dpc-2137	91	15	in	in	ADP
dpc-2137	91	16	the	the	DET
dpc-2137	91	17	literature	literature	NOUN
dpc-2137	91	18	regarding	regard	VERB
dpc-2137	91	19	immunotherapy	immunotherapy	NOUN
dpc-2137	91	20	in	in	ADP
dpc-2137	91	21	cscc	cscc	ADJ
dpc-2137	91	22	“	"	PUNCT
dpc-2137	91	23	special	special	ADJ
dpc-2137	91	24	populations	population	NOUN
dpc-2137	91	25	”	"	PUNCT
dpc-2137	91	26	.	.	PUNCT
dpc-2137	92	1	data	datum	NOUN
dpc-2137	92	2	are	be	AUX
dpc-2137	92	3	mostly	mostly	ADV
dpc-2137	92	4	derived	derive	VERB
dpc-2137	92	5	from	from	ADP
dpc-2137	92	6	case	case	NOUN
dpc-2137	92	7	reports	report	NOUN
dpc-2137	92	8	,	,	PUNCT
dpc-2137	92	9	case	case	NOUN
dpc-2137	92	10	series	series	NOUN
dpc-2137	92	11	,	,	PUNCT
dpc-2137	92	12	or	or	CCONJ
dpc-2137	92	13	retrospective	retrospective	ADJ
dpc-2137	92	14	data	datum	NOUN
dpc-2137	92	15	.	.	PUNCT
dpc-2137	93	1	an	an	DET
dpc-2137	93	2	immune	immune	NOUN
dpc-2137	93	3	-	-	PUNCT
dpc-2137	93	4	suppressed	suppress	VERB
dpc-2137	93	5	patient	patient	NOUN
dpc-2137	93	6	with	with	ADP
dpc-2137	93	7	hiv	hiv	PROPN
dpc-2137	93	8	and	and	CCONJ
dpc-2137	93	9	metastatic	metastatic	ADJ
dpc-2137	93	10	cscc	cscc	NOUN
dpc-2137	93	11	has	have	AUX
dpc-2137	93	12	been	be	AUX
dpc-2137	93	13	reported	report	VERB
dpc-2137	93	14	to	to	PART
dpc-2137	93	15	experience	experience	VERB
dpc-2137	93	16	stabilization	stabilization	NOUN
dpc-2137	93	17	of	of	ADP
dpc-2137	93	18	disease	disease	NOUN
dpc-2137	93	19	and	and	CCONJ
dpc-2137	93	20	no	no	DET
dpc-2137	93	21	side	side	NOUN
dpc-2137	93	22	effects	effect	NOUN
dpc-2137	93	23	with	with	ADP
dpc-2137	93	24	pembrolizumab	pembrolizumab	NOUN
dpc-2137	93	25	as	as	ADP
dpc-2137	93	26	third	third	ADJ
dpc-2137	93	27	-	-	PUNCT
dpc-2137	93	28	line	line	NOUN
dpc-2137	93	29	systemic	systemic	ADJ
dpc-2137	93	30	treatment	treatment	NOUN
dpc-2137	93	31	[	[	X
dpc-2137	93	32	42	42	NUM
dpc-2137	93	33	]	]	PUNCT
dpc-2137	93	34	.	.	PUNCT
dpc-2137	94	1	a	a	DET
dpc-2137	94	2	patient	patient	NOUN
dpc-2137	94	3	with	with	ADP
dpc-2137	94	4	a	a	DET
dpc-2137	94	5	kidney	kidney	NOUN
dpc-2137	94	6	transplant	transplant	NOUN
dpc-2137	94	7	showed	show	VERB
dpc-2137	94	8	complete	complete	ADJ
dpc-2137	94	9	pathological	pathological	ADJ
dpc-2137	94	10	response	response	NOUN
dpc-2137	94	11	to	to	ADP
dpc-2137	94	12	the	the	DET
dpc-2137	94	13	combination	combination	NOUN
dpc-2137	94	14	of	of	ADP
dpc-2137	94	15	nivolumab	nivolumab	NOUN
dpc-2137	94	16	+	+	CCONJ
dpc-2137	94	17	ipilimumab	ipilimumab	ADJ
dpc-2137	94	18	,	,	PUNCT
dpc-2137	94	19	but	but	CCONJ
dpc-2137	94	20	experienced	experienced	ADJ
dpc-2137	94	21	allograft	allograft	NOUN
dpc-2137	94	22	rejection	rejection	NOUN
dpc-2137	94	23	[	[	X
dpc-2137	94	24	43	43	NUM
dpc-2137	94	25	]	]	PUNCT
dpc-2137	94	26	.	.	PUNCT
dpc-2137	95	1	two	two	NUM
dpc-2137	95	2	other	other	ADJ
dpc-2137	95	3	cases	case	NOUN
dpc-2137	95	4	were	be	AUX
dpc-2137	95	5	affected	affect	VERB
dpc-2137	95	6	by	by	ADP
dpc-2137	95	7	advanced	advanced	ADJ
dpc-2137	95	8	scalp	scalp	NOUN
dpc-2137	95	9	squamous	squamous	ADJ
dpc-2137	95	10	cell	cell	NOUN
dpc-2137	95	11	carcinoma	carcinoma	NOUN
dpc-2137	95	12	and	and	CCONJ
dpc-2137	95	13	kidney	kidney	NOUN
dpc-2137	95	14	transplant	transplant	NOUN
dpc-2137	95	15	recipients	recipient	NOUN
dpc-2137	95	16	have	have	AUX
dpc-2137	95	17	been	be	AUX
dpc-2137	95	18	successfully	successfully	ADV
dpc-2137	95	19	treated	treat	VERB
dpc-2137	95	20	with	with	ADP
dpc-2137	95	21	cemiplimab	cemiplimab	NOUN
dpc-2137	95	22	[	[	X
dpc-2137	95	23	44,45	44,45	X
dpc-2137	95	24	]	]	X
dpc-2137	95	25	.	.	PUNCT
dpc-2137	96	1	real	real	ADJ
dpc-2137	96	2	-	-	PUNCT
dpc-2137	96	3	world	world	NOUN
dpc-2137	96	4	retrospective	retrospective	ADJ
dpc-2137	96	5	series	series	NOUN
dpc-2137	96	6	on	on	ADP
dpc-2137	96	7	patients	patient	NOUN
dpc-2137	96	8	affected	affect	VERB
dpc-2137	96	9	by	by	ADP
dpc-2137	96	10	cscc	cscc	PROPN
dpc-2137	97	1	[	[	X
dpc-2137	97	2	46	46	NUM
dpc-2137	97	3	]	]	PUNCT
dpc-2137	97	4	showed	show	VERB
dpc-2137	97	5	a	a	DET
dpc-2137	97	6	response	response	NOUN
dpc-2137	97	7	rate	rate	NOUN
dpc-2137	97	8	of	of	ADP
dpc-2137	97	9	42	42	NUM
dpc-2137	97	10	%	%	NOUN
dpc-2137	97	11	and	and	CCONJ
dpc-2137	97	12	duration	duration	NOUN
dpc-2137	97	13	of	of	ADP
dpc-2137	97	14	response	response	NOUN
dpc-2137	97	15	of	of	ADP
dpc-2137	97	16	2	2	NUM
dpc-2137	97	17	years	year	NOUN
dpc-2137	97	18	(	(	PUNCT
dpc-2137	97	19	range	range	NOUN
dpc-2137	97	20	:	:	PUNCT
dpc-2137	97	21	1–32	1–32	NUM
dpc-2137	97	22	months	month	NOUN
dpc-2137	97	23	)	)	PUNCT
dpc-2137	97	24	with	with	ADP
dpc-2137	97	25	cemiplimab	cemiplimab	NOUN
dpc-2137	97	26	in	in	ADP
dpc-2137	97	27	immunosuppressed	immunosuppressed	ADJ
dpc-2137	97	28	patients	patient	NOUN
dpc-2137	97	29	,	,	PUNCT
dpc-2137	97	30	described	describe	VERB
dpc-2137	97	31	as	as	ADP
dpc-2137	97	32	patients	patient	NOUN
dpc-2137	97	33	who	who	PRON
dpc-2137	97	34	needs	need	VERB
dpc-2137	97	35	chronic	chronic	ADJ
dpc-2137	97	36	immune	immune	ADJ
dpc-2137	97	37	suppression	suppression	NOUN
dpc-2137	97	38	due	due	ADP
dpc-2137	97	39	to	to	ADP
dpc-2137	97	40	hiv	hiv	PROPN
dpc-2137	97	41	,	,	PUNCT
dpc-2137	97	42	hematologic	hematologic	NOUN
dpc-2137	97	43	malignancies	malignancy	NOUN
dpc-2137	97	44	,	,	PUNCT
dpc-2137	97	45	sot	sot	ADJ
dpc-2137	97	46	recipients	recipient	NOUN
dpc-2137	97	47	,	,	PUNCT
dpc-2137	97	48	and	and	CCONJ
dpc-2137	97	49	autoimmune	autoimmune	ADJ
dpc-2137	97	50	disorders	disorder	NOUN
dpc-2137	97	51	.	.	PUNCT
dpc-2137	98	1	out	out	ADP
dpc-2137	98	2	of	of	ADP
dpc-2137	98	3	5	5	NUM
dpc-2137	98	4	sot	sot	ADJ
dpc-2137	98	5	recipients	recipient	NOUN
dpc-2137	98	6	,	,	PUNCT
dpc-2137	98	7	the	the	DET
dpc-2137	98	8	duration	duration	NOUN
dpc-2137	98	9	of	of	ADP
dpc-2137	98	10	response	response	NOUN
dpc-2137	98	11	was	be	AUX
dpc-2137	98	12	20	20	NUM
dpc-2137	98	13	months	month	NOUN
dpc-2137	98	14	and	and	CCONJ
dpc-2137	98	15	just	just	ADV
dpc-2137	98	16	1	1	NUM
dpc-2137	98	17	patient	patient	NOUN
dpc-2137	98	18	experienced	experience	VERB
dpc-2137	98	19	acute	acute	ADJ
dpc-2137	98	20	allograft	allograft	NOUN
dpc-2137	98	21	rejection	rejection	NOUN
dpc-2137	98	22	.	.	PUNCT
dpc-2137	99	1	a	a	DET
dpc-2137	99	2	low	low	ADJ
dpc-2137	99	3	rate	rate	NOUN
dpc-2137	99	4	of	of	ADP
dpc-2137	99	5	rejection	rejection	NOUN
dpc-2137	99	6	was	be	AUX
dpc-2137	99	7	probably	probably	ADV
dpc-2137	99	8	due	due	ADJ
dpc-2137	99	9	to	to	ADP
dpc-2137	99	10	the	the	DET
dpc-2137	99	11	fact	fact	NOUN
dpc-2137	99	12	that	that	SCONJ
dpc-2137	99	13	3	3	NUM
dpc-2137	99	14	out	out	ADV
dpc-2137	99	15	5	5	NUM
dpc-2137	99	16	sot	sot	ADJ
dpc-2137	99	17	recipients	recipient	NOUN
dpc-2137	99	18	were	be	AUX
dpc-2137	99	19	receiving	receive	VERB
dpc-2137	99	20	immunosuppression	immunosuppression	NOUN
dpc-2137	99	21	with	with	ADP
dpc-2137	99	22	prednisone	prednisone	NOUN
dpc-2137	99	23	+	+	NUM
dpc-2137	99	24	mtor	mtor	NOUN
dpc-2137	99	25	inhibitors	inhibitor	NOUN
dpc-2137	99	26	.	.	PUNCT
dpc-2137	100	1	intriguingly	intriguingly	ADV
dpc-2137	100	2	,	,	PUNCT
dpc-2137	100	3	the	the	DET
dpc-2137	100	4	rate	rate	NOUN
dpc-2137	100	5	of	of	ADP
dpc-2137	100	6	grade	grade	NOUN
dpc-2137	100	7	3	3	NUM
dpc-2137	100	8	or	or	CCONJ
dpc-2137	100	9	4	4	NUM
dpc-2137	100	10	adverse	adverse	ADJ
dpc-2137	100	11	events	event	NOUN
dpc-2137	100	12	(	(	PUNCT
dpc-2137	100	13	21	21	NUM
dpc-2137	100	14	%	%	NOUN
dpc-2137	100	15	)	)	PUNCT
dpc-2137	100	16	was	be	AUX
dpc-2137	100	17	not	not	PART
dpc-2137	100	18	statistically	statistically	ADV
dpc-2137	100	19	different	different	ADJ
dpc-2137	100	20	between	between	ADP
dpc-2137	100	21	the	the	DET
dpc-2137	100	22	immunosuppressed	immunosuppressed	ADJ
dpc-2137	100	23	population	population	NOUN
dpc-2137	100	24	and	and	CCONJ
dpc-2137	100	25	the	the	DET
dpc-2137	100	26	immunocompetent	immunocompetent	ADJ
dpc-2137	100	27	population	population	NOUN
dpc-2137	100	28	.	.	PUNCT
dpc-2137	101	1	all	all	DET
dpc-2137	101	2	patients	patient	NOUN
dpc-2137	101	3	with	with	ADP
dpc-2137	101	4	rheumatologic	rheumatologic	ADJ
dpc-2137	101	5	disease	disease	NOUN
dpc-2137	101	6	experienced	experience	VERB
dpc-2137	101	7	lower	low	ADJ
dpc-2137	101	8	-	-	PUNCT
dpc-2137	101	9	grade	grade	NOUN
dpc-2137	101	10	immune	immune	ADJ
dpc-2137	101	11	exacerbation	exacerbation	NOUN
dpc-2137	101	12	.	.	PUNCT
dpc-2137	102	1	a	a	DET
dpc-2137	102	2	french	french	ADJ
dpc-2137	102	3	case	case	NOUN
dpc-2137	102	4	series	series	NOUN
dpc-2137	102	5	on	on	ADP
dpc-2137	102	6	patients	patient	NOUN
dpc-2137	102	7	receiving	receive	VERB
dpc-2137	102	8	icis	icis	NOUN
dpc-2137	102	9	for	for	ADP
dpc-2137	102	10	advanced	advanced	ADJ
dpc-2137	102	11	cscc	cscc	NOUN
dpc-2137	102	12	[	[	X
dpc-2137	102	13	47	47	NUM
dpc-2137	102	14	]	]	PUNCT
dpc-2137	102	15	showed	show	VERB
dpc-2137	102	16	3	3	NUM
dpc-2137	102	17	serious	serious	ADJ
dpc-2137	102	18	adverse	adverse	ADJ
dpc-2137	102	19	events	event	NOUN
dpc-2137	102	20	out	out	ADP
dpc-2137	102	21	of	of	ADP
dpc-2137	102	22	8	8	NUM
dpc-2137	102	23	immune	immune	NOUN
dpc-2137	102	24	-	-	PUNCT
dpc-2137	102	25	compromised	compromise	VERB
dpc-2137	102	26	patients	patient	NOUN
dpc-2137	102	27	(	(	PUNCT
dpc-2137	102	28	due	due	ADP
dpc-2137	102	29	to	to	ADP
dpc-2137	102	30	hematological	hematological	ADJ
dpc-2137	102	31	disease	disease	NOUN
dpc-2137	102	32	and	and	CCONJ
dpc-2137	102	33	hiv	hiv	NOUN
dpc-2137	102	34	infection	infection	NOUN
dpc-2137	102	35	)	)	PUNCT
dpc-2137	102	36	.	.	PUNCT
dpc-2137	103	1	the	the	DET
dpc-2137	103	2	cemiplimab	cemiplimab	NOUN
dpc-2137	103	3	-	-	PUNCT
dpc-2137	103	4	rwlc	rwlc	NOUN
dpc-2137	103	5	survivorship	survivorship	NOUN
dpc-2137	103	6	and	and	CCONJ
dpc-2137	103	7	epidemiology	epidemiology	NOUN
dpc-2137	103	8	(	(	PUNCT
dpc-2137	103	9	c.a.s.e	c.a.s.e	PROPN
dpc-2137	103	10	.	.	PUNCT
dpc-2137	103	11	)	)	PUNCT
dpc-2137	104	1	study	study	NOUN
dpc-2137	104	2	,	,	PUNCT
dpc-2137	104	3	is	be	AUX
dpc-2137	104	4	a	a	DET
dpc-2137	104	5	prospective	prospective	ADJ
dpc-2137	104	6	study	study	NOUN
dpc-2137	104	7	aimed	aim	VERB
dpc-2137	104	8	at	at	ADP
dpc-2137	104	9	evaluating	evaluate	VERB
dpc-2137	104	10	safety	safety	NOUN
dpc-2137	104	11	and	and	CCONJ
dpc-2137	104	12	effectiveness	effectiveness	NOUN
dpc-2137	104	13	of	of	ADP
dpc-2137	104	14	cemiplimab	cemiplimab	NOUN
dpc-2137	104	15	in	in	ADP
dpc-2137	104	16	a	a	DET
dpc-2137	104	17	real	real	ADJ
dpc-2137	104	18	-	-	PUNCT
dpc-2137	104	19	life	life	NOUN
dpc-2137	104	20	setting	setting	NOUN
dpc-2137	104	21	.	.	PUNCT
dpc-2137	105	1	among	among	ADP
dpc-2137	105	2	the	the	DET
dpc-2137	105	3	138	138	NUM
dpc-2137	105	4	patients	patient	NOUN
dpc-2137	105	5	enrolled	enrol	VERB
dpc-2137	105	6	up	up	ADP
dpc-2137	105	7	to	to	ADP
dpc-2137	105	8	now	now	ADV
dpc-2137	105	9	,	,	PUNCT
dpc-2137	105	10	30	30	NUM
dpc-2137	105	11	were	be	AUX
dpc-2137	105	12	immunocompromised	immunocompromise	VERB
dpc-2137	105	13	or	or	CCONJ
dpc-2137	105	14	immunosuppressed	immunosuppressed	ADJ
dpc-2137	105	15	;	;	PUNCT
dpc-2137	105	16	1	1	NUM
dpc-2137	105	17	patient	patient	NOUN
dpc-2137	105	18	experienced	experience	VERB
dpc-2137	105	19	an	an	DET
dpc-2137	105	20	acute	acute	ADJ
dpc-2137	105	21	renal	renal	ADJ
dpc-2137	105	22	failure	failure	NOUN
dpc-2137	105	23	,	,	PUNCT
dpc-2137	105	24	and	and	CCONJ
dpc-2137	105	25	no	no	DET
dpc-2137	105	26	treatment	treatment	NOUN
dpc-2137	105	27	-	-	PUNCT
dpc-2137	105	28	related	relate	VERB
dpc-2137	105	29	deaths	death	NOUN
dpc-2137	105	30	were	be	AUX
dpc-2137	105	31	reported	report	VERB
dpc-2137	105	32	,	,	PUNCT
dpc-2137	105	33	while	while	SCONJ
dpc-2137	105	34	the	the	DET
dpc-2137	105	35	overall	overall	ADJ
dpc-2137	105	36	response	response	NOUN
dpc-2137	105	37	rate	rate	NOUN
dpc-2137	105	38	(	(	PUNCT
dpc-2137	105	39	45.5	45.5	NUM
dpc-2137	105	40	%	%	NOUN
dpc-2137	105	41	)	)	PUNCT
dpc-2137	105	42	was	be	AUX
dpc-2137	105	43	superimposable	superimposable	ADJ
dpc-2137	105	44	of	of	ADP
dpc-2137	105	45	that	that	PRON
dpc-2137	105	46	obtained	obtain	VERB
dpc-2137	105	47	in	in	ADP
dpc-2137	105	48	other	other	ADJ
dpc-2137	105	49	clinical	clinical	ADJ
dpc-2137	105	50	trials	trial	NOUN
dpc-2137	105	51	with	with	ADP
dpc-2137	105	52	no	no	DET
dpc-2137	105	53	“	"	PUNCT
dpc-2137	105	54	special	special	ADJ
dpc-2137	105	55	populations	population	NOUN
dpc-2137	105	56	”	"	PUNCT
dpc-2137	106	1	[	[	X
dpc-2137	106	2	48	48	NUM
dpc-2137	106	3	]	]	PUNCT
dpc-2137	106	4	.	.	PUNCT
dpc-2137	107	1	conclusion	conclusion	NOUN
dpc-2137	107	2	what	what	PRON
dpc-2137	107	3	to	to	PART
dpc-2137	107	4	do	do	VERB
dpc-2137	107	5	before	before	ADP
dpc-2137	107	6	starting	start	VERB
dpc-2137	107	7	icis	icis	NOUN
dpc-2137	107	8	in	in	ADP
dpc-2137	107	9	a	a	DET
dpc-2137	107	10	cscc	cscc	ADJ
dpc-2137	107	11	special	special	ADJ
dpc-2137	107	12	patient	patient	ADJ
dpc-2137	107	13	population	population	NOUN
dpc-2137	107	14	?	?	PUNCT
dpc-2137	108	1	management	management	NOUN
dpc-2137	108	2	of	of	ADP
dpc-2137	108	3	patients	patient	NOUN
dpc-2137	108	4	with	with	ADP
dpc-2137	108	5	advanced	advanced	ADJ
dpc-2137	108	6	cscc	cscc	NOUN
dpc-2137	108	7	changed	change	VERB
dpc-2137	108	8	with	with	ADP
dpc-2137	108	9	the	the	DET
dpc-2137	108	10	introduction	introduction	NOUN
dpc-2137	108	11	of	of	ADP
dpc-2137	108	12	icis	icis	PROPN
dpc-2137	108	13	;	;	PUNCT
dpc-2137	108	14	however	however	ADV
dpc-2137	108	15	,	,	PUNCT
dpc-2137	108	16	treatment	treatment	NOUN
dpc-2137	108	17	for	for	ADP
dpc-2137	108	18	the	the	DET
dpc-2137	108	19	“	"	PUNCT
dpc-2137	108	20	special	special	ADJ
dpc-2137	108	21	population	population	NOUN
dpc-2137	108	22	”	"	PUNCT
dpc-2137	108	23	remains	remain	VERB
dpc-2137	108	24	an	an	DET
dpc-2137	108	25	important	important	ADJ
dpc-2137	108	26	unmet	unmet	NOUN
dpc-2137	108	27	medical	medical	ADJ
dpc-2137	108	28	need	need	NOUN
dpc-2137	108	29	.	.	PUNCT
dpc-2137	109	1	it	it	PRON
dpc-2137	109	2	is	be	AUX
dpc-2137	109	3	important	important	ADJ
dpc-2137	109	4	to	to	PART
dpc-2137	109	5	carefully	carefully	ADV
dpc-2137	109	6	detail	detail	VERB
dpc-2137	109	7	immunotherapy	immunotherapy	NOUN
dpc-2137	109	8	’s	’s	PART
dpc-2137	109	9	pros	pro	NOUN
dpc-2137	109	10	and	and	CCONJ
dpc-2137	109	11	cons	con	NOUN
dpc-2137	109	12	to	to	ADP
dpc-2137	109	13	patients	patient	NOUN
dpc-2137	109	14	,	,	PUNCT
dpc-2137	109	15	considering	consider	VERB
dpc-2137	109	16	the	the	DET
dpc-2137	109	17	impact	impact	NOUN
dpc-2137	109	18	on	on	ADP
dpc-2137	109	19	prognosis	prognosis	NOUN
dpc-2137	109	20	and	and	CCONJ
dpc-2137	109	21	the	the	DET
dpc-2137	109	22	possible	possible	ADJ
dpc-2137	109	23	toxicities	toxicity	NOUN
dpc-2137	109	24	that	that	PRON
dpc-2137	109	25	could	could	AUX
dpc-2137	109	26	develop	develop	VERB
dpc-2137	109	27	and	and	CCONJ
dpc-2137	109	28	could	could	AUX
dpc-2137	109	29	potentially	potentially	ADV
dpc-2137	109	30	be	be	AUX
dpc-2137	109	31	life	life	NOUN
dpc-2137	109	32	-	-	PUNCT
dpc-2137	109	33	threatening	threatening	ADJ
dpc-2137	109	34	.	.	PUNCT
dpc-2137	110	1	to	to	PART
dpc-2137	110	2	reduce	reduce	VERB
dpc-2137	110	3	the	the	DET
dpc-2137	110	4	risk	risk	NOUN
dpc-2137	110	5	of	of	ADP
dpc-2137	110	6	possible	possible	ADJ
dpc-2137	110	7	immune	immune	ADJ
dpc-2137	110	8	complications	complication	NOUN
dpc-2137	110	9	,	,	PUNCT
dpc-2137	110	10	in	in	ADP
dpc-2137	110	11	the	the	DET
dpc-2137	110	12	case	case	NOUN
dpc-2137	110	13	of	of	ADP
dpc-2137	110	14	sot	sot	ADJ
dpc-2137	110	15	recipients	recipient	NOUN
dpc-2137	110	16	,	,	PUNCT
dpc-2137	110	17	the	the	DET
dpc-2137	110	18	change	change	NOUN
dpc-2137	110	19	of	of	ADP
dpc-2137	110	20	the	the	DET
dpc-2137	110	21	immunosuppressive	immunosuppressive	ADJ
dpc-2137	110	22	regimens	regimen	NOUN
dpc-2137	110	23	from	from	ADP
dpc-2137	110	24	the	the	DET
dpc-2137	110	25	inhibitor	inhibitor	NOUN
dpc-2137	110	26	of	of	ADP
dpc-2137	110	27	calcineurin	calcineurin	NOUN
dpc-2137	110	28	to	to	ADP
dpc-2137	110	29	mtor	mtor	PROPN
dpc-2137	110	30	inhibitors	inhibitor	NOUN
dpc-2137	110	31	is	be	AUX
dpc-2137	110	32	indicated	indicate	VERB
dpc-2137	110	33	.	.	PUNCT
dpc-2137	111	1	steroids	steroid	NOUN
dpc-2137	111	2	are	be	AUX
dpc-2137	111	3	often	often	ADV
dpc-2137	111	4	employed	employ	VERB
dpc-2137	111	5	as	as	ADP
dpc-2137	111	6	preventative	preventative	ADJ
dpc-2137	111	7	measures	measure	NOUN
dpc-2137	111	8	in	in	ADP
dpc-2137	111	9	high	high	ADJ
dpc-2137	111	10	-	-	PUNCT
dpc-2137	111	11	risk	risk	NOUN
dpc-2137	111	12	cases	case	NOUN
dpc-2137	111	13	,	,	PUNCT
dpc-2137	111	14	even	even	ADV
dpc-2137	111	15	if	if	SCONJ
dpc-2137	111	16	there	there	PRON
dpc-2137	111	17	are	be	VERB
dpc-2137	111	18	no	no	DET
dpc-2137	111	19	clear	clear	ADJ
dpc-2137	111	20	dose	dose	NOUN
dpc-2137	111	21	and	and	CCONJ
dpc-2137	111	22	time	time	NOUN
dpc-2137	111	23	indications	indication	NOUN
dpc-2137	111	24	.	.	PUNCT
dpc-2137	112	1	we	we	PRON
dpc-2137	112	2	suggest	suggest	VERB
dpc-2137	112	3	adjusting	adjust	VERB
dpc-2137	112	4	the	the	DET
dpc-2137	112	5	dose	dose	NOUN
dpc-2137	112	6	of	of	ADP
dpc-2137	112	7	steroids	steroid	NOUN
dpc-2137	112	8	according	accord	VERB
dpc-2137	112	9	to	to	ADP
dpc-2137	112	10	the	the	DET
dpc-2137	112	11	foreseen	foreseen	ADJ
dpc-2137	112	12	risk	risk	NOUN
dpc-2137	112	13	and	and	CCONJ
dpc-2137	112	14	the	the	DET
dpc-2137	112	15	developed	develop	VERB
dpc-2137	112	16	toxicities	toxicity	NOUN
dpc-2137	112	17	,	,	PUNCT
dpc-2137	112	18	to	to	PART
dpc-2137	112	19	balance	balance	VERB
dpc-2137	112	20	the	the	DET
dpc-2137	112	21	need	need	NOUN
dpc-2137	112	22	of	of	ADP
dpc-2137	112	23	limiting	limit	VERB
dpc-2137	112	24	adverse	adverse	ADJ
dpc-2137	112	25	effects	effect	NOUN
dpc-2137	112	26	of	of	ADP
dpc-2137	112	27	exaggerated	exaggerated	ADJ
dpc-2137	112	28	immune	immune	ADJ
dpc-2137	112	29	activation	activation	NOUN
dpc-2137	112	30	with	with	ADP
dpc-2137	112	31	the	the	DET
dpc-2137	112	32	possibility	possibility	NOUN
dpc-2137	112	33	to	to	PART
dpc-2137	112	34	achieve	achieve	VERB
dpc-2137	112	35	clinical	clinical	ADJ
dpc-2137	112	36	response	response	NOUN
dpc-2137	112	37	and	and	CCONJ
dpc-2137	112	38	not	not	PART
dpc-2137	112	39	to	to	PART
dpc-2137	112	40	compromise	compromise	VERB
dpc-2137	112	41	therapeutic	therapeutic	ADJ
dpc-2137	112	42	effectiveness	effectiveness	NOUN
dpc-2137	112	43	.	.	PUNCT
dpc-2137	113	1	each	each	DET
dpc-2137	113	2	case	case	NOUN
dpc-2137	113	3	of	of	ADP
dpc-2137	113	4	cscc	cscc	ADJ
dpc-2137	113	5	patient	patient	NOUN
dpc-2137	113	6	belonging	belong	VERB
dpc-2137	113	7	to	to	ADP
dpc-2137	113	8	the	the	DET
dpc-2137	113	9	“	"	PUNCT
dpc-2137	113	10	special	special	ADJ
dpc-2137	113	11	population	population	NOUN
dpc-2137	113	12	”	"	PUNCT
dpc-2137	113	13	needs	need	VERB
dpc-2137	113	14	to	to	PART
dpc-2137	113	15	be	be	AUX
dpc-2137	113	16	discussed	discuss	VERB
dpc-2137	113	17	and	and	CCONJ
dpc-2137	113	18	treated	treat	VERB
dpc-2137	113	19	within	within	ADP
dpc-2137	113	20	a	a	DET
dpc-2137	113	21	multidisciplinary	multidisciplinary	ADJ
dpc-2137	113	22	team	team	NOUN
dpc-2137	113	23	of	of	ADP
dpc-2137	113	24	experts	expert	NOUN
dpc-2137	113	25	,	,	PUNCT
dpc-2137	113	26	aiming	aim	VERB
dpc-2137	113	27	to	to	PART
dpc-2137	113	28	offer	offer	VERB
dpc-2137	113	29	the	the	DET
dpc-2137	113	30	best	good	ADJ
dpc-2137	113	31	possible	possible	ADJ
dpc-2137	113	32	therapeutic	therapeutic	ADJ
dpc-2137	113	33	armamentarium	armamentarium	NOUN
dpc-2137	113	34	built	build	VERB
dpc-2137	113	35	ad	ad	X
dpc-2137	113	36	hoc	hoc	X
dpc-2137	113	37	depending	depend	VERB
dpc-2137	113	38	on	on	ADP
dpc-2137	113	39	the	the	DET
dpc-2137	113	40	required	require	VERB
dpc-2137	113	41	needs	need	NOUN
dpc-2137	113	42	.	.	PUNCT
dpc-2137	114	1	lastly	lastly	ADV
dpc-2137	114	2	,	,	PUNCT
dpc-2137	114	3	considering	consider	VERB
dpc-2137	114	4	constraints	constraint	NOUN
dpc-2137	114	5	of	of	ADP
dpc-2137	114	6	enrolling	enrol	VERB
dpc-2137	114	7	these	these	DET
dpc-2137	114	8	patients	patient	NOUN
dpc-2137	114	9	in	in	ADP
dpc-2137	114	10	randomized	randomized	ADJ
dpc-2137	114	11	clinical	clinical	ADJ
dpc-2137	114	12	trials	trial	NOUN
dpc-2137	114	13	,	,	PUNCT
dpc-2137	114	14	the	the	DET
dpc-2137	114	15	enrollment	enrollment	NOUN
dpc-2137	114	16	of	of	ADP
dpc-2137	114	17	“	"	PUNCT
dpc-2137	114	18	special	special	ADJ
dpc-2137	114	19	patient	patient	NOUN
dpc-2137	114	20	populations	population	NOUN
dpc-2137	114	21	”	"	PUNCT
dpc-2137	114	22	treated	treat	VERB
dpc-2137	114	23	with	with	ADP
dpc-2137	114	24	immunotherapy	immunotherapy	NOUN
dpc-2137	114	25	in	in	ADP
dpc-2137	114	26	observational	observational	ADJ
dpc-2137	114	27	studies	study	NOUN
dpc-2137	114	28	may	may	AUX
dpc-2137	114	29	contribute	contribute	VERB
dpc-2137	114	30	to	to	PART
dpc-2137	114	31	increase	increase	VERB
dpc-2137	114	32	the	the	DET
dpc-2137	114	33	understanding	understanding	NOUN
dpc-2137	114	34	of	of	ADP
dpc-2137	114	35	their	their	PRON
dpc-2137	114	36	treatment	treatment	NOUN
dpc-2137	114	37	opportunities	opportunity	NOUN
dpc-2137	114	38	.	.	PUNCT
dpc-2137	115	1	references	reference	NOUN
dpc-2137	115	2	1	1	NUM
dpc-2137	115	3	.	.	PUNCT
dpc-2137	116	1	rogers	rogers	PROPN
dpc-2137	116	2	hw	hw	PROPN
dpc-2137	116	3	,	,	PUNCT
dpc-2137	116	4	weinstock	weinstock	PROPN
dpc-2137	116	5	ma	ma	PROPN
dpc-2137	116	6	,	,	PUNCT
dpc-2137	116	7	harris	harris	PROPN
dpc-2137	116	8	ar	ar	PROPN
dpc-2137	116	9	,	,	PUNCT
dpc-2137	116	10	et	et	PROPN
dpc-2137	116	11	al	al	PROPN
dpc-2137	116	12	.	.	PUNCT
dpc-2137	116	13	incidence	incidence	ADJ
dpc-2137	116	14	estimate	estimate	NOUN
dpc-2137	116	15	of	of	ADP
dpc-2137	116	16	nonmelanoma	nonmelanoma	ADJ
dpc-2137	116	17	skin	skin	NOUN
dpc-2137	116	18	cancer	cancer	NOUN
dpc-2137	116	19	in	in	ADP
dpc-2137	116	20	the	the	DET
dpc-2137	116	21	united	united	PROPN
dpc-2137	116	22	states	states	PROPN
dpc-2137	116	23	,	,	PUNCT
dpc-2137	116	24	2006	2006	NUM
dpc-2137	116	25	.	.	PUNCT
dpc-2137	117	1	arch	arch	ADJ
dpc-2137	117	2	dermatol	dermatol	NOUN
dpc-2137	117	3	.	.	PUNCT
dpc-2137	118	1	2010;146(3):283	2010;146(3):283	NUM
dpc-2137	118	2	-	-	SYM
dpc-2137	118	3	287	287	NUM
dpc-2137	118	4	.	.	PUNCT
dpc-2137	119	1	doi:10.1001	doi:10.1001	PROPN
dpc-2137	119	2	/	/	SYM
dpc-2137	119	3	archdermatol.2010.19	archdermatol.2010.19	PROPN
dpc-2137	119	4	.	.	PUNCT
dpc-2137	120	1	pmid	pmid	NOUN
dpc-2137	120	2	:	:	PUNCT
dpc-2137	120	3	20231499	20231499	NUM
dpc-2137	120	4	.	.	PUNCT
dpc-2137	121	1	2	2	X
dpc-2137	121	2	.	.	X
dpc-2137	121	3	green	green	PROPN
dpc-2137	121	4	ac	ac	PROPN
dpc-2137	121	5	,	,	PUNCT
dpc-2137	121	6	olsen	olsen	NOUN
dpc-2137	121	7	cm	cm	NOUN
dpc-2137	121	8	.	.	PUNCT
dpc-2137	122	1	cutaneous	cutaneous	ADJ
dpc-2137	122	2	squamous	squamous	ADJ
dpc-2137	122	3	cell	cell	NOUN
dpc-2137	122	4	carcinoma	carcinoma	NOUN
dpc-2137	122	5	:	:	PUNCT
dpc-2137	122	6	an	an	DET
dpc-2137	122	7	epidemiological	epidemiological	ADJ
dpc-2137	122	8	review	review	NOUN
dpc-2137	122	9	.	.	PUNCT
dpc-2137	123	1	br	br	PROPN
dpc-2137	123	2	j	j	PROPN
dpc-2137	123	3	dermatol	dermatol	NOUN
dpc-2137	123	4	.	.	PUNCT
dpc-2137	124	1	2017;177(2):373–81	2017;177(2):373–81	NUM
dpc-2137	124	2	.	.	PUNCT
dpc-2137	124	3	doi	doi	PROPN
dpc-2137	124	4	.	.	PUNCT
dpc-2137	124	5	10.1111	10.1111	NUM
dpc-2137	124	6	/	/	SYM
dpc-2137	124	7	bjd.15324	bjd.15324	PROPN
dpc-2137	124	8	.	.	PUNCT
dpc-2137	125	1	pmid	pmid	NOUN
dpc-2137	125	2	:	:	PUNCT
dpc-2137	125	3	28211039	28211039	NUM
dpc-2137	125	4	.	.	PUNCT
dpc-2137	126	1	review	review	VERB
dpc-2137	126	2	|	|	ADV
dpc-2137	126	3	dermatol	dermatol	ADJ
dpc-2137	126	4	pract	pract	NOUN
dpc-2137	126	5	concept	concept	NOUN
dpc-2137	126	6	.	.	PUNCT
dpc-2137	127	1	2021:11(s2):e2021170s	2021:11(s2):e2021170s	NUM
dpc-2137	127	2	5	5	NUM
dpc-2137	127	3	3	3	NUM
dpc-2137	127	4	.	.	PUNCT
dpc-2137	128	1	boyers	boyer	NOUN
dpc-2137	128	2	ln	ln	PROPN
dpc-2137	128	3	,	,	PUNCT
dpc-2137	128	4	karimkhani	karimkhani	PROPN
dpc-2137	128	5	c	c	PROPN
dpc-2137	128	6	,	,	PUNCT
dpc-2137	128	7	naghavi	naghavi	ADJ
dpc-2137	128	8	m	m	PROPN
dpc-2137	128	9	,	,	PUNCT
dpc-2137	128	10	sherwood	sherwood	PROPN
dpc-2137	128	11	d	d	PROPN
dpc-2137	128	12	,	,	PUNCT
dpc-2137	128	13	margolis	margolis	PROPN
dpc-2137	128	14	dj	dj	PROPN
dpc-2137	128	15	,	,	PUNCT
dpc-2137	128	16	hay	hay	PROPN
dpc-2137	128	17	rj	rj	PROPN
dpc-2137	128	18	,	,	PUNCT
dpc-2137	128	19	et	et	PROPN
dpc-2137	128	20	al	al	PROPN
dpc-2137	128	21	.	.	PUNCT
dpc-2137	129	1	global	global	ADJ
dpc-2137	129	2	mortality	mortality	NOUN
dpc-2137	129	3	from	from	ADP
dpc-2137	129	4	conditions	condition	NOUN
dpc-2137	129	5	with	with	ADP
dpc-2137	129	6	skin	skin	NOUN
dpc-2137	129	7	manifestations	manifestation	NOUN
dpc-2137	129	8	.	.	PUNCT
dpc-2137	130	1	j	j	PROPN
dpc-2137	130	2	am	be	AUX
dpc-2137	130	3	acad	acad	ADJ
dpc-2137	130	4	dermatol	dermatol	NOUN
dpc-2137	130	5	.	.	PUNCT
dpc-2137	131	1	2014;71(6):1137	2014;71(6):1137	NUM
dpc-2137	131	2	-	-	SYM
dpc-2137	131	3	1143.e17	1143.e17	PROPN
dpc-2137	131	4	.	.	PUNCT
dpc-2137	132	1	doi	doi	NOUN
dpc-2137	132	2	:	:	PUNCT
dpc-2137	132	3	10.1016	10.1016	NUM
dpc-2137	132	4	/	/	SYM
dpc-2137	132	5	j.jaad.2014.08.022	j.jaad.2014.08.022	PROPN
dpc-2137	132	6	.	.	PUNCT
dpc-2137	133	1	pmid	pmid	NOUN
dpc-2137	133	2	:	:	PUNCT
dpc-2137	133	3	25282129	25282129	NUM
dpc-2137	133	4	.	.	PUNCT
dpc-2137	134	1	4	4	X
dpc-2137	134	2	.	.	X
dpc-2137	134	3	eisemann	eisemann	PROPN
dpc-2137	134	4	n	n	SYM
dpc-2137	134	5	,	,	PUNCT
dpc-2137	134	6	jansen	jansen	PROPN
dpc-2137	134	7	l	l	PROPN
dpc-2137	134	8	,	,	PUNCT
dpc-2137	134	9	castro	castro	PROPN
dpc-2137	134	10	fa	fa	PROPN
dpc-2137	134	11	,	,	PUNCT
dpc-2137	134	12	et	et	PROPN
dpc-2137	134	13	al	al	PROPN
dpc-2137	134	14	.	.	PROPN
dpc-2137	134	15	survival	survival	PROPN
dpc-2137	134	16	with	with	ADP
dpc-2137	134	17	nonmelanoma	nonmelanoma	PROPN
dpc-2137	134	18	skin	skin	NOUN
dpc-2137	134	19	cancer	cancer	NOUN
dpc-2137	134	20	in	in	ADP
dpc-2137	134	21	germany	germany	PROPN
dpc-2137	134	22	.	.	PUNCT
dpc-2137	135	1	br	br	PROPN
dpc-2137	135	2	j	j	PROPN
dpc-2137	135	3	dermatol	dermatol	NOUN
dpc-2137	135	4	.	.	PUNCT
dpc-2137	136	1	2016;174(4):778–85	2016;174(4):778–85	NUM
dpc-2137	136	2	.	.	PUNCT
dpc-2137	137	1	doi	doi	NOUN
dpc-2137	137	2	:	:	PUNCT
dpc-2137	137	3	10.1111	10.1111	NUM
dpc-2137	137	4	/	/	SYM
dpc-2137	137	5	bjd.14352	bjd.14352	VERB
dpc-2137	137	6	.	.	PUNCT
dpc-2137	138	1	pmid	pmid	NOUN
dpc-2137	138	2	:	:	PUNCT
dpc-2137	138	3	26676514	26676514	NUM
dpc-2137	138	4	.	.	PUNCT
dpc-2137	139	1	5	5	X
dpc-2137	139	2	.	.	X
dpc-2137	139	3	patel	patel	PROPN
dpc-2137	139	4	r	r	PROPN
dpc-2137	139	5	,	,	PUNCT
dpc-2137	139	6	chang	chang	PROPN
dpc-2137	139	7	als	als	PROPN
dpc-2137	139	8	.	.	PUNCT
dpc-2137	140	1	immune	immune	ADJ
dpc-2137	140	2	checkpoint	checkpoint	NOUN
dpc-2137	140	3	inhibitors	inhibitor	NOUN
dpc-2137	140	4	for	for	ADP
dpc-2137	140	5	treating	treat	VERB
dpc-2137	140	6	advanced	advanced	ADJ
dpc-2137	140	7	cutaneous	cutaneous	ADJ
dpc-2137	140	8	squamous	squamous	ADJ
dpc-2137	140	9	cell	cell	NOUN
dpc-2137	140	10	carcinoma	carcinoma	NOUN
dpc-2137	140	11	.	.	PUNCT
dpc-2137	141	1	am	be	AUX
dpc-2137	141	2	j	j	PROPN
dpc-2137	141	3	clin	clin	PROPN
dpc-2137	141	4	dermatol	dermatol	NOUN
dpc-2137	141	5	.	.	PUNCT
dpc-2137	142	1	2019;20(4):477–82	2019;20(4):477–82	X
dpc-2137	142	2	.	.	X
dpc-2137	142	3	doi	doi	NOUN
dpc-2137	142	4	:	:	PUNCT
dpc-2137	142	5	10.1007	10.1007	NUM
dpc-2137	142	6	/	/	SYM
dpc-2137	142	7	s40257	s40257	NOUN
dpc-2137	142	8	-	-	PUNCT
dpc-2137	142	9	01900426	01900426	NUM
dpc-2137	142	10	-	-	PUNCT
dpc-2137	142	11	w.	w.	NOUN
dpc-2137	142	12	pmid	pmid	PROPN
dpc-2137	142	13	:	:	PUNCT
dpc-2137	142	14	30737731	30737731	NUM
dpc-2137	142	15	.	.	PUNCT
dpc-2137	143	1	6	6	NUM
dpc-2137	143	2	.	.	X
dpc-2137	143	3	rischin	rischin	PROPN
dpc-2137	143	4	d	d	PROPN
dpc-2137	143	5	,	,	PUNCT
dpc-2137	143	6	khushalani	khushalani	PROPN
dpc-2137	143	7	ni	ni	PROPN
dpc-2137	143	8	,	,	PUNCT
dpc-2137	143	9	schmults	schmults	PROPN
dpc-2137	143	10	cd	cd	PROPN
dpc-2137	143	11	,	,	PUNCT
dpc-2137	143	12	guminski	guminski	ADJ
dpc-2137	143	13	ad	ad	NOUN
dpc-2137	143	14	,	,	PUNCT
dpc-2137	143	15	chang	chang	PROPN
dpc-2137	143	16	als	als	PROPN
dpc-2137	143	17	,	,	PUNCT
dpc-2137	143	18	lewis	lewis	PROPN
dpc-2137	143	19	kd	kd	PROPN
dpc-2137	143	20	,	,	PUNCT
dpc-2137	143	21	et	et	PROPN
dpc-2137	143	22	al	al	PROPN
dpc-2137	143	23	.	.	PROPN
dpc-2137	143	24	phase	phase	PROPN
dpc-2137	143	25	ii	ii	PROPN
dpc-2137	143	26	study	study	NOUN
dpc-2137	143	27	of	of	ADP
dpc-2137	143	28	cemiplimab	cemiplimab	NOUN
dpc-2137	143	29	in	in	ADP
dpc-2137	143	30	patients	patient	NOUN
dpc-2137	143	31	(	(	PUNCT
dpc-2137	143	32	pts	pt	NOUN
dpc-2137	143	33	)	)	PUNCT
dpc-2137	143	34	with	with	ADP
dpc-2137	143	35	advanced	advanced	ADJ
dpc-2137	143	36	cutaneous	cutaneous	ADJ
dpc-2137	143	37	squamous	squamous	ADJ
dpc-2137	143	38	cell	cell	NOUN
dpc-2137	143	39	carcinoma	carcinoma	NOUN
dpc-2137	143	40	(	(	PUNCT
dpc-2137	143	41	cscc	cscc	ADJ
dpc-2137	143	42	):	):	PUNCT
dpc-2137	143	43	longer	long	ADV
dpc-2137	143	44	follow	follow	VERB
dpc-2137	143	45	-	-	PUNCT
dpc-2137	143	46	up	up	NOUN
dpc-2137	143	47	.	.	PUNCT
dpc-2137	144	1	jco	jco	PROPN
dpc-2137	144	2	.	.	PUNCT
dpc-2137	144	3	2020;38(15_suppl):10018–10018	2020;38(15_suppl):10018–10018	PROPN
dpc-2137	144	4	.	.	PUNCT
dpc-2137	145	1	doi	doi	NOUN
dpc-2137	145	2	:	:	PUNCT
dpc-2137	145	3	10.1200	10.1200	NUM
dpc-2137	145	4	/	/	SYM
dpc-2137	145	5	jco.2020.38.15_suppl.10018	jco.2020.38.15_suppl.10018	NOUN
dpc-2137	145	6	.	.	PUNCT
dpc-2137	146	1	7	7	X
dpc-2137	146	2	.	.	X
dpc-2137	146	3	saha	saha	PROPN
dpc-2137	146	4	a	a	PRON
dpc-2137	146	5	,	,	PUNCT
dpc-2137	146	6	aoyama	aoyama	PROPN
dpc-2137	146	7	k	k	PROPN
dpc-2137	146	8	,	,	PUNCT
dpc-2137	146	9	taylor	taylor	PROPN
dpc-2137	146	10	pa	pa	PROPN
dpc-2137	146	11	,	,	PUNCT
dpc-2137	147	1	et	et	PROPN
dpc-2137	147	2	al	al	PROPN
dpc-2137	147	3	.	.	PROPN
dpc-2137	147	4	host	host	PROPN
dpc-2137	147	5	programmed	program	VERB
dpc-2137	147	6	death	death	NOUN
dpc-2137	147	7	ligand	ligand	NOUN
dpc-2137	147	8	1	1	NUM
dpc-2137	147	9	is	be	AUX
dpc-2137	147	10	dominant	dominant	ADJ
dpc-2137	147	11	over	over	ADP
dpc-2137	147	12	programmed	program	VERB
dpc-2137	147	13	death	death	NOUN
dpc-2137	147	14	ligand	ligand	NOUN
dpc-2137	147	15	2	2	NUM
dpc-2137	147	16	expression	expression	NOUN
dpc-2137	147	17	in	in	ADP
dpc-2137	147	18	regulating	regulate	VERB
dpc-2137	147	19	graft	graft	NOUN
dpc-2137	147	20	-	-	PUNCT
dpc-2137	147	21	versus	versus	ADP
dpc-2137	147	22	-	-	PUNCT
dpc-2137	147	23	host	host	NOUN
dpc-2137	147	24	disease	disease	NOUN
dpc-2137	147	25	lethality	lethality	NOUN
dpc-2137	147	26	.	.	PUNCT
dpc-2137	148	1	blood	blood	NOUN
dpc-2137	148	2	.	.	PUNCT
dpc-2137	149	1	2013;122(17):3062–73	2013;122(17):3062–73	NUM
dpc-2137	149	2	.	.	X
dpc-2137	149	3	doi	doi	NOUN
dpc-2137	149	4	:	:	PUNCT
dpc-2137	149	5	10.1182	10.1182	NUM
dpc-2137	149	6	/	/	SYM
dpc-2137	149	7	blood-2013	blood-2013	NOUN
dpc-2137	149	8	-	-	PUNCT
dpc-2137	149	9	05	05	NUM
dpc-2137	149	10	-	-	PUNCT
dpc-2137	149	11	500801	500801	NUM
dpc-2137	149	12	.	.	PUNCT
dpc-2137	150	1	pmid	pmid	NOUN
dpc-2137	150	2	:	:	PUNCT
dpc-2137	150	3	24030385.pmcid	24030385.pmcid	NUM
dpc-2137	150	4	:	:	PUNCT
dpc-2137	150	5	pmc3811178	pmc3811178	NOUN
dpc-2137	150	6	.	.	PUNCT
dpc-2137	151	1	8	8	X
dpc-2137	151	2	.	.	X
dpc-2137	151	3	johnson	johnson	PROPN
dpc-2137	151	4	db	db	PROPN
dpc-2137	151	5	,	,	PUNCT
dpc-2137	151	6	sullivan	sullivan	PROPN
dpc-2137	151	7	rj	rj	PROPN
dpc-2137	151	8	,	,	PUNCT
dpc-2137	151	9	menzies	menzies	PROPN
dpc-2137	151	10	am	be	AUX
dpc-2137	151	11	.	.	PUNCT
dpc-2137	151	12	immune	immune	ADJ
dpc-2137	151	13	checkpoint	checkpoint	NOUN
dpc-2137	151	14	inhibitors	inhibitor	NOUN
dpc-2137	151	15	in	in	ADP
dpc-2137	151	16	challenging	challenge	VERB
dpc-2137	151	17	populations	population	NOUN
dpc-2137	151	18	:	:	PUNCT
dpc-2137	151	19	immune	immune	ADJ
dpc-2137	151	20	therapy	therapy	NOUN
dpc-2137	151	21	in	in	ADP
dpc-2137	151	22	difficult	difficult	ADJ
dpc-2137	151	23	populations	population	NOUN
dpc-2137	151	24	.	.	PUNCT
dpc-2137	152	1	cancer	cancer	NOUN
dpc-2137	152	2	.	.	PUNCT
dpc-2137	153	1	2017;123(11):1904–11	2017;123(11):1904–11	X
dpc-2137	153	2	.	.	PUNCT
dpc-2137	153	3	doi	doi	NOUN
dpc-2137	153	4	:	:	PUNCT
dpc-2137	153	5	10.1002/	10.1002/	NUM
dpc-2137	153	6	cncr.30642	cncr.30642	X
dpc-2137	153	7	.	.	PUNCT
dpc-2137	154	1	pmid	pmid	NOUN
dpc-2137	154	2	:	:	PUNCT
dpc-2137	154	3	28241095	28241095	NUM
dpc-2137	154	4	.	.	PUNCT
dpc-2137	155	1	pmcid	pmcid	NOUN
dpc-2137	155	2	:	:	PUNCT
dpc-2137	155	3	pmc5445005	pmc5445005	NOUN
dpc-2137	155	4	.	.	PUNCT
dpc-2137	156	1	9	9	X
dpc-2137	156	2	.	.	X
dpc-2137	156	3	chae	chae	PROPN
dpc-2137	156	4	yk	yk	PROPN
dpc-2137	156	5	,	,	PUNCT
dpc-2137	156	6	galvez	galvez	PROPN
dpc-2137	156	7	c	c	PROPN
dpc-2137	156	8	,	,	PUNCT
dpc-2137	156	9	anker	anker	PROPN
dpc-2137	156	10	jf	jf	PROPN
dpc-2137	156	11	,	,	PUNCT
dpc-2137	156	12	iams	iams	PROPN
dpc-2137	156	13	wt	wt	PROPN
dpc-2137	156	14	,	,	PUNCT
dpc-2137	156	15	bhave	bhave	NOUN
dpc-2137	156	16	m.	m.	NOUN
dpc-2137	156	17	cancer	cancer	PROPN
dpc-2137	156	18	immunotherapy	immunotherapy	NOUN
dpc-2137	156	19	in	in	ADP
dpc-2137	156	20	a	a	DET
dpc-2137	156	21	neglected	neglect	VERB
dpc-2137	156	22	population	population	NOUN
dpc-2137	156	23	:	:	PUNCT
dpc-2137	156	24	the	the	DET
dpc-2137	156	25	current	current	ADJ
dpc-2137	156	26	use	use	NOUN
dpc-2137	156	27	and	and	CCONJ
dpc-2137	156	28	future	future	NOUN
dpc-2137	156	29	of	of	ADP
dpc-2137	156	30	t	t	PROPN
dpc-2137	156	31	-	-	PUNCT
dpc-2137	156	32	cell	cell	NOUN
dpc-2137	156	33	-	-	PUNCT
dpc-2137	156	34	mediated	mediate	VERB
dpc-2137	156	35	checkpoint	checkpoint	NOUN
dpc-2137	156	36	inhibitors	inhibitor	NOUN
dpc-2137	156	37	in	in	ADP
dpc-2137	156	38	organ	organ	NOUN
dpc-2137	156	39	transplant	transplant	NOUN
dpc-2137	156	40	patients	patient	NOUN
dpc-2137	156	41	.	.	PUNCT
dpc-2137	157	1	cancer	cancer	NOUN
dpc-2137	157	2	treatment	treatment	NOUN
dpc-2137	157	3	reviews	review	NOUN
dpc-2137	157	4	.	.	PUNCT
dpc-2137	158	1	2018;63:116–21	2018;63:116–21	X
dpc-2137	158	2	.	.	PUNCT
dpc-2137	158	3	doi	doi	PROPN
dpc-2137	158	4	.	.	PUNCT
dpc-2137	159	1	10.1016	10.1016	NUM
dpc-2137	159	2	/	/	SYM
dpc-2137	159	3	j.	j.	PROPN
dpc-2137	159	4	ctrv.2017.12.004	ctrv.2017.12.004	PROPN
dpc-2137	159	5	.	.	PUNCT
dpc-2137	160	1	pmid	pmid	PROPN
dpc-2137	160	2	:	:	PUNCT
dpc-2137	160	3	29276997	29276997	NUM
dpc-2137	160	4	.	.	PUNCT
dpc-2137	161	1	10	10	NUM
dpc-2137	161	2	.	.	PUNCT
dpc-2137	161	3	gassmann	gassmann	PROPN
dpc-2137	161	4	d	d	PROPN
dpc-2137	161	5	,	,	PUNCT
dpc-2137	161	6	weiler	weiler	PROPN
dpc-2137	161	7	s	s	PROPN
dpc-2137	161	8	,	,	PUNCT
dpc-2137	161	9	mertens	mertens	PROPN
dpc-2137	161	10	jc	jc	PROPN
dpc-2137	161	11	,	,	PUNCT
dpc-2137	161	12	reiner	reiner	PROPN
dpc-2137	161	13	cs	cs	PROPN
dpc-2137	161	14	,	,	PUNCT
dpc-2137	161	15	vrugt	vrugt	PROPN
dpc-2137	161	16	b	b	PROPN
dpc-2137	161	17	,	,	PUNCT
dpc-2137	161	18	nägeli	nägeli	PROPN
dpc-2137	161	19	m	m	PROPN
dpc-2137	161	20	,	,	PUNCT
dpc-2137	161	21	et	et	PROPN
dpc-2137	161	22	al	al	PROPN
dpc-2137	161	23	.	.	PUNCT
dpc-2137	162	1	liver	liver	NOUN
dpc-2137	162	2	allograft	allograft	NOUN
dpc-2137	162	3	failure	failure	NOUN
dpc-2137	162	4	after	after	ADP
dpc-2137	162	5	nivolumab	nivolumab	NOUN
dpc-2137	162	6	treatment	treatment	NOUN
dpc-2137	162	7	—	—	PUNCT
dpc-2137	162	8	a	a	DET
dpc-2137	162	9	case	case	NOUN
dpc-2137	162	10	report	report	NOUN
dpc-2137	162	11	with	with	ADP
dpc-2137	162	12	systematic	systematic	ADJ
dpc-2137	162	13	literature	literature	NOUN
dpc-2137	162	14	research	research	NOUN
dpc-2137	162	15	.	.	PUNCT
dpc-2137	163	1	transplantation	transplantation	NOUN
dpc-2137	163	2	direct	direct	ADJ
dpc-2137	163	3	.	.	PUNCT
dpc-2137	164	1	2018;4(8):e376	2018;4(8):e376	NOUN
dpc-2137	164	2	.	.	PUNCT
dpc-2137	165	1	doi	doi	NOUN
dpc-2137	165	2	:	:	PUNCT
dpc-2137	165	3	10.1097	10.1097	NUM
dpc-2137	165	4	/	/	SYM
dpc-2137	165	5	txd.0000000000000814	txd.0000000000000814	NUM
dpc-2137	165	6	.	.	PUNCT
dpc-2137	166	1	pmid	pmid	NOUN
dpc-2137	166	2	:	:	PUNCT
dpc-2137	166	3	30255136	30255136	NUM
dpc-2137	166	4	.	.	PUNCT
dpc-2137	167	1	pmcid	pmcid	ADJ
dpc-2137	167	2	:	:	PUNCT
dpc-2137	167	3	pmc6092180	pmc6092180	NOUN
dpc-2137	167	4	.	.	PUNCT
dpc-2137	168	1	11	11	NUM
dpc-2137	168	2	.	.	X
dpc-2137	168	3	de	de	PROPN
dpc-2137	168	4	bruyn	bruyn	PROPN
dpc-2137	168	5	p	p	NOUN
dpc-2137	168	6	,	,	PUNCT
dpc-2137	168	7	van	van	PROPN
dpc-2137	168	8	gestel	gestel	PROPN
dpc-2137	168	9	d	d	PROPN
dpc-2137	168	10	,	,	PUNCT
dpc-2137	168	11	ost	ost	ADV
dpc-2137	168	12	p	p	NOUN
dpc-2137	168	13	,	,	PUNCT
dpc-2137	168	14	kruse	kruse	PROPN
dpc-2137	168	15	v	v	PROPN
dpc-2137	168	16	,	,	PUNCT
dpc-2137	168	17	brochez	brochez	PROPN
dpc-2137	168	18	l	l	NOUN
dpc-2137	168	19	,	,	PUNCT
dpc-2137	168	20	van	van	PROPN
dpc-2137	168	21	vlierberghe	vlierberghe	PROPN
dpc-2137	168	22	h	h	PROPN
dpc-2137	168	23	,	,	PUNCT
dpc-2137	168	24	et	et	PROPN
dpc-2137	168	25	al	al	PROPN
dpc-2137	168	26	.	.	PROPN
dpc-2137	168	27	immune	immune	ADJ
dpc-2137	168	28	checkpoint	checkpoint	NOUN
dpc-2137	168	29	blockade	blockade	NOUN
dpc-2137	168	30	for	for	ADP
dpc-2137	168	31	organ	organ	NOUN
dpc-2137	168	32	transplant	transplant	NOUN
dpc-2137	168	33	patients	patient	NOUN
dpc-2137	168	34	with	with	ADP
dpc-2137	168	35	advanced	advanced	ADJ
dpc-2137	168	36	cancer	cancer	NOUN
dpc-2137	168	37	:	:	PUNCT
dpc-2137	168	38	how	how	SCONJ
dpc-2137	168	39	far	far	ADV
dpc-2137	168	40	can	can	AUX
dpc-2137	168	41	we	we	PRON
dpc-2137	168	42	go	go	VERB
dpc-2137	168	43	?	?	PUNCT
dpc-2137	169	1	current	current	ADJ
dpc-2137	169	2	opinion	opinion	NOUN
dpc-2137	169	3	in	in	ADP
dpc-2137	169	4	oncology	oncology	NOUN
dpc-2137	169	5	.	.	PUNCT
dpc-2137	170	1	2019;31(2):54–64	2019;31(2):54–64	PROPN
dpc-2137	170	2	.	.	PUNCT
dpc-2137	170	3	doi	doi	PROPN
dpc-2137	170	4	:	:	PUNCT
dpc-2137	170	5	10.1097/	10.1097/	NUM
dpc-2137	170	6	cco.0000000000000505	cco.0000000000000505	NOUN
dpc-2137	170	7	.	.	PUNCT
dpc-2137	171	1	pmid	pmid	NOUN
dpc-2137	171	2	:	:	PUNCT
dpc-2137	171	3	30694841	30694841	NUM
dpc-2137	171	4	.	.	PUNCT
dpc-2137	172	1	12	12	NUM
dpc-2137	172	2	.	.	PUNCT
dpc-2137	173	1	manohar	manohar	PROPN
dpc-2137	173	2	s	s	PROPN
dpc-2137	173	3	,	,	PUNCT
dpc-2137	173	4	thongprayoon	thongprayoon	PROPN
dpc-2137	173	5	c	c	NOUN
dpc-2137	173	6	,	,	PUNCT
dpc-2137	173	7	cheungpasitporn	cheungpasitporn	PROPN
dpc-2137	173	8	w	w	PROPN
dpc-2137	173	9	,	,	PUNCT
dpc-2137	173	10	markovic	markovic	PROPN
dpc-2137	173	11	sn	sn	PROPN
dpc-2137	173	12	,	,	PUNCT
dpc-2137	173	13	herrmann	herrmann	PROPN
dpc-2137	173	14	sm	sm	PROPN
dpc-2137	173	15	.	.	PROPN
dpc-2137	173	16	systematic	systematic	PROPN
dpc-2137	173	17	review	review	NOUN
dpc-2137	173	18	of	of	ADP
dpc-2137	173	19	the	the	DET
dpc-2137	173	20	safety	safety	NOUN
dpc-2137	173	21	of	of	ADP
dpc-2137	173	22	immune	immune	ADJ
dpc-2137	173	23	checkpoint	checkpoint	NOUN
dpc-2137	173	24	inhibitors	inhibitor	NOUN
dpc-2137	173	25	among	among	ADP
dpc-2137	173	26	kidney	kidney	NOUN
dpc-2137	173	27	transplant	transplant	NOUN
dpc-2137	173	28	patients	patient	NOUN
dpc-2137	173	29	.	.	PUNCT
dpc-2137	174	1	kidney	kidney	PROPN
dpc-2137	174	2	international	international	ADJ
dpc-2137	174	3	reports	report	NOUN
dpc-2137	174	4	.	.	PUNCT
dpc-2137	175	1	2020;5(2):149–58	2020;5(2):149–58	NUM
dpc-2137	175	2	.	.	PUNCT
dpc-2137	176	1	doi	doi	NOUN
dpc-2137	176	2	:	:	PUNCT
dpc-2137	176	3	10.1016	10.1016	NUM
dpc-2137	176	4	/	/	SYM
dpc-2137	176	5	j.	j.	PROPN
dpc-2137	176	6	ekir.2019.11.015	ekir.2019.11.015	PROPN
dpc-2137	176	7	.	.	PUNCT
dpc-2137	177	1	pmid	pmid	NOUN
dpc-2137	177	2	:	:	PUNCT
dpc-2137	177	3	32043028	32043028	NUM
dpc-2137	177	4	.	.	PUNCT
dpc-2137	178	1	pmcid	pmcid	NOUN
dpc-2137	178	2	:	:	PUNCT
dpc-2137	178	3	pmc7000848	pmc7000848	NOUN
dpc-2137	178	4	.	.	PUNCT
dpc-2137	179	1	13	13	NUM
dpc-2137	179	2	.	.	PUNCT
dpc-2137	180	1	d’izarny	d’izarny	NOUN
dpc-2137	180	2	-	-	PUNCT
dpc-2137	180	3	gargas	gargas	PROPN
dpc-2137	180	4	t	t	PROPN
dpc-2137	180	5	,	,	PUNCT
dpc-2137	180	6	durrbach	durrbach	VERB
dpc-2137	180	7	a	a	PRON
dpc-2137	180	8	,	,	PUNCT
dpc-2137	180	9	zaidan	zaidan	PROPN
dpc-2137	180	10	m.	m.	NOUN
dpc-2137	180	11	efficacy	efficacy	NOUN
dpc-2137	180	12	and	and	CCONJ
dpc-2137	180	13	tolerance	tolerance	NOUN
dpc-2137	180	14	of	of	ADP
dpc-2137	180	15	immune	immune	ADJ
dpc-2137	180	16	checkpoint	checkpoint	NOUN
dpc-2137	180	17	inhibitors	inhibitor	NOUN
dpc-2137	180	18	in	in	ADP
dpc-2137	180	19	transplant	transplant	NOUN
dpc-2137	180	20	patients	patient	NOUN
dpc-2137	180	21	with	with	ADP
dpc-2137	180	22	cancer	cancer	NOUN
dpc-2137	180	23	:	:	PUNCT
dpc-2137	180	24	a	a	DET
dpc-2137	180	25	systematic	systematic	ADJ
dpc-2137	180	26	review	review	NOUN
dpc-2137	180	27	.	.	PUNCT
dpc-2137	181	1	am	be	AUX
dpc-2137	181	2	j	j	PROPN
dpc-2137	181	3	transplant	transplant	NOUN
dpc-2137	181	4	.	.	PUNCT
dpc-2137	182	1	2020;20(9):2457–65	2020;20(9):2457–65	PROPN
dpc-2137	182	2	.	.	PUNCT
dpc-2137	183	1	doi	doi	NOUN
dpc-2137	183	2	:	:	PUNCT
dpc-2137	183	3	10.1111	10.1111	NUM
dpc-2137	183	4	/	/	SYM
dpc-2137	183	5	ajt.15811	ajt.15811	NOUN
dpc-2137	183	6	.	.	PUNCT
dpc-2137	184	1	pmid	pmid	NOUN
dpc-2137	184	2	:	:	PUNCT
dpc-2137	184	3	32027461	32027461	NUM
dpc-2137	184	4	.	.	PUNCT
dpc-2137	185	1	14	14	NUM
dpc-2137	185	2	.	.	PUNCT
dpc-2137	186	1	esfahani	esfahani	PROPN
dpc-2137	186	2	k	k	PROPN
dpc-2137	186	3	,	,	PUNCT
dpc-2137	186	4	al	al	PROPN
dpc-2137	186	5	-	-	PUNCT
dpc-2137	186	6	aubodah	aubodah	NOUN
dpc-2137	186	7	t	t	PROPN
dpc-2137	186	8	-	-	PUNCT
dpc-2137	186	9	a	a	NOUN
dpc-2137	186	10	,	,	PUNCT
dpc-2137	186	11	thebault	thebault	NOUN
dpc-2137	186	12	p	p	NOUN
dpc-2137	186	13	,	,	PUNCT
dpc-2137	186	14	lapointe	lapointe	PROPN
dpc-2137	186	15	r	r	PROPN
dpc-2137	186	16	,	,	PUNCT
dpc-2137	186	17	hudson	hudson	PROPN
dpc-2137	186	18	m	m	PROPN
dpc-2137	186	19	,	,	PUNCT
dpc-2137	186	20	johnson	johnson	PROPN
dpc-2137	186	21	na	na	PROPN
dpc-2137	186	22	,	,	PUNCT
dpc-2137	186	23	et	et	PROPN
dpc-2137	186	24	al	al	PROPN
dpc-2137	186	25	.	.	PUNCT
dpc-2137	187	1	targeting	target	VERB
dpc-2137	187	2	the	the	DET
dpc-2137	187	3	mtor	mtor	PROPN
dpc-2137	187	4	pathway	pathway	NOUN
dpc-2137	187	5	uncouples	uncouple	VERB
dpc-2137	187	6	the	the	DET
dpc-2137	187	7	efficacy	efficacy	NOUN
dpc-2137	187	8	and	and	CCONJ
dpc-2137	187	9	toxicity	toxicity	NOUN
dpc-2137	187	10	of	of	ADP
dpc-2137	187	11	pd-1	pd-1	ADJ
dpc-2137	187	12	blockade	blockade	NOUN
dpc-2137	187	13	in	in	ADP
dpc-2137	187	14	renal	renal	ADJ
dpc-2137	187	15	transplantation	transplantation	NOUN
dpc-2137	187	16	.	.	PUNCT
dpc-2137	188	1	nat	nat	PROPN
dpc-2137	188	2	commun	commun	PROPN
dpc-2137	188	3	.	.	PUNCT
dpc-2137	189	1	2019;10(1):4712	2019;10(1):4712	PROPN
dpc-2137	189	2	.	.	PUNCT
dpc-2137	190	1	doi	doi	NOUN
dpc-2137	190	2	:	:	PUNCT
dpc-2137	190	3	10.1038	10.1038	NUM
dpc-2137	190	4	/	/	SYM
dpc-2137	190	5	s41467	s41467	NOUN
dpc-2137	190	6	-	-	PUNCT
dpc-2137	190	7	01912628	01912628	NUM
dpc-2137	190	8	-	-	PUNCT
dpc-2137	190	9	1	1	NUM
dpc-2137	190	10	.	.	PUNCT
dpc-2137	191	1	pmid	pmid	NOUN
dpc-2137	191	2	:	:	PUNCT
dpc-2137	191	3	31624262	31624262	NUM
dpc-2137	191	4	.	.	PUNCT
dpc-2137	192	1	pmcid	pmcid	NOUN
dpc-2137	192	2	:	:	PUNCT
dpc-2137	192	3	pmc6797722	pmc6797722	NOUN
dpc-2137	192	4	.	.	PUNCT
dpc-2137	193	1	15	15	X
dpc-2137	193	2	.	.	PUNCT
dpc-2137	194	1	rzeniewicz	rzeniewicz	PROPN
dpc-2137	194	2	k	k	PROPN
dpc-2137	194	3	,	,	PUNCT
dpc-2137	194	4	larkin	larkin	PROPN
dpc-2137	194	5	j	j	PROPN
dpc-2137	194	6	,	,	PUNCT
dpc-2137	194	7	menzies	menzies	PROPN
dpc-2137	194	8	am	be	AUX
dpc-2137	194	9	,	,	PUNCT
dpc-2137	194	10	turajlic	turajlic	ADJ
dpc-2137	194	11	s.	s.	PROPN
dpc-2137	194	12	immunotherapy	immunotherapy	NOUN
dpc-2137	194	13	use	use	VERB
dpc-2137	194	14	outside	outside	ADP
dpc-2137	194	15	clinical	clinical	ADJ
dpc-2137	194	16	trial	trial	NOUN
dpc-2137	194	17	populations	population	NOUN
dpc-2137	194	18	:	:	PUNCT
dpc-2137	194	19	never	never	ADV
dpc-2137	194	20	say	say	VERB
dpc-2137	194	21	never	never	ADV
dpc-2137	194	22	?	?	PUNCT
dpc-2137	195	1	annals	annal	NOUN
dpc-2137	195	2	of	of	ADP
dpc-2137	195	3	oncology	oncology	NOUN
dpc-2137	195	4	.	.	PUNCT
dpc-2137	196	1	2021;32(7):866–80	2021;32(7):866–80	NUM
dpc-2137	196	2	.	.	PUNCT
dpc-2137	196	3	doi	doi	NOUN
dpc-2137	196	4	:	:	PUNCT
dpc-2137	196	5	10.1016	10.1016	NUM
dpc-2137	196	6	/	/	SYM
dpc-2137	196	7	j.annonc.2021.03.199	j.annonc.2021.03.199	PROPN
dpc-2137	196	8	.	.	PUNCT
dpc-2137	197	1	pmid	pmid	NOUN
dpc-2137	197	2	:	:	PUNCT
dpc-2137	197	3	33771665	33771665	NUM
dpc-2137	197	4	.	.	PUNCT
dpc-2137	198	1	16	16	NUM
dpc-2137	198	2	.	.	PUNCT
dpc-2137	199	1	luan	luan	PROPN
dpc-2137	199	2	fl	fl	PROPN
dpc-2137	199	3	,	,	PUNCT
dpc-2137	199	4	hojo	hojo	PROPN
dpc-2137	199	5	m	m	PROPN
dpc-2137	199	6	,	,	PUNCT
dpc-2137	199	7	maluccio	maluccio	PROPN
dpc-2137	199	8	m	m	PROPN
dpc-2137	199	9	,	,	PUNCT
dpc-2137	199	10	yamaji	yamaji	PROPN
dpc-2137	199	11	k	k	PROPN
dpc-2137	199	12	,	,	PUNCT
dpc-2137	199	13	suthanthiran	suthanthiran	VERB
dpc-2137	199	14	m.	m.	NOUN
dpc-2137	199	15	rapamycin	rapamycin	VERB
dpc-2137	199	16	blocks	blocks	ADP
dpc-2137	199	17	tumor	tumor	NOUN
dpc-2137	199	18	progression	progression	NOUN
dpc-2137	199	19	:	:	PUNCT
dpc-2137	199	20	unlinking	unlinke	VERB
dpc-2137	199	21	immunosuppression	immunosuppression	NOUN
dpc-2137	199	22	from	from	ADP
dpc-2137	199	23	antitumor	antitumor	PROPN
dpc-2137	199	24	efficacy1	efficacy1	PROPN
dpc-2137	199	25	.	.	PUNCT
dpc-2137	200	1	transplantation	transplantation	NOUN
dpc-2137	200	2	.	.	PUNCT
dpc-2137	201	1	2002;73(10):1565	2002;73(10):1565	X
dpc-2137	201	2	-	-	SYM
dpc-2137	201	3	1572	1572	NUM
dpc-2137	201	4	.	.	PUNCT
dpc-2137	202	1	doi	doi	NOUN
dpc-2137	202	2	:	:	PUNCT
dpc-2137	202	3	10.1097/00007890	10.1097/00007890	NUM
dpc-2137	202	4	-	-	NOUN
dpc-2137	202	5	20020527000008	20020527000008	NUM
dpc-2137	202	6	.	.	PUNCT
dpc-2137	203	1	pmid	pmid	NOUN
dpc-2137	203	2	:	:	PUNCT
dpc-2137	203	3	12042641	12042641	NUM
dpc-2137	203	4	.	.	PUNCT
dpc-2137	204	1	17	17	NUM
dpc-2137	204	2	.	.	PUNCT
dpc-2137	204	3	karia	karia	PROPN
dpc-2137	204	4	ps	ps	PROPN
dpc-2137	204	5	,	,	PUNCT
dpc-2137	204	6	azzi	azzi	PROPN
dpc-2137	204	7	jr	jr	PROPN
dpc-2137	204	8	,	,	PUNCT
dpc-2137	204	9	heher	heher	PROPN
dpc-2137	204	10	ec	ec	PROPN
dpc-2137	204	11	,	,	PUNCT
dpc-2137	204	12	hills	hills	PROPN
dpc-2137	204	13	vm	vm	PROPN
dpc-2137	204	14	,	,	PUNCT
dpc-2137	204	15	schmults	schmults	PROPN
dpc-2137	204	16	cd	cd	PROPN
dpc-2137	204	17	.	.	PROPN
dpc-2137	204	18	association	association	PROPN
dpc-2137	204	19	of	of	ADP
dpc-2137	204	20	sirolimus	sirolimus	PROPN
dpc-2137	204	21	use	use	NOUN
dpc-2137	204	22	with	with	ADP
dpc-2137	204	23	risk	risk	NOUN
dpc-2137	204	24	for	for	ADP
dpc-2137	204	25	skin	skin	NOUN
dpc-2137	204	26	cancer	cancer	NOUN
dpc-2137	204	27	in	in	ADP
dpc-2137	204	28	a	a	DET
dpc-2137	204	29	mixed	mixed	ADJ
dpc-2137	204	30	-	-	PUNCT
dpc-2137	204	31	organ	organ	NOUN
dpc-2137	204	32	cohort	cohort	NOUN
dpc-2137	204	33	of	of	ADP
dpc-2137	204	34	solid	solid	ADJ
dpc-2137	204	35	-	-	PUNCT
dpc-2137	204	36	organ	organ	NOUN
dpc-2137	204	37	transplant	transplant	NOUN
dpc-2137	204	38	recipients	recipient	NOUN
dpc-2137	204	39	with	with	ADP
dpc-2137	204	40	a	a	DET
dpc-2137	204	41	history	history	NOUN
dpc-2137	204	42	of	of	ADP
dpc-2137	204	43	cancer	cancer	NOUN
dpc-2137	204	44	.	.	PUNCT
dpc-2137	205	1	jama	jama	PROPN
dpc-2137	205	2	dermatol	dermatol	NOUN
dpc-2137	205	3	.	.	PUNCT
dpc-2137	206	1	2016;152(5):533	2016;152(5):533	NUM
dpc-2137	206	2	.	.	PUNCT
dpc-2137	207	1	doi	doi	NOUN
dpc-2137	207	2	:	:	PUNCT
dpc-2137	207	3	10.1001/	10.1001/	NUM
dpc-2137	207	4	jamadermatol.2015.5548	jamadermatol.2015.5548	NOUN
dpc-2137	207	5	.	.	PUNCT
dpc-2137	208	1	pmid	pmid	NOUN
dpc-2137	208	2	:	:	PUNCT
dpc-2137	208	3	26792250	26792250	NUM
dpc-2137	208	4	.	.	PUNCT
dpc-2137	209	1	18	18	NUM
dpc-2137	209	2	.	.	X
dpc-2137	209	3	delanoy	delanoy	PROPN
dpc-2137	209	4	n	n	CCONJ
dpc-2137	209	5	,	,	PUNCT
dpc-2137	209	6	michot	michot	VERB
dpc-2137	209	7	j	j	PROPN
dpc-2137	209	8	-	-	PUNCT
dpc-2137	209	9	m	m	PROPN
dpc-2137	209	10	,	,	PUNCT
dpc-2137	209	11	comont	comont	ADJ
dpc-2137	209	12	t	t	PROPN
dpc-2137	209	13	,	,	PUNCT
dpc-2137	209	14	kramkimel	kramkimel	PROPN
dpc-2137	209	15	n	n	CCONJ
dpc-2137	209	16	,	,	PUNCT
dpc-2137	209	17	lazarovici	lazarovici	PROPN
dpc-2137	209	18	j	j	PROPN
dpc-2137	209	19	,	,	PUNCT
dpc-2137	209	20	dupont	dupont	PROPN
dpc-2137	209	21	r	r	PROPN
dpc-2137	209	22	,	,	PUNCT
dpc-2137	209	23	et	et	PROPN
dpc-2137	209	24	al	al	PROPN
dpc-2137	209	25	.	.	PUNCT
dpc-2137	209	26	haematological	haematological	ADJ
dpc-2137	209	27	immune	immune	NOUN
dpc-2137	209	28	-	-	PUNCT
dpc-2137	209	29	related	relate	VERB
dpc-2137	209	30	adverse	adverse	ADJ
dpc-2137	209	31	events	event	NOUN
dpc-2137	209	32	induced	induce	VERB
dpc-2137	209	33	by	by	ADP
dpc-2137	209	34	anti	anti	ADJ
dpc-2137	209	35	-	-	ADJ
dpc-2137	209	36	pd-1	pd-1	ADJ
dpc-2137	209	37	or	or	CCONJ
dpc-2137	209	38	anti	anti	ADJ
dpc-2137	209	39	-	-	ADJ
dpc-2137	209	40	pd	pd	ADJ
dpc-2137	209	41	-	-	PROPN
dpc-2137	209	42	l1	l1	PROPN
dpc-2137	209	43	immunotherapy	immunotherapy	NOUN
dpc-2137	209	44	:	:	PUNCT
dpc-2137	209	45	a	a	DET
dpc-2137	209	46	descriptive	descriptive	ADJ
dpc-2137	209	47	observational	observational	ADJ
dpc-2137	209	48	study	study	NOUN
dpc-2137	209	49	.	.	PUNCT
dpc-2137	210	1	the	the	DET
dpc-2137	210	2	lancet	lancet	PROPN
dpc-2137	210	3	haematology	haematology	PROPN
dpc-2137	210	4	.	.	PUNCT
dpc-2137	211	1	2019;6(1):e48–57	2019;6(1):e48–57	NOUN
dpc-2137	211	2	.	.	PUNCT
dpc-2137	212	1	doi	doi	NOUN
dpc-2137	212	2	:	:	PUNCT
dpc-2137	212	3	10.1016	10.1016	NUM
dpc-2137	212	4	/	/	SYM
dpc-2137	212	5	s2352	s2352	PROPN
dpc-2137	212	6	-	-	PUNCT
dpc-2137	212	7	3026(18)30175	3026(18)30175	NUM
dpc-2137	212	8	-	-	PUNCT
dpc-2137	212	9	3	3	NUM
dpc-2137	212	10	.	.	NOUN
dpc-2137	212	11	19	19	NUM
dpc-2137	212	12	.	.	NUM
dpc-2137	213	1	haverkos	haverkos	PROPN
dpc-2137	213	2	bm	bm	PROPN
dpc-2137	213	3	,	,	PUNCT
dpc-2137	213	4	abbott	abbott	PROPN
dpc-2137	213	5	d	d	PROPN
dpc-2137	213	6	,	,	PUNCT
dpc-2137	213	7	hamadani	hamadani	PROPN
dpc-2137	213	8	m	m	PROPN
dpc-2137	213	9	,	,	PUNCT
dpc-2137	213	10	armand	armand	PROPN
dpc-2137	213	11	p	p	NOUN
dpc-2137	213	12	,	,	PUNCT
dpc-2137	213	13	flowers	flower	NOUN
dpc-2137	213	14	me	i	PRON
dpc-2137	213	15	,	,	PUNCT
dpc-2137	213	16	merryman	merryman	ADJ
dpc-2137	213	17	r	r	NOUN
dpc-2137	213	18	,	,	PUNCT
dpc-2137	213	19	et	et	PROPN
dpc-2137	213	20	al	al	PROPN
dpc-2137	213	21	.	.	PROPN
dpc-2137	213	22	pd-1	pd-1	ADP
dpc-2137	213	23	blockade	blockade	NOUN
dpc-2137	213	24	for	for	ADP
dpc-2137	213	25	relapsed	relapse	VERB
dpc-2137	213	26	lymphoma	lymphoma	NOUN
dpc-2137	213	27	post	post	ADJ
dpc-2137	213	28	–	–	PUNCT
dpc-2137	213	29	allogeneic	allogeneic	ADJ
dpc-2137	213	30	hematopoietic	hematopoietic	ADJ
dpc-2137	213	31	cell	cell	NOUN
dpc-2137	213	32	transplant	transplant	NOUN
dpc-2137	213	33	:	:	PUNCT
dpc-2137	213	34	high	high	ADJ
dpc-2137	213	35	response	response	NOUN
dpc-2137	213	36	rate	rate	NOUN
dpc-2137	213	37	but	but	CCONJ
dpc-2137	213	38	frequent	frequent	ADJ
dpc-2137	213	39	gvhd	gvhd	NOUN
dpc-2137	213	40	.	.	PUNCT
dpc-2137	214	1	blood	blood	NOUN
dpc-2137	214	2	.	.	PUNCT
dpc-2137	215	1	2017;130(2):221–8	2017;130(2):221–8	NUM
dpc-2137	215	2	.	.	PUNCT
dpc-2137	216	1	doi	doi	NOUN
dpc-2137	216	2	:	:	PUNCT
dpc-2137	216	3	10.1182	10.1182	NUM
dpc-2137	216	4	/	/	SYM
dpc-2137	216	5	blood-2017	blood-2017	NOUN
dpc-2137	216	6	-	-	PUNCT
dpc-2137	216	7	01	01	NUM
dpc-2137	216	8	-	-	PUNCT
dpc-2137	216	9	761346	761346	NUM
dpc-2137	216	10	.	.	PUNCT
dpc-2137	217	1	pmid	pmid	NOUN
dpc-2137	217	2	:	:	PUNCT
dpc-2137	217	3	28468799	28468799	NUM
dpc-2137	217	4	.	.	PUNCT
dpc-2137	218	1	pmcid	pmcid	NOUN
dpc-2137	218	2	:	:	PUNCT
dpc-2137	218	3	pmc5510790	pmc5510790	NOUN
dpc-2137	218	4	.	.	PUNCT
dpc-2137	219	1	20	20	NUM
dpc-2137	219	2	.	.	PUNCT
dpc-2137	220	1	davids	davids	PROPN
dpc-2137	220	2	ms	ms	PROPN
dpc-2137	220	3	,	,	PUNCT
dpc-2137	220	4	kim	kim	PROPN
dpc-2137	220	5	ht	ht	PROPN
dpc-2137	220	6	,	,	PUNCT
dpc-2137	220	7	bachireddy	bachireddy	NOUN
dpc-2137	220	8	p	p	NOUN
dpc-2137	220	9	,	,	PUNCT
dpc-2137	220	10	costello	costello	PROPN
dpc-2137	220	11	c	c	PROPN
dpc-2137	220	12	,	,	PUNCT
dpc-2137	220	13	liguori	liguori	ADJ
dpc-2137	220	14	r	r	NOUN
dpc-2137	220	15	,	,	PUNCT
dpc-2137	220	16	savell	savell	NOUN
dpc-2137	220	17	a	a	X
dpc-2137	220	18	,	,	PUNCT
dpc-2137	220	19	et	et	PROPN
dpc-2137	220	20	al	al	PROPN
dpc-2137	220	21	.	.	PROPN
dpc-2137	220	22	ipilimumab	ipilimumab	PROPN
dpc-2137	220	23	for	for	ADP
dpc-2137	220	24	patients	patient	NOUN
dpc-2137	220	25	with	with	ADP
dpc-2137	220	26	relapse	relapse	NOUN
dpc-2137	220	27	after	after	ADP
dpc-2137	220	28	allogeneic	allogeneic	ADJ
dpc-2137	220	29	transplantation	transplantation	NOUN
dpc-2137	220	30	.	.	PUNCT
dpc-2137	221	1	n	n	CCONJ
dpc-2137	221	2	engl	engl	PROPN
dpc-2137	221	3	j	j	PROPN
dpc-2137	221	4	med	med	PROPN
dpc-2137	221	5	.	.	PUNCT
dpc-2137	222	1	2016;375(2):143–53	2016;375(2):143–53	NUM
dpc-2137	222	2	.	.	PUNCT
dpc-2137	223	1	21	21	NUM
dpc-2137	223	2	.	.	PUNCT
dpc-2137	224	1	ijaz	ijaz	PROPN
dpc-2137	224	2	a	a	PROPN
dpc-2137	224	3	,	,	PUNCT
dpc-2137	224	4	khan	khan	PROPN
dpc-2137	224	5	ay	ay	PROPN
dpc-2137	224	6	,	,	PUNCT
dpc-2137	224	7	malik	malik	PROPN
dpc-2137	224	8	su	su	PROPN
dpc-2137	224	9	,	,	PUNCT
dpc-2137	224	10	faridi	faridi	PROPN
dpc-2137	224	11	w	w	PROPN
dpc-2137	224	12	,	,	PUNCT
dpc-2137	224	13	fraz	fraz	PROPN
dpc-2137	224	14	ma	ma	PROPN
dpc-2137	224	15	,	,	PUNCT
dpc-2137	224	16	usman	usman	PROPN
dpc-2137	224	17	m	m	PROPN
dpc-2137	224	18	,	,	PUNCT
dpc-2137	224	19	et	et	PROPN
dpc-2137	224	20	al	al	PROPN
dpc-2137	224	21	.	.	PUNCT
dpc-2137	225	1	significant	significant	ADJ
dpc-2137	225	2	risk	risk	NOUN
dpc-2137	225	3	of	of	ADP
dpc-2137	225	4	graft	graft	NOUN
dpc-2137	225	5	-	-	PUNCT
dpc-2137	225	6	versus	versus	ADP
dpc-2137	225	7	-	-	PUNCT
dpc-2137	225	8	host	host	NOUN
dpc-2137	225	9	disease	disease	NOUN
dpc-2137	225	10	with	with	ADP
dpc-2137	225	11	exposure	exposure	NOUN
dpc-2137	225	12	to	to	PART
dpc-2137	225	13	checkpoint	checkpoint	VERB
dpc-2137	225	14	inhibitors	inhibitor	NOUN
dpc-2137	225	15	before	before	ADP
dpc-2137	225	16	and	and	CCONJ
dpc-2137	225	17	after	after	ADP
dpc-2137	225	18	allogeneic	allogeneic	ADJ
dpc-2137	225	19	transplantation	transplantation	NOUN
dpc-2137	225	20	.	.	PUNCT
dpc-2137	226	1	biology	biology	NOUN
dpc-2137	226	2	of	of	ADP
dpc-2137	226	3	blood	blood	NOUN
dpc-2137	226	4	and	and	CCONJ
dpc-2137	226	5	marrow	marrow	PROPN
dpc-2137	226	6	transplantation	transplantation	NOUN
dpc-2137	226	7	.	.	PUNCT
dpc-2137	227	1	2019;25(1):94–9	2019;25(1):94–9	X
dpc-2137	227	2	.	.	PUNCT
dpc-2137	228	1	doi	doi	NOUN
dpc-2137	228	2	:	:	PUNCT
dpc-2137	228	3	10.1016	10.1016	NUM
dpc-2137	228	4	/	/	SYM
dpc-2137	228	5	j.bbmt.2018.08.028	j.bbmt.2018.08.028	PROPN
dpc-2137	228	6	.	.	PUNCT
dpc-2137	229	1	pmid	pmid	NOUN
dpc-2137	229	2	:	:	PUNCT
dpc-2137	229	3	30195074	30195074	NUM
dpc-2137	229	4	.	.	PUNCT
dpc-2137	230	1	pmcid	pmcid	NOUN
dpc-2137	230	2	:	:	PUNCT
dpc-2137	230	3	pmc6310648	pmc6310648	VERB
dpc-2137	230	4	.	.	PUNCT
dpc-2137	231	1	22	22	NUM
dpc-2137	231	2	.	.	PUNCT
dpc-2137	232	1	klocke	klocke	PROPN
dpc-2137	232	2	k	k	PROPN
dpc-2137	232	3	,	,	PUNCT
dpc-2137	232	4	sakaguchi	sakaguchi	PROPN
dpc-2137	232	5	s	s	PROPN
dpc-2137	232	6	,	,	PUNCT
dpc-2137	232	7	holmdahl	holmdahl	PROPN
dpc-2137	232	8	r	r	NOUN
dpc-2137	232	9	,	,	PUNCT
dpc-2137	232	10	wing	wing	NOUN
dpc-2137	232	11	k.	k.	NOUN
dpc-2137	232	12	induction	induction	NOUN
dpc-2137	232	13	of	of	ADP
dpc-2137	232	14	autoimmune	autoimmune	ADJ
dpc-2137	232	15	disease	disease	NOUN
dpc-2137	232	16	by	by	ADP
dpc-2137	232	17	deletion	deletion	NOUN
dpc-2137	232	18	of	of	ADP
dpc-2137	232	19	ctla-4	ctla-4	NOUN
dpc-2137	232	20	in	in	ADP
dpc-2137	232	21	mice	mouse	NOUN
dpc-2137	232	22	in	in	ADP
dpc-2137	232	23	adulthood	adulthood	NOUN
dpc-2137	232	24	.	.	PUNCT
dpc-2137	233	1	proc	proc	PROPN
dpc-2137	233	2	natl	natl	PROPN
dpc-2137	233	3	acad	acad	PROPN
dpc-2137	233	4	sci	sci	PROPN
dpc-2137	233	5	usa	usa	PROPN
dpc-2137	233	6	.	.	PROPN
dpc-2137	234	1	2016;113(17):e2383–92	2016;113(17):e2383–92	NUM
dpc-2137	234	2	.	.	PUNCT
dpc-2137	234	3	doi	doi	NOUN
dpc-2137	234	4	:	:	PUNCT
dpc-2137	234	5	10.1073/	10.1073/	NUM
dpc-2137	234	6	pnas.1603892113	pnas.1603892113	PROPN
dpc-2137	234	7	.	.	PUNCT
dpc-2137	235	1	pmid	pmid	NOUN
dpc-2137	235	2	:	:	PUNCT
dpc-2137	235	3	27071130	27071130	NUM
dpc-2137	235	4	.	.	PUNCT
dpc-2137	236	1	pmcid	pmcid	ADJ
dpc-2137	236	2	:	:	PUNCT
dpc-2137	236	3	pmc4855592	pmc4855592	NOUN
dpc-2137	236	4	.	.	PUNCT
dpc-2137	237	1	23	23	NUM
dpc-2137	237	2	.	.	PUNCT
dpc-2137	237	3	khan	khan	PROPN
dpc-2137	237	4	sa	sa	PROPN
dpc-2137	237	5	,	,	PUNCT
dpc-2137	237	6	pruitt	pruitt	PROPN
dpc-2137	237	7	sl	sl	PROPN
dpc-2137	237	8	,	,	PUNCT
dpc-2137	237	9	xuan	xuan	PROPN
dpc-2137	237	10	l	l	PROPN
dpc-2137	237	11	,	,	PUNCT
dpc-2137	237	12	gerber	gerber	PROPN
dpc-2137	237	13	de	de	PROPN
dpc-2137	237	14	.	.	PROPN
dpc-2137	237	15	prevalence	prevalence	NOUN
dpc-2137	237	16	of	of	ADP
dpc-2137	237	17	autoimmune	autoimmune	ADJ
dpc-2137	237	18	disease	disease	NOUN
dpc-2137	237	19	among	among	ADP
dpc-2137	237	20	patients	patient	NOUN
dpc-2137	237	21	with	with	ADP
dpc-2137	237	22	lung	lung	NOUN
dpc-2137	237	23	cancer	cancer	NOUN
dpc-2137	237	24	:	:	PUNCT
dpc-2137	237	25	implications	implication	NOUN
dpc-2137	237	26	for	for	ADP
dpc-2137	237	27	immunotherapy	immunotherapy	NOUN
dpc-2137	237	28	treatment	treatment	NOUN
dpc-2137	237	29	options	option	NOUN
dpc-2137	237	30	.	.	PUNCT
dpc-2137	238	1	jama	jama	PROPN
dpc-2137	238	2	oncol	oncol	ADJ
dpc-2137	238	3	.	.	PUNCT
dpc-2137	239	1	2016;2(11):1507	2016;2(11):1507	X
dpc-2137	239	2	.	.	PUNCT
dpc-2137	240	1	doi	doi	NOUN
dpc-2137	240	2	:	:	PUNCT
dpc-2137	240	3	10.1001	10.1001	NUM
dpc-2137	240	4	/	/	SYM
dpc-2137	240	5	jamaoncol.2016.2238	jamaoncol.2016.2238	PROPN
dpc-2137	240	6	.	.	PUNCT
dpc-2137	241	1	pmid	pmid	NOUN
dpc-2137	241	2	:	:	PUNCT
dpc-2137	241	3	27262099	27262099	NUM
dpc-2137	241	4	.	.	PUNCT
dpc-2137	242	1	pmcid	pmcid	NOUN
dpc-2137	242	2	:	:	PUNCT
dpc-2137	242	3	pmc5656433	pmc5656433	PROPN
dpc-2137	242	4	.	.	PUNCT
dpc-2137	243	1	24	24	NUM
dpc-2137	243	2	.	.	PUNCT
dpc-2137	243	3	johnson	johnson	PROPN
dpc-2137	243	4	db	db	PROPN
dpc-2137	243	5	,	,	PUNCT
dpc-2137	243	6	sullivan	sullivan	PROPN
dpc-2137	243	7	rj	rj	PROPN
dpc-2137	243	8	,	,	PUNCT
dpc-2137	243	9	ott	ott	PROPN
dpc-2137	243	10	pa	pa	PROPN
dpc-2137	243	11	,	,	PUNCT
dpc-2137	243	12	et	et	PROPN
dpc-2137	243	13	al	al	PROPN
dpc-2137	243	14	.	.	PROPN
dpc-2137	243	15	ipilimumab	ipilimumab	PROPN
dpc-2137	243	16	therapy	therapy	NOUN
dpc-2137	243	17	in	in	ADP
dpc-2137	243	18	patients	patient	NOUN
dpc-2137	243	19	with	with	ADP
dpc-2137	243	20	advanced	advanced	ADJ
dpc-2137	243	21	melanoma	melanoma	NOUN
dpc-2137	243	22	and	and	CCONJ
dpc-2137	243	23	preexisting	preexist	VERB
dpc-2137	243	24	autoimmune	autoimmune	ADJ
dpc-2137	243	25	disorders	disorder	NOUN
dpc-2137	243	26	.	.	PUNCT
dpc-2137	244	1	jama	jama	PROPN
dpc-2137	244	2	oncology	oncology	PROPN
dpc-2137	244	3	.	.	PUNCT
dpc-2137	245	1	2016;2(2):234–40	2016;2(2):234–40	NUM
dpc-2137	245	2	.	.	X
dpc-2137	246	1	doi	doi	NOUN
dpc-2137	246	2	:	:	PUNCT
dpc-2137	246	3	10.1001/	10.1001/	NUM
dpc-2137	246	4	jamaoncol.2015.4368	jamaoncol.2015.4368	PROPN
dpc-2137	246	5	.	.	PUNCT
dpc-2137	247	1	pmid	pmid	NOUN
dpc-2137	247	2	:	:	PUNCT
dpc-2137	247	3	26633184	26633184	NUM
dpc-2137	247	4	.	.	PUNCT
dpc-2137	248	1	25	25	NUM
dpc-2137	248	2	.	.	PUNCT
dpc-2137	249	1	menzies	menzies	PROPN
dpc-2137	249	2	am	be	AUX
dpc-2137	249	3	,	,	PUNCT
dpc-2137	249	4	johnson	johnson	PROPN
dpc-2137	249	5	db	db	PROPN
dpc-2137	249	6	,	,	PUNCT
dpc-2137	249	7	ramanujam	ramanujam	VERB
dpc-2137	249	8	s	s	PROPN
dpc-2137	249	9	,	,	PUNCT
dpc-2137	249	10	et	et	PROPN
dpc-2137	249	11	al	al	PROPN
dpc-2137	249	12	.	.	PUNCT
dpc-2137	250	1	anti	anti	ADJ
dpc-2137	250	2	-	-	ADJ
dpc-2137	250	3	pd-1	pd-1	ADJ
dpc-2137	250	4	therapy	therapy	NOUN
dpc-2137	250	5	in	in	ADP
dpc-2137	250	6	patients	patient	NOUN
dpc-2137	250	7	with	with	ADP
dpc-2137	250	8	advanced	advanced	ADJ
dpc-2137	250	9	melanoma	melanoma	NOUN
dpc-2137	250	10	and	and	CCONJ
dpc-2137	250	11	preexisting	preexist	VERB
dpc-2137	250	12	autoimmune	autoimmune	ADJ
dpc-2137	250	13	disorders	disorder	NOUN
dpc-2137	250	14	or	or	CCONJ
dpc-2137	250	15	major	major	ADJ
dpc-2137	250	16	toxicity	toxicity	NOUN
dpc-2137	250	17	with	with	ADP
dpc-2137	250	18	ipilimumab	ipilimumab	NOUN
dpc-2137	250	19	.	.	PUNCT
dpc-2137	251	1	annals	annal	NOUN
dpc-2137	251	2	of	of	ADP
dpc-2137	251	3	oncology	oncology	NOUN
dpc-2137	251	4	.	.	PUNCT
dpc-2137	252	1	2017;28(2):368–76	2017;28(2):368–76	X
dpc-2137	252	2	.	.	PUNCT
dpc-2137	253	1	doi	doi	NOUN
dpc-2137	253	2	:	:	PUNCT
dpc-2137	253	3	10.1093	10.1093	NUM
dpc-2137	253	4	/	/	SYM
dpc-2137	253	5	annonc	annonc	ADJ
dpc-2137	253	6	/	/	SYM
dpc-2137	253	7	mdw443	mdw443	NOUN
dpc-2137	253	8	.	.	PUNCT
dpc-2137	254	1	pmid	pmid	NOUN
dpc-2137	254	2	:	:	PUNCT
dpc-2137	254	3	27687304	27687304	NUM
dpc-2137	254	4	.	.	PUNCT
dpc-2137	255	1	26	26	NUM
dpc-2137	255	2	.	.	PUNCT
dpc-2137	256	1	weinstock	weinstock	PROPN
dpc-2137	256	2	c	c	PROPN
dpc-2137	256	3	,	,	PUNCT
dpc-2137	256	4	singh	singh	PROPN
dpc-2137	256	5	h	h	NOUN
dpc-2137	256	6	,	,	PUNCT
dpc-2137	256	7	maher	maher	PROPN
dpc-2137	256	8	ve	ve	PROPN
dpc-2137	256	9	,	,	PUNCT
dpc-2137	256	10	kim	kim	PROPN
dpc-2137	256	11	g	g	PROPN
dpc-2137	256	12	,	,	PUNCT
dpc-2137	256	13	pazdur	pazdur	PROPN
dpc-2137	256	14	r.	r.	PROPN
dpc-2137	256	15	fda	fda	PROPN
dpc-2137	256	16	analysis	analysis	NOUN
dpc-2137	256	17	of	of	ADP
dpc-2137	256	18	patients	patient	NOUN
dpc-2137	256	19	with	with	ADP
dpc-2137	256	20	baseline	baseline	ADJ
dpc-2137	256	21	autoimmune	autoimmune	ADJ
dpc-2137	256	22	diseases	disease	NOUN
dpc-2137	256	23	treated	treat	VERB
dpc-2137	256	24	with	with	ADP
dpc-2137	256	25	pd-1	pd-1	ADP
dpc-2137	256	26	/	/	SYM
dpc-2137	256	27	pd	pd	ADJ
dpc-2137	256	28	-	-	PROPN
dpc-2137	256	29	l1	l1	PROPN
dpc-2137	256	30	immunotherapy	immunotherapy	NOUN
dpc-2137	256	31	agents	agent	NOUN
dpc-2137	256	32	.	.	PUNCT
dpc-2137	257	1	jco	jco	PROPN
dpc-2137	257	2	.	.	PUNCT
dpc-2137	258	1	2017;35(15_suppl):3018–3018	2017;35(15_suppl):3018–3018	PUNCT
dpc-2137	258	2	.	.	PUNCT
dpc-2137	259	1	doi	doi	NOUN
dpc-2137	259	2	:	:	PUNCT
dpc-2137	259	3	10.1200	10.1200	NUM
dpc-2137	259	4	/	/	SYM
dpc-2137	259	5	jco.2017.35.15_suppl.3018	jco.2017.35.15_suppl.3018	NOUN
dpc-2137	259	6	.	.	PUNCT
dpc-2137	260	1	27	27	NUM
dpc-2137	260	2	.	.	PUNCT
dpc-2137	261	1	danlos	danlos	PROPN
dpc-2137	261	2	f	f	PROPN
dpc-2137	261	3	-	-	PUNCT
dpc-2137	261	4	x	x	PROPN
dpc-2137	261	5	,	,	PUNCT
dpc-2137	261	6	voisin	voisin	X
dpc-2137	261	7	a	a	PROPN
dpc-2137	261	8	-	-	PUNCT
dpc-2137	261	9	l	l	NOUN
dpc-2137	261	10	,	,	PUNCT
dpc-2137	261	11	dyevre	dyevre	NOUN
dpc-2137	261	12	v	v	PROPN
dpc-2137	261	13	,	,	PUNCT
dpc-2137	261	14	et	et	PROPN
dpc-2137	261	15	al	al	PROPN
dpc-2137	261	16	.	.	PROPN
dpc-2137	261	17	safety	safety	NOUN
dpc-2137	261	18	and	and	CCONJ
dpc-2137	261	19	efficacy	efficacy	NOUN
dpc-2137	261	20	of	of	ADP
dpc-2137	261	21	anti	anti	ADJ
dpc-2137	261	22	-	-	ADJ
dpc-2137	261	23	programmed	programmed	ADJ
dpc-2137	261	24	death	death	NOUN
dpc-2137	261	25	1	1	NUM
dpc-2137	261	26	antibodies	antibodie	VERB
dpc-2137	261	27	in	in	ADP
dpc-2137	261	28	patients	patient	NOUN
dpc-2137	261	29	with	with	ADP
dpc-2137	261	30	cancer	cancer	NOUN
dpc-2137	261	31	and	and	CCONJ
dpc-2137	261	32	pre	pre	ADJ
dpc-2137	261	33	-	-	ADJ
dpc-2137	261	34	existing	exist	VERB
dpc-2137	261	35	autoimmune	autoimmune	ADJ
dpc-2137	261	36	or	or	CCONJ
dpc-2137	261	37	inflammatory	inflammatory	ADJ
dpc-2137	261	38	disease	disease	NOUN
dpc-2137	261	39	.	.	PUNCT
dpc-2137	262	1	european	european	PROPN
dpc-2137	262	2	journal	journal	PROPN
dpc-2137	262	3	of	of	ADP
dpc-2137	262	4	cancer	cancer	NOUN
dpc-2137	262	5	.	.	PUNCT
dpc-2137	263	1	2018;91:21–9	2018;91:21–9	NOUN
dpc-2137	263	2	.	.	PUNCT
dpc-2137	263	3	doi	doi	PROPN
dpc-2137	263	4	:	:	PUNCT
dpc-2137	263	5	10.1016	10.1016	NUM
dpc-2137	263	6	/	/	SYM
dpc-2137	263	7	j.ejca.2017.12.008	j.ejca.2017.12.008	PROPN
dpc-2137	263	8	.	.	PUNCT
dpc-2137	264	1	pmid	pmid	NOUN
dpc-2137	264	2	:	:	PUNCT
dpc-2137	264	3	29331748	29331748	NUM
dpc-2137	264	4	.	.	PUNCT
dpc-2137	265	1	28	28	NUM
dpc-2137	265	2	.	.	PUNCT
dpc-2137	265	3	leonardi	leonardi	PROPN
dpc-2137	265	4	gc	gc	PROPN
dpc-2137	265	5	,	,	PUNCT
dpc-2137	265	6	gainor	gainor	PROPN
dpc-2137	265	7	jf	jf	PROPN
dpc-2137	265	8	,	,	PUNCT
dpc-2137	265	9	altan	altan	PROPN
dpc-2137	265	10	m	m	PROPN
dpc-2137	265	11	,	,	PUNCT
dpc-2137	265	12	et	et	PROPN
dpc-2137	265	13	al	al	PROPN
dpc-2137	265	14	.	.	PROPN
dpc-2137	265	15	safety	safety	NOUN
dpc-2137	265	16	of	of	ADP
dpc-2137	265	17	programmed	program	VERB
dpc-2137	265	18	death–1	death–1	NOUN
dpc-2137	265	19	pathway	pathway	NOUN
dpc-2137	265	20	inhibitors	inhibitor	NOUN
dpc-2137	265	21	among	among	ADP
dpc-2137	265	22	patients	patient	NOUN
dpc-2137	265	23	with	with	ADP
dpc-2137	265	24	non	non	ADJ
dpc-2137	265	25	–	–	NOUN
dpc-2137	265	26	smallcell	smallcell	ADJ
dpc-2137	265	27	lung	lung	NOUN
dpc-2137	265	28	cancer	cancer	NOUN
dpc-2137	265	29	and	and	CCONJ
dpc-2137	265	30	preexisting	preexist	VERB
dpc-2137	265	31	autoimmune	autoimmune	ADJ
dpc-2137	265	32	disorders	disorder	NOUN
dpc-2137	265	33	.	.	PUNCT
dpc-2137	266	1	jco	jco	PROPN
dpc-2137	266	2	.	.	PUNCT
dpc-2137	267	1	2018;36(19):1905–12	2018;36(19):1905–12	NUM
dpc-2137	267	2	.	.	PUNCT
dpc-2137	268	1	doi	doi	NOUN
dpc-2137	268	2	:	:	PUNCT
dpc-2137	268	3	10.1200	10.1200	NUM
dpc-2137	268	4	/	/	SYM
dpc-2137	268	5	jco.2017.77.0305	jco.2017.77.0305	PROPN
dpc-2137	268	6	.	.	PUNCT
dpc-2137	269	1	pmid	pmid	NOUN
dpc-2137	269	2	:	:	PUNCT
dpc-2137	269	3	29746230	29746230	NUM
dpc-2137	269	4	.	.	PUNCT
dpc-2137	270	1	29	29	NUM
dpc-2137	270	2	.	.	PUNCT
dpc-2137	270	3	toi	toi	PROPN
dpc-2137	270	4	y	y	PROPN
dpc-2137	270	5	,	,	PUNCT
dpc-2137	270	6	sugawara	sugawara	PROPN
dpc-2137	270	7	s	s	PROPN
dpc-2137	270	8	,	,	PUNCT
dpc-2137	270	9	kawashima	kawashima	PROPN
dpc-2137	270	10	y	y	PROPN
dpc-2137	270	11	,	,	PUNCT
dpc-2137	270	12	et	et	PROPN
dpc-2137	270	13	al	al	PROPN
dpc-2137	270	14	.	.	PROPN
dpc-2137	270	15	association	association	PROPN
dpc-2137	270	16	of	of	ADP
dpc-2137	270	17	immune	immune	NOUN
dpc-2137	270	18	-	-	PUNCT
dpc-2137	270	19	related	relate	VERB
dpc-2137	270	20	adverse	adverse	ADJ
dpc-2137	270	21	events	event	NOUN
dpc-2137	270	22	with	with	ADP
dpc-2137	270	23	clinical	clinical	ADJ
dpc-2137	270	24	benefit	benefit	NOUN
dpc-2137	270	25	in	in	ADP
dpc-2137	270	26	patients	patient	NOUN
dpc-2137	270	27	with	with	ADP
dpc-2137	270	28	6	6	NUM
dpc-2137	270	29	review	review	NOUN
dpc-2137	270	30	|	|	ADV
dpc-2137	270	31	dermatol	dermatol	ADJ
dpc-2137	270	32	pract	pract	NOUN
dpc-2137	270	33	concept	concept	NOUN
dpc-2137	270	34	.	.	PUNCT
dpc-2137	271	1	2021:11(s2):e2021170s	2021:11(s2):e2021170s	NUM
dpc-2137	271	2	advanced	advanced	ADJ
dpc-2137	271	3	non	non	ADJ
dpc-2137	271	4	-	-	ADJ
dpc-2137	271	5	small	small	ADJ
dpc-2137	271	6	-	-	PUNCT
dpc-2137	271	7	cell	cell	NOUN
dpc-2137	271	8	lung	lung	NOUN
dpc-2137	271	9	cancer	cancer	NOUN
dpc-2137	271	10	treated	treat	VERB
dpc-2137	271	11	with	with	ADP
dpc-2137	271	12	nivolumab	nivolumab	NOUN
dpc-2137	271	13	.	.	PUNCT
dpc-2137	272	1	the	the	DET
dpc-2137	272	2	oncol	oncol	ADJ
dpc-2137	272	3	.	.	PUNCT
dpc-2137	273	1	2018;23(11):1358–65	2018;23(11):1358–65	NUM
dpc-2137	273	2	.	.	PUNCT
dpc-2137	274	1	doi	doi	NOUN
dpc-2137	274	2	:	:	PUNCT
dpc-2137	274	3	10.1634	10.1634	NUM
dpc-2137	274	4	/	/	SYM
dpc-2137	274	5	theoncologist.2017	theoncologist.2017	NOUN
dpc-2137	274	6	-	-	PUNCT
dpc-2137	274	7	0384	0384	NUM
dpc-2137	274	8	.	.	PUNCT
dpc-2137	275	1	pmid	pmid	NOUN
dpc-2137	275	2	:	:	PUNCT
dpc-2137	275	3	29934411	29934411	NUM
dpc-2137	275	4	.	.	PUNCT
dpc-2137	276	1	pmcid	pmcid	NOUN
dpc-2137	276	2	:	:	PUNCT
dpc-2137	276	3	pmc6291330	pmc6291330	NOUN
dpc-2137	276	4	.	.	PUNCT
dpc-2137	277	1	30	30	NUM
dpc-2137	277	2	.	.	PUNCT
dpc-2137	278	1	cortellini	cortellini	PROPN
dpc-2137	278	2	a	a	PRON
dpc-2137	278	3	,	,	PUNCT
dpc-2137	278	4	buti	buti	PROPN
dpc-2137	278	5	s	s	PROPN
dpc-2137	278	6	,	,	PUNCT
dpc-2137	278	7	santini	santini	PROPN
dpc-2137	278	8	d	d	PROPN
dpc-2137	278	9	,	,	PUNCT
dpc-2137	278	10	et	et	PROPN
dpc-2137	278	11	al	al	PROPN
dpc-2137	278	12	.	.	PUNCT
dpc-2137	279	1	clinical	clinical	ADJ
dpc-2137	279	2	outcomes	outcome	NOUN
dpc-2137	279	3	of	of	ADP
dpc-2137	279	4	patients	patient	NOUN
dpc-2137	279	5	with	with	ADP
dpc-2137	279	6	advanced	advanced	ADJ
dpc-2137	279	7	cancer	cancer	NOUN
dpc-2137	279	8	and	and	CCONJ
dpc-2137	279	9	pre	pre	ADJ
dpc-2137	279	10	-	-	ADJ
dpc-2137	279	11	existing	existing	ADJ
dpc-2137	279	12	autoimmune	autoimmune	ADJ
dpc-2137	279	13	diseases	disease	NOUN
dpc-2137	279	14	treated	treat	VERB
dpc-2137	279	15	with	with	ADP
dpc-2137	279	16	anti	anti	ADJ
dpc-2137	279	17	-	-	ADJ
dpc-2137	279	18	programmed	program	VERB
dpc-2137	279	19	death-1	death-1	NUM
dpc-2137	279	20	immunotherapy	immunotherapy	NOUN
dpc-2137	279	21	:	:	PUNCT
dpc-2137	279	22	a	a	DET
dpc-2137	279	23	real	real	ADJ
dpc-2137	279	24	-	-	PUNCT
dpc-2137	279	25	world	world	NOUN
dpc-2137	279	26	transverse	transverse	NOUN
dpc-2137	279	27	study	study	NOUN
dpc-2137	279	28	.	.	PUNCT
dpc-2137	280	1	the	the	DET
dpc-2137	280	2	oncol	oncol	ADJ
dpc-2137	280	3	.	.	PUNCT
dpc-2137	281	1	2019;24(6):e327	2019;24(6):e327	NUM
dpc-2137	281	2	-	-	PUNCT
dpc-2137	281	3	e337	e337	PROPN
dpc-2137	281	4	.	.	PUNCT
dpc-2137	282	1	doi	doi	NOUN
dpc-2137	282	2	:	:	PUNCT
dpc-2137	282	3	10.1634	10.1634	NUM
dpc-2137	282	4	/	/	SYM
dpc-2137	282	5	theoncologist.2018	theoncologist.2018	NOUN
dpc-2137	282	6	-	-	PUNCT
dpc-2137	282	7	0618	0618	NUM
dpc-2137	282	8	.	.	PUNCT
dpc-2137	283	1	pmid	pmid	NOUN
dpc-2137	283	2	:	:	PUNCT
dpc-2137	283	3	30796151	30796151	NUM
dpc-2137	283	4	.	.	PUNCT
dpc-2137	284	1	pmcid	pmcid	NOUN
dpc-2137	284	2	:	:	PUNCT
dpc-2137	284	3	pmc6656514	pmc6656514	NOUN
dpc-2137	284	4	.	.	PUNCT
dpc-2137	285	1	31	31	NUM
dpc-2137	285	2	.	.	PUNCT
dpc-2137	286	1	ribas	ribas	PROPN
dpc-2137	286	2	a	a	PRON
dpc-2137	286	3	,	,	PUNCT
dpc-2137	286	4	puzanov	puzanov	NOUN
dpc-2137	286	5	i	i	PROPN
dpc-2137	286	6	,	,	PUNCT
dpc-2137	286	7	dummer	dummer	PROPN
dpc-2137	286	8	r	r	PROPN
dpc-2137	286	9	,	,	PUNCT
dpc-2137	286	10	schadendorf	schadendorf	PROPN
dpc-2137	286	11	d	d	PROPN
dpc-2137	286	12	,	,	PUNCT
dpc-2137	286	13	hamid	hamid	PROPN
dpc-2137	286	14	o	o	PROPN
dpc-2137	286	15	,	,	PUNCT
dpc-2137	286	16	robert	robert	PROPN
dpc-2137	286	17	c	c	PROPN
dpc-2137	286	18	,	,	PUNCT
dpc-2137	286	19	et	et	PROPN
dpc-2137	286	20	al	al	PROPN
dpc-2137	286	21	.	.	PROPN
dpc-2137	286	22	pembrolizumab	pembrolizumab	NOUN
dpc-2137	286	23	versus	versus	ADP
dpc-2137	286	24	investigator	investigator	NOUN
dpc-2137	286	25	-	-	PUNCT
dpc-2137	286	26	choice	choice	NOUN
dpc-2137	286	27	chemotherapy	chemotherapy	NOUN
dpc-2137	286	28	for	for	ADP
dpc-2137	286	29	ipilimumab	ipilimumab	ADJ
dpc-2137	286	30	-	-	PUNCT
dpc-2137	286	31	refractory	refractory	NOUN
dpc-2137	286	32	melanoma	melanoma	NOUN
dpc-2137	286	33	(	(	PUNCT
dpc-2137	286	34	keynote-002	keynote-002	PROPN
dpc-2137	286	35	):	):	PUNCT
dpc-2137	286	36	a	a	DET
dpc-2137	286	37	randomised	randomise	VERB
dpc-2137	286	38	,	,	PUNCT
dpc-2137	286	39	controlled	control	VERB
dpc-2137	286	40	,	,	PUNCT
dpc-2137	286	41	phase	phase	NOUN
dpc-2137	286	42	2	2	NUM
dpc-2137	286	43	trial	trial	NOUN
dpc-2137	286	44	.	.	PUNCT
dpc-2137	287	1	the	the	DET
dpc-2137	287	2	lancet	lancet	PROPN
dpc-2137	287	3	oncology	oncology	NOUN
dpc-2137	287	4	.	.	PUNCT
dpc-2137	288	1	2015;16(8):908–18	2015;16(8):908–18	NUM
dpc-2137	288	2	.	.	PUNCT
dpc-2137	289	1	32	32	NUM
dpc-2137	289	2	.	.	PUNCT
dpc-2137	290	1	weber	weber	PROPN
dpc-2137	290	2	js	js	PROPN
dpc-2137	290	3	,	,	PUNCT
dpc-2137	290	4	d’angelo	d’angelo	NOUN
dpc-2137	290	5	sp	sp	NOUN
dpc-2137	290	6	,	,	PUNCT
dpc-2137	290	7	minor	minor	ADJ
dpc-2137	290	8	d	d	PROPN
dpc-2137	290	9	,	,	PUNCT
dpc-2137	290	10	hodi	hodi	PROPN
dpc-2137	290	11	fs	fs	PROPN
dpc-2137	290	12	,	,	PUNCT
dpc-2137	290	13	gutzmer	gutzmer	NOUN
dpc-2137	290	14	r	r	NOUN
dpc-2137	290	15	,	,	PUNCT
dpc-2137	290	16	neyns	neyns	NOUN
dpc-2137	290	17	b	b	PROPN
dpc-2137	290	18	,	,	PUNCT
dpc-2137	290	19	et	et	PROPN
dpc-2137	290	20	al	al	PROPN
dpc-2137	290	21	.	.	PROPN
dpc-2137	290	22	nivolumab	nivolumab	X
dpc-2137	290	23	versus	versus	ADP
dpc-2137	290	24	chemotherapy	chemotherapy	NOUN
dpc-2137	290	25	in	in	ADP
dpc-2137	290	26	patients	patient	NOUN
dpc-2137	290	27	with	with	ADP
dpc-2137	290	28	advanced	advanced	ADJ
dpc-2137	290	29	melanoma	melanoma	NOUN
dpc-2137	290	30	who	who	PRON
dpc-2137	290	31	progressed	progress	VERB
dpc-2137	290	32	after	after	ADP
dpc-2137	290	33	anti	anti	ADJ
dpc-2137	290	34	-	-	ADJ
dpc-2137	290	35	ctla-4	ctla-4	NOUN
dpc-2137	290	36	treatment	treatment	NOUN
dpc-2137	290	37	(	(	PUNCT
dpc-2137	290	38	checkmate	checkmate	NOUN
dpc-2137	290	39	037	037	NUM
dpc-2137	290	40	):	):	PUNCT
dpc-2137	290	41	a	a	DET
dpc-2137	290	42	randomised	randomise	VERB
dpc-2137	290	43	,	,	PUNCT
dpc-2137	290	44	controlled	control	VERB
dpc-2137	290	45	,	,	PUNCT
dpc-2137	290	46	open	open	ADJ
dpc-2137	290	47	-	-	PUNCT
dpc-2137	290	48	label	label	NOUN
dpc-2137	290	49	,	,	PUNCT
dpc-2137	290	50	phase	phase	NOUN
dpc-2137	290	51	3	3	NUM
dpc-2137	290	52	trial	trial	NOUN
dpc-2137	290	53	.	.	PUNCT
dpc-2137	291	1	the	the	DET
dpc-2137	291	2	lancet	lancet	PROPN
dpc-2137	291	3	oncology	oncology	NOUN
dpc-2137	291	4	.	.	PUNCT
dpc-2137	292	1	2015;16(4):375–84	2015;16(4):375–84	NOUN
dpc-2137	292	2	.	.	PUNCT
dpc-2137	293	1	doi	doi	NOUN
dpc-2137	293	2	:	:	PUNCT
dpc-2137	293	3	10.1016/	10.1016/	NUM
dpc-2137	293	4	s1470	s1470	PROPN
dpc-2137	293	5	-	-	PUNCT
dpc-2137	293	6	2045(15)70076	2045(15)70076	NUM
dpc-2137	293	7	-	-	PUNCT
dpc-2137	293	8	8	8	NUM
dpc-2137	293	9	.	.	X
dpc-2137	294	1	33	33	NUM
dpc-2137	294	2	.	.	PUNCT
dpc-2137	295	1	margolin	margolin	PROPN
dpc-2137	295	2	k	k	PROPN
dpc-2137	295	3	,	,	PUNCT
dpc-2137	295	4	ernstoff	ernstoff	PROPN
dpc-2137	295	5	ms	ms	PROPN
dpc-2137	295	6	,	,	PUNCT
dpc-2137	295	7	hamid	hamid	PROPN
dpc-2137	295	8	o	o	PROPN
dpc-2137	295	9	,	,	PUNCT
dpc-2137	295	10	et	et	PROPN
dpc-2137	295	11	al	al	PROPN
dpc-2137	295	12	.	.	PROPN
dpc-2137	295	13	ipilimumab	ipilimumab	PROPN
dpc-2137	295	14	in	in	ADP
dpc-2137	295	15	patients	patient	NOUN
dpc-2137	295	16	with	with	ADP
dpc-2137	295	17	melanoma	melanoma	NOUN
dpc-2137	295	18	and	and	CCONJ
dpc-2137	295	19	brain	brain	NOUN
dpc-2137	295	20	metastases	metastasis	NOUN
dpc-2137	295	21	:	:	PUNCT
dpc-2137	295	22	an	an	DET
dpc-2137	295	23	open	open	ADJ
dpc-2137	295	24	-	-	PUNCT
dpc-2137	295	25	label	label	NOUN
dpc-2137	295	26	,	,	PUNCT
dpc-2137	295	27	phase	phase	NOUN
dpc-2137	295	28	2	2	NUM
dpc-2137	295	29	trial	trial	NOUN
dpc-2137	295	30	.	.	PUNCT
dpc-2137	296	1	the	the	DET
dpc-2137	296	2	lancet	lancet	PROPN
dpc-2137	296	3	oncology	oncology	NOUN
dpc-2137	296	4	.	.	PUNCT
dpc-2137	297	1	2012;13(5):459–65	2012;13(5):459–65	X
dpc-2137	297	2	.	.	PUNCT
dpc-2137	298	1	doi	doi	NOUN
dpc-2137	298	2	:	:	PUNCT
dpc-2137	298	3	10.1016/	10.1016/	NUM
dpc-2137	298	4	s1470	s1470	PROPN
dpc-2137	298	5	-	-	PUNCT
dpc-2137	298	6	2045(12)70090	2045(12)70090	NUM
dpc-2137	298	7	-	-	SYM
dpc-2137	298	8	6	6	NUM
dpc-2137	298	9	.	.	NOUN
dpc-2137	298	10	34	34	NUM
dpc-2137	298	11	.	.	PUNCT
dpc-2137	299	1	maslov	maslov	PROPN
dpc-2137	299	2	dv	dv	PROPN
dpc-2137	299	3	,	,	PUNCT
dpc-2137	299	4	tawagi	tawagi	PROPN
dpc-2137	299	5	k	k	PROPN
dpc-2137	299	6	,	,	PUNCT
dpc-2137	299	7	kc	kc	PROPN
dpc-2137	299	8	m	m	PROPN
dpc-2137	299	9	,	,	PUNCT
dpc-2137	299	10	simenson	simenson	NOUN
dpc-2137	299	11	v	v	NOUN
dpc-2137	299	12	,	,	PUNCT
dpc-2137	299	13	et	et	PROPN
dpc-2137	299	14	al	al	PROPN
dpc-2137	299	15	.	.	PUNCT
dpc-2137	300	1	timing	timing	NOUN
dpc-2137	300	2	of	of	ADP
dpc-2137	300	3	steroid	steroid	NOUN
dpc-2137	300	4	initiation	initiation	NOUN
dpc-2137	300	5	and	and	CCONJ
dpc-2137	300	6	response	response	NOUN
dpc-2137	300	7	rates	rate	NOUN
dpc-2137	300	8	to	to	ADP
dpc-2137	300	9	immune	immune	ADJ
dpc-2137	300	10	checkpoint	checkpoint	NOUN
dpc-2137	300	11	inhibitors	inhibitor	NOUN
dpc-2137	300	12	in	in	ADP
dpc-2137	300	13	metastatic	metastatic	ADJ
dpc-2137	300	14	cancer	cancer	NOUN
dpc-2137	300	15	.	.	PUNCT
dpc-2137	301	1	j	j	PROPN
dpc-2137	301	2	immunother	immunother	ADJ
dpc-2137	301	3	cancer	cancer	NOUN
dpc-2137	301	4	.	.	PUNCT
dpc-2137	302	1	2021;9(7):e002261	2021;9(7):e002261	X
dpc-2137	302	2	.	.	PUNCT
dpc-2137	302	3	doi	doi	PROPN
dpc-2137	302	4	.	.	PROPN
dpc-2137	303	1	10.1136	10.1136	NUM
dpc-2137	303	2	/	/	SYM
dpc-2137	303	3	jitc-2020	jitc-2020	NOUN
dpc-2137	303	4	-	-	PUNCT
dpc-2137	303	5	002261	002261	NUM
dpc-2137	303	6	.	.	PUNCT
dpc-2137	304	1	pmid	pmid	NOUN
dpc-2137	304	2	:	:	PUNCT
dpc-2137	304	3	34226279	34226279	NUM
dpc-2137	304	4	.	.	PUNCT
dpc-2137	305	1	pmcid	pmcid	NOUN
dpc-2137	305	2	:	:	PUNCT
dpc-2137	305	3	pmc8258666	pmc8258666	ADJ
dpc-2137	305	4	.	.	PUNCT
dpc-2137	306	1	35	35	NUM
dpc-2137	306	2	.	.	PUNCT
dpc-2137	307	1	sylvie	sylvie	PROPN
dpc-2137	307	2	e	e	PROPN
dpc-2137	307	3	,	,	PUNCT
dpc-2137	307	4	jean	jean	PROPN
dpc-2137	307	5	k	k	PROPN
dpc-2137	307	6	,	,	PUNCT
dpc-2137	307	7	alain	alain	PROPN
dpc-2137	307	8	c.	c.	PROPN
dpc-2137	307	9	skin	skin	NOUN
dpc-2137	307	10	cancers	cancer	NOUN
dpc-2137	307	11	after	after	ADP
dpc-2137	307	12	organ	organ	NOUN
dpc-2137	307	13	transplantation	transplantation	NOUN
dpc-2137	307	14	.	.	PUNCT
dpc-2137	308	1	the	the	DET
dpc-2137	308	2	new	new	PROPN
dpc-2137	308	3	england	england	PROPN
dpc-2137	308	4	journal	journal	PROPN
dpc-2137	308	5	of	of	ADP
dpc-2137	308	6	medicine	medicine	NOUN
dpc-2137	308	7	.	.	PUNCT
dpc-2137	309	1	2003;11	2003;11	NOUN
dpc-2137	309	2	.	.	PUNCT
dpc-2137	310	1	36	36	NUM
dpc-2137	310	2	.	.	PUNCT
dpc-2137	310	3	que	que	PROPN
dpc-2137	310	4	skt	skt	PROPN
dpc-2137	310	5	,	,	PUNCT
dpc-2137	310	6	zwald	zwald	NOUN
dpc-2137	310	7	fo	fo	PROPN
dpc-2137	310	8	,	,	PUNCT
dpc-2137	310	9	schmults	schmult	NOUN
dpc-2137	310	10	cd	cd	PROPN
dpc-2137	310	11	.	.	PUNCT
dpc-2137	311	1	cutaneous	cutaneous	ADJ
dpc-2137	311	2	squamous	squamous	ADJ
dpc-2137	311	3	cell	cell	NOUN
dpc-2137	311	4	carcinoma	carcinoma	NOUN
dpc-2137	311	5	.	.	PUNCT
dpc-2137	312	1	j	j	PROPN
dpc-2137	312	2	am	be	AUX
dpc-2137	312	3	acad	acad	ADJ
dpc-2137	312	4	dermatol	dermatol	NOUN
dpc-2137	312	5	.	.	PUNCT
dpc-2137	313	1	2018;78(2):237–47	2018;78(2):237–47	X
dpc-2137	313	2	.	.	PUNCT
dpc-2137	314	1	doi	doi	NOUN
dpc-2137	314	2	:	:	PUNCT
dpc-2137	314	3	10.1016	10.1016	NUM
dpc-2137	314	4	/	/	SYM
dpc-2137	314	5	j.jaad.2017.08.059	j.jaad.2017.08.059	PROPN
dpc-2137	314	6	.	.	PUNCT
dpc-2137	315	1	pmid	pmid	NOUN
dpc-2137	315	2	:	:	PUNCT
dpc-2137	315	3	29332704	29332704	NUM
dpc-2137	315	4	.	.	PUNCT
dpc-2137	316	1	37	37	NUM
dpc-2137	316	2	.	.	PUNCT
dpc-2137	316	3	garrett	garrett	PROPN
dpc-2137	316	4	gl	gl	PROPN
dpc-2137	316	5	,	,	PUNCT
dpc-2137	316	6	lowenstein	lowenstein	PROPN
dpc-2137	316	7	se	se	PROPN
dpc-2137	316	8	,	,	PUNCT
dpc-2137	316	9	singer	singer	NOUN
dpc-2137	316	10	jp	jp	NOUN
dpc-2137	316	11	,	,	PUNCT
dpc-2137	316	12	he	he	PRON
dpc-2137	316	13	sy	sy	VERB
dpc-2137	316	14	,	,	PUNCT
dpc-2137	316	15	arron	arron	PROPN
dpc-2137	316	16	st	st	PROPN
dpc-2137	316	17	.	.	PROPN
dpc-2137	316	18	trends	trend	NOUN
dpc-2137	316	19	of	of	ADP
dpc-2137	316	20	skin	skin	NOUN
dpc-2137	316	21	cancer	cancer	NOUN
dpc-2137	316	22	mortality	mortality	NOUN
dpc-2137	316	23	after	after	ADP
dpc-2137	316	24	transplantation	transplantation	NOUN
dpc-2137	316	25	in	in	ADP
dpc-2137	316	26	the	the	DET
dpc-2137	316	27	united	united	PROPN
dpc-2137	316	28	states	states	PROPN
dpc-2137	316	29	:	:	PUNCT
dpc-2137	316	30	1987	1987	NUM
dpc-2137	316	31	to	to	ADP
dpc-2137	316	32	2013	2013	NUM
dpc-2137	316	33	.	.	PUNCT
dpc-2137	317	1	j	j	PROPN
dpc-2137	317	2	am	be	AUX
dpc-2137	317	3	acad	acad	ADJ
dpc-2137	317	4	dermatol	dermatol	NOUN
dpc-2137	317	5	.	.	PUNCT
dpc-2137	318	1	2016;75(1):106–12	2016;75(1):106–12	NUM
dpc-2137	318	2	.	.	PUNCT
dpc-2137	319	1	doi	doi	NOUN
dpc-2137	319	2	:	:	PUNCT
dpc-2137	319	3	10.1016	10.1016	NUM
dpc-2137	319	4	/	/	SYM
dpc-2137	319	5	j.jaad.2016.02.1155	j.jaad.2016.02.1155	PROPN
dpc-2137	319	6	.	.	PUNCT
dpc-2137	320	1	pmid	pmid	NOUN
dpc-2137	320	2	:	:	PUNCT
dpc-2137	320	3	27067869	27067869	NUM
dpc-2137	320	4	.	.	PUNCT
dpc-2137	321	1	38	38	NUM
dpc-2137	321	2	.	.	PUNCT
dpc-2137	322	1	hughes	hughes	PROPN
dpc-2137	322	2	bgm	bgm	PROPN
dpc-2137	322	3	,	,	PUNCT
dpc-2137	322	4	munoz	munoz	PROPN
dpc-2137	322	5	-	-	PUNCT
dpc-2137	322	6	couselo	couselo	NOUN
dpc-2137	322	7	e	e	NOUN
dpc-2137	322	8	,	,	PUNCT
dpc-2137	322	9	mortier	mortier	NOUN
dpc-2137	322	10	l	l	PROPN
dpc-2137	322	11	,	,	PUNCT
dpc-2137	322	12	et	et	PROPN
dpc-2137	322	13	al	al	PROPN
dpc-2137	322	14	.	.	PROPN
dpc-2137	322	15	pembrolizumab	pembrolizumab	NOUN
dpc-2137	322	16	for	for	ADP
dpc-2137	322	17	locally	locally	ADV
dpc-2137	322	18	advanced	advanced	ADJ
dpc-2137	322	19	and	and	CCONJ
dpc-2137	322	20	recurrent	recurrent	ADJ
dpc-2137	322	21	/	/	SYM
dpc-2137	322	22	metastatic	metastatic	ADJ
dpc-2137	322	23	cutaneous	cutaneous	ADJ
dpc-2137	322	24	squamous	squamous	ADJ
dpc-2137	322	25	cell	cell	NOUN
dpc-2137	322	26	carcinoma	carcinoma	NOUN
dpc-2137	322	27	(	(	PUNCT
dpc-2137	322	28	keynote-629	keynote-629	ADJ
dpc-2137	322	29	study	study	PROPN
dpc-2137	322	30	):	):	PUNCT
dpc-2137	322	31	an	an	DET
dpc-2137	322	32	open	open	ADJ
dpc-2137	322	33	-	-	PUNCT
dpc-2137	322	34	label	label	NOUN
dpc-2137	322	35	,	,	PUNCT
dpc-2137	322	36	nonrandomized	nonrandomize	VERB
dpc-2137	322	37	,	,	PUNCT
dpc-2137	322	38	multicenter	multicenter	NOUN
dpc-2137	322	39	,	,	PUNCT
dpc-2137	322	40	phase	phase	NOUN
dpc-2137	322	41	ii	ii	NOUN
dpc-2137	322	42	trial	trial	NOUN
dpc-2137	322	43	.	.	PUNCT
dpc-2137	323	1	annals	annal	NOUN
dpc-2137	323	2	of	of	ADP
dpc-2137	323	3	oncology	oncology	NOUN
dpc-2137	323	4	.	.	PUNCT
dpc-2137	324	1	2021;s0923753421021864	2021;s0923753421021864	NUM
dpc-2137	324	2	.	.	PUNCT
dpc-2137	325	1	doi	doi	NOUN
dpc-2137	325	2	:	:	PUNCT
dpc-2137	325	3	10.1016	10.1016	NUM
dpc-2137	325	4	/	/	SYM
dpc-2137	325	5	j.annonc.2021.07.008	j.annonc.2021.07.008	PROPN
dpc-2137	325	6	.	.	PUNCT
dpc-2137	326	1	pmid	pmid	NOUN
dpc-2137	326	2	:	:	PUNCT
dpc-2137	326	3	34293460	34293460	NUM
dpc-2137	326	4	.	.	PUNCT
dpc-2137	327	1	39	39	NUM
dpc-2137	327	2	.	.	PUNCT
dpc-2137	328	1	https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_it.pdf	https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_it.pdf	PROPN
dpc-2137	328	2	.	.	PROPN
dpc-2137	328	3	accessed	access	VERB
dpc-2137	328	4	date	date	NOUN
dpc-2137	328	5	september	september	PROPN
dpc-2137	328	6	30	30	NUM
dpc-2137	328	7	,	,	PUNCT
dpc-2137	328	8	2021	2021	NUM
dpc-2137	328	9	.	.	PUNCT
dpc-2137	329	1	40	40	NUM
dpc-2137	329	2	.	.	PUNCT
dpc-2137	330	1	jarkowski	jarkowski	VERB
dpc-2137	330	2	a	a	PRON
dpc-2137	330	3	,	,	PUNCT
dpc-2137	330	4	hare	hare	NOUN
dpc-2137	330	5	r	r	NOUN
dpc-2137	330	6	,	,	PUNCT
dpc-2137	330	7	loud	loud	ADJ
dpc-2137	330	8	p	p	NOUN
dpc-2137	330	9	,	,	PUNCT
dpc-2137	330	10	et	et	PROPN
dpc-2137	330	11	al	al	PROPN
dpc-2137	330	12	.	.	PUNCT
dpc-2137	331	1	systemic	systemic	ADJ
dpc-2137	331	2	therapy	therapy	NOUN
dpc-2137	331	3	in	in	ADP
dpc-2137	331	4	advanced	advanced	ADJ
dpc-2137	331	5	cutaneous	cutaneous	ADJ
dpc-2137	331	6	squamous	squamous	ADJ
dpc-2137	331	7	cell	cell	NOUN
dpc-2137	331	8	carcinoma	carcinoma	NOUN
dpc-2137	331	9	(	(	PUNCT
dpc-2137	331	10	cscc	cscc	ADJ
dpc-2137	331	11	):	):	PUNCT
dpc-2137	331	12	the	the	DET
dpc-2137	331	13	roswell	roswell	PROPN
dpc-2137	331	14	park	park	NOUN
dpc-2137	331	15	experience	experience	NOUN
dpc-2137	331	16	and	and	CCONJ
dpc-2137	331	17	a	a	DET
dpc-2137	331	18	review	review	NOUN
dpc-2137	331	19	of	of	ADP
dpc-2137	331	20	the	the	DET
dpc-2137	331	21	literature	literature	NOUN
dpc-2137	331	22	.	.	PUNCT
dpc-2137	332	1	american	american	PROPN
dpc-2137	332	2	journal	journal	PROPN
dpc-2137	332	3	of	of	ADP
dpc-2137	332	4	clinical	clinical	ADJ
dpc-2137	332	5	oncology	oncology	NOUN
dpc-2137	332	6	.	.	PUNCT
dpc-2137	333	1	2016;39(6):545–8	2016;39(6):545–8	NUM
dpc-2137	333	2	.	.	PUNCT
dpc-2137	333	3	doi	doi	NOUN
dpc-2137	333	4	:	:	PUNCT
dpc-2137	333	5	10.1097/	10.1097/	NUM
dpc-2137	333	6	coc.0000000000000088	coc.0000000000000088	NUM
dpc-2137	333	7	.	.	PUNCT
dpc-2137	334	1	pmid	pmid	NOUN
dpc-2137	334	2	:	:	PUNCT
dpc-2137	334	3	24879468	24879468	NUM
dpc-2137	334	4	.	.	PUNCT
dpc-2137	335	1	41	41	NUM
dpc-2137	335	2	.	.	PUNCT
dpc-2137	336	1	maubec	maubec	PROPN
dpc-2137	336	2	e	e	PROPN
dpc-2137	336	3	,	,	PUNCT
dpc-2137	336	4	petrow	petrow	VERB
dpc-2137	336	5	p	p	NOUN
dpc-2137	336	6	,	,	PUNCT
dpc-2137	336	7	scheer	scheer	PROPN
dpc-2137	336	8	-	-	PUNCT
dpc-2137	336	9	senyarich	senyarich	NOUN
dpc-2137	336	10	i	i	PROPN
dpc-2137	336	11	,	,	PUNCT
dpc-2137	336	12	duvillard	duvillard	NOUN
dpc-2137	336	13	p	p	X
dpc-2137	336	14	,	,	PUNCT
dpc-2137	336	15	lacroix	lacroix	PROPN
dpc-2137	336	16	l	l	PROPN
dpc-2137	336	17	,	,	PUNCT
dpc-2137	336	18	gelly	gelly	PROPN
dpc-2137	336	19	j	j	PROPN
dpc-2137	336	20	,	,	PUNCT
dpc-2137	336	21	et	et	PROPN
dpc-2137	336	22	al	al	PROPN
dpc-2137	336	23	.	.	PROPN
dpc-2137	336	24	phase	phase	PROPN
dpc-2137	336	25	ii	ii	PROPN
dpc-2137	336	26	study	study	NOUN
dpc-2137	336	27	of	of	ADP
dpc-2137	336	28	cetuximab	cetuximab	NOUN
dpc-2137	336	29	as	as	ADP
dpc-2137	336	30	first	first	ADJ
dpc-2137	336	31	-	-	PUNCT
dpc-2137	336	32	line	line	NOUN
dpc-2137	336	33	single	single	ADJ
dpc-2137	336	34	-	-	PUNCT
dpc-2137	336	35	drug	drug	NOUN
dpc-2137	336	36	therapy	therapy	NOUN
dpc-2137	336	37	in	in	ADP
dpc-2137	336	38	patients	patient	NOUN
dpc-2137	336	39	with	with	ADP
dpc-2137	336	40	unresectable	unresectable	ADJ
dpc-2137	336	41	squamous	squamous	ADJ
dpc-2137	336	42	cell	cell	NOUN
dpc-2137	336	43	carcinoma	carcinoma	NOUN
dpc-2137	336	44	of	of	ADP
dpc-2137	336	45	the	the	DET
dpc-2137	336	46	skin	skin	NOUN
dpc-2137	336	47	.	.	PUNCT
dpc-2137	337	1	jco	jco	PROPN
dpc-2137	337	2	.	.	PUNCT
dpc-2137	338	1	2011;29(25):3419–26	2011;29(25):3419–26	NUM
dpc-2137	338	2	.	.	PUNCT
dpc-2137	339	1	doi	doi	PROPN
dpc-2137	339	2	.	.	PUNCT
dpc-2137	340	1	10.1200	10.1200	NUM
dpc-2137	340	2	/	/	SYM
dpc-2137	340	3	jco.2010.34.1735	jco.2010.34.1735	PROPN
dpc-2137	340	4	.	.	PUNCT
dpc-2137	341	1	pmid	pmid	PROPN
dpc-2137	341	2	:	:	PUNCT
dpc-2137	341	3	21810686	21810686	NUM
dpc-2137	341	4	.	.	PUNCT
dpc-2137	342	1	42	42	NUM
dpc-2137	342	2	.	.	PUNCT
dpc-2137	343	1	borradori	borradori	PROPN
dpc-2137	343	2	l	l	PROPN
dpc-2137	343	3	,	,	PUNCT
dpc-2137	343	4	sutton	sutton	PROPN
dpc-2137	343	5	b	b	PROPN
dpc-2137	343	6	,	,	PUNCT
dpc-2137	343	7	shayesteh	shayesteh	NOUN
dpc-2137	343	8	p	p	PROPN
dpc-2137	343	9	,	,	PUNCT
dpc-2137	343	10	daniels	daniels	PROPN
dpc-2137	343	11	ga	ga	PROPN
dpc-2137	343	12	.	.	PUNCT
dpc-2137	343	13	rescue	rescue	NOUN
dpc-2137	343	14	therapy	therapy	NOUN
dpc-2137	343	15	with	with	ADP
dpc-2137	343	16	anti	anti	ADJ
dpc-2137	343	17	-	-	ADJ
dpc-2137	343	18	programmed	programmed	ADJ
dpc-2137	343	19	cell	cell	NOUN
dpc-2137	343	20	death	death	NOUN
dpc-2137	343	21	protein	protein	NOUN
dpc-2137	343	22	1	1	NUM
dpc-2137	343	23	inhibitors	inhibitor	NOUN
dpc-2137	343	24	of	of	ADP
dpc-2137	343	25	advanced	advanced	ADJ
dpc-2137	343	26	cutaneous	cutaneous	ADJ
dpc-2137	343	27	squamous	squamous	ADJ
dpc-2137	343	28	cell	cell	NOUN
dpc-2137	343	29	carcinoma	carcinoma	NOUN
dpc-2137	343	30	and	and	CCONJ
dpc-2137	343	31	basosquamous	basosquamous	ADJ
dpc-2137	343	32	carcinoma	carcinoma	NOUN
dpc-2137	343	33	:	:	PUNCT
dpc-2137	343	34	preliminary	preliminary	ADJ
dpc-2137	343	35	experience	experience	NOUN
dpc-2137	343	36	in	in	ADP
dpc-2137	343	37	five	five	NUM
dpc-2137	343	38	cases	case	NOUN
dpc-2137	343	39	.	.	PUNCT
dpc-2137	344	1	br	br	PROPN
dpc-2137	344	2	j	j	PROPN
dpc-2137	344	3	dermatol	dermatol	NOUN
dpc-2137	344	4	.	.	PUNCT
dpc-2137	345	1	2016;175(6):1382–6	2016;175(6):1382–6	X
dpc-2137	345	2	.	.	X
dpc-2137	345	3	doi	doi	NOUN
dpc-2137	345	4	:	:	PUNCT
dpc-2137	345	5	10.1111	10.1111	NUM
dpc-2137	345	6	/	/	SYM
dpc-2137	345	7	bjd.14642	bjd.14642	PROPN
dpc-2137	345	8	.	.	PUNCT
dpc-2137	346	1	pmid	pmid	NOUN
dpc-2137	346	2	:	:	PUNCT
dpc-2137	346	3	27059424	27059424	NUM
dpc-2137	346	4	.	.	PUNCT
dpc-2137	347	1	43	43	NUM
dpc-2137	347	2	.	.	PUNCT
dpc-2137	348	1	miller	miller	PROPN
dpc-2137	348	2	dm	dm	PROPN
dpc-2137	348	3	,	,	PUNCT
dpc-2137	348	4	faulkner	faulkner	NOUN
dpc-2137	348	5	-	-	PUNCT
dpc-2137	348	6	jones	jones	PROPN
dpc-2137	348	7	be	be	AUX
dpc-2137	348	8	,	,	PUNCT
dpc-2137	348	9	stone	stone	PROPN
dpc-2137	348	10	jr	jr	PROPN
dpc-2137	348	11	,	,	PUNCT
dpc-2137	348	12	drews	drews	PROPN
dpc-2137	348	13	re	re	NOUN
dpc-2137	348	14	.	.	PUNCT
dpc-2137	349	1	complete	complete	VERB
dpc-2137	349	2	pathologic	pathologic	ADJ
dpc-2137	349	3	response	response	NOUN
dpc-2137	349	4	of	of	ADP
dpc-2137	349	5	metastatic	metastatic	ADJ
dpc-2137	349	6	cutaneous	cutaneous	ADJ
dpc-2137	349	7	squamous	squamous	ADJ
dpc-2137	349	8	cell	cell	NOUN
dpc-2137	349	9	carcinoma	carcinoma	NOUN
dpc-2137	349	10	and	and	CCONJ
dpc-2137	349	11	allograft	allograft	VERB
dpc-2137	349	12	rejection	rejection	NOUN
dpc-2137	349	13	after	after	ADP
dpc-2137	349	14	treatment	treatment	NOUN
dpc-2137	349	15	with	with	ADP
dpc-2137	349	16	combination	combination	NOUN
dpc-2137	349	17	immune	immune	ADJ
dpc-2137	349	18	checkpoint	checkpoint	NOUN
dpc-2137	349	19	blockade	blockade	NOUN
dpc-2137	349	20	.	.	PUNCT
dpc-2137	350	1	jaad	jaad	NOUN
dpc-2137	350	2	case	case	NOUN
dpc-2137	350	3	reports	report	VERB
dpc-2137	350	4	.	.	PUNCT
dpc-2137	351	1	2017;3(5):412–5	2017;3(5):412–5	X
dpc-2137	351	2	.	.	PUNCT
dpc-2137	351	3	doi	doi	PROPN
dpc-2137	351	4	:	:	PUNCT
dpc-2137	352	1	10.1016	10.1016	NUM
dpc-2137	352	2	/	/	SYM
dpc-2137	352	3	j.jdcr.2017.06.005	j.jdcr.2017.06.005	PROPN
dpc-2137	352	4	.	.	PUNCT
dpc-2137	353	1	pmid	pmid	NOUN
dpc-2137	353	2	:	:	PUNCT
dpc-2137	353	3	28932782	28932782	NUM
dpc-2137	353	4	.	.	PUNCT
dpc-2137	354	1	44	44	NUM
dpc-2137	354	2	.	.	PUNCT
dpc-2137	355	1	paoluzzi	paoluzzi	PROPN
dpc-2137	355	2	l	l	PROPN
dpc-2137	355	3	,	,	PUNCT
dpc-2137	355	4	ow	ow	PROPN
dpc-2137	355	5	tj	tj	PROPN
dpc-2137	355	6	.	.	PUNCT
dpc-2137	355	7	safe	safe	ADJ
dpc-2137	355	8	administration	administration	NOUN
dpc-2137	355	9	of	of	ADP
dpc-2137	355	10	cemiplimab	cemiplimab	NOUN
dpc-2137	355	11	to	to	ADP
dpc-2137	355	12	a	a	DET
dpc-2137	355	13	kidney	kidney	NOUN
dpc-2137	355	14	transplant	transplant	NOUN
dpc-2137	355	15	patient	patient	NOUN
dpc-2137	355	16	with	with	ADP
dpc-2137	355	17	locally	locally	ADV
dpc-2137	355	18	advanced	advanced	ADJ
dpc-2137	355	19	squamous	squamous	ADJ
dpc-2137	355	20	cell	cell	NOUN
dpc-2137	355	21	carcinoma	carcinoma	NOUN
dpc-2137	355	22	of	of	ADP
dpc-2137	355	23	the	the	DET
dpc-2137	355	24	scalp	scalp	NOUN
dpc-2137	355	25	.	.	PUNCT
dpc-2137	356	1	current	current	ADJ
dpc-2137	356	2	oncology	oncology	NOUN
dpc-2137	356	3	.	.	PUNCT
dpc-2137	357	1	2021;28(1):574–80	2021;28(1):574–80	NUM
dpc-2137	357	2	.	.	PUNCT
dpc-2137	358	1	doi	doi	NOUN
dpc-2137	358	2	:	:	PUNCT
dpc-2137	358	3	10.3390	10.3390	NUM
dpc-2137	358	4	/	/	SYM
dpc-2137	358	5	curroncol28010057	curroncol28010057	NOUN
dpc-2137	358	6	.	.	PUNCT
dpc-2137	359	1	pmid	pmid	NOUN
dpc-2137	359	2	:	:	PUNCT
dpc-2137	359	3	33477979	33477979	NUM
dpc-2137	359	4	.	.	PUNCT
dpc-2137	360	1	pmcid	pmcid	NOUN
dpc-2137	360	2	:	:	PUNCT
dpc-2137	360	3	pmc7903284	pmc7903284	NOUN
dpc-2137	360	4	.	.	PUNCT
dpc-2137	361	1	45	45	NUM
dpc-2137	361	2	.	.	X
dpc-2137	361	3	ali	ali	PROPN
dpc-2137	361	4	sa	sa	PROPN
dpc-2137	361	5	,	,	PUNCT
dpc-2137	361	6	arman	arman	PROPN
dpc-2137	361	7	he	he	PRON
dpc-2137	361	8	,	,	PUNCT
dpc-2137	361	9	patel	patel	PROPN
dpc-2137	361	10	aa	aa	PROPN
dpc-2137	361	11	,	,	PUNCT
dpc-2137	361	12	birhiray	birhiray	PROPN
dpc-2137	361	13	re	re	NOUN
dpc-2137	361	14	.	.	PUNCT
dpc-2137	362	1	successful	successful	ADJ
dpc-2137	362	2	administration	administration	NOUN
dpc-2137	362	3	of	of	ADP
dpc-2137	362	4	cemiplimab	cemiplimab	NOUN
dpc-2137	362	5	to	to	ADP
dpc-2137	362	6	a	a	DET
dpc-2137	362	7	patient	patient	NOUN
dpc-2137	362	8	with	with	ADP
dpc-2137	362	9	advanced	advanced	ADJ
dpc-2137	362	10	cutaneous	cutaneous	ADJ
dpc-2137	362	11	squamous	squamous	ADJ
dpc-2137	362	12	cell	cell	NOUN
dpc-2137	362	13	carcinoma	carcinoma	NOUN
dpc-2137	362	14	after	after	ADP
dpc-2137	362	15	renal	renal	ADJ
dpc-2137	362	16	transplantation	transplantation	NOUN
dpc-2137	362	17	.	.	PUNCT
dpc-2137	363	1	jco	jco	PROPN
dpc-2137	363	2	oncology	oncology	NOUN
dpc-2137	363	3	practice	practice	NOUN
dpc-2137	363	4	.	.	PUNCT
dpc-2137	364	1	2020;16(3):137–8	2020;16(3):137–8	X
dpc-2137	364	2	.	.	PUNCT
dpc-2137	365	1	doi	doi	NOUN
dpc-2137	365	2	:	:	PUNCT
dpc-2137	365	3	10.1200	10.1200	NUM
dpc-2137	365	4	/	/	SYM
dpc-2137	365	5	jop.19.00567	jop.19.00567	PROPN
dpc-2137	365	6	.	.	PUNCT
dpc-2137	366	1	pmid	pmid	NOUN
dpc-2137	366	2	:	:	PUNCT
dpc-2137	366	3	31770056	31770056	NUM
dpc-2137	366	4	.	.	PUNCT
dpc-2137	367	1	46	46	NUM
dpc-2137	367	2	.	.	PUNCT
dpc-2137	367	3	hanna	hanna	PROPN
dpc-2137	367	4	gj	gj	PROPN
dpc-2137	367	5	,	,	PUNCT
dpc-2137	367	6	ruiz	ruiz	NOUN
dpc-2137	367	7	es	es	PROPN
dpc-2137	367	8	,	,	PUNCT
dpc-2137	367	9	leboeuf	leboeuf	NOUN
dpc-2137	367	10	nr	nr	PROPN
dpc-2137	367	11	,	,	PUNCT
dpc-2137	367	12	et	et	PROPN
dpc-2137	367	13	al	al	PROPN
dpc-2137	367	14	.	.	PUNCT
dpc-2137	368	1	real	real	ADJ
dpc-2137	368	2	-	-	PUNCT
dpc-2137	368	3	world	world	NOUN
dpc-2137	368	4	outcomes	outcome	NOUN
dpc-2137	368	5	treating	treat	VERB
dpc-2137	368	6	patients	patient	NOUN
dpc-2137	368	7	with	with	ADP
dpc-2137	368	8	advanced	advanced	ADJ
dpc-2137	368	9	cutaneous	cutaneous	ADJ
dpc-2137	368	10	squamous	squamous	ADJ
dpc-2137	368	11	cell	cell	NOUN
dpc-2137	368	12	carcinoma	carcinoma	NOUN
dpc-2137	368	13	with	with	ADP
dpc-2137	368	14	immune	immune	ADJ
dpc-2137	368	15	checkpoint	checkpoint	NOUN
dpc-2137	368	16	inhibitors	inhibitor	NOUN
dpc-2137	368	17	(	(	PUNCT
dpc-2137	368	18	cpi	cpi	PROPN
dpc-2137	368	19	)	)	PUNCT
dpc-2137	368	20	.	.	PUNCT
dpc-2137	369	1	br	br	PROPN
dpc-2137	369	2	j	j	PROPN
dpc-2137	369	3	cancer	cancer	NOUN
dpc-2137	369	4	.	.	PUNCT
dpc-2137	370	1	2020;123(10):1535–42	2020;123(10):1535–42	NUM
dpc-2137	370	2	.	.	PUNCT
dpc-2137	370	3	doi	doi	NOUN
dpc-2137	370	4	:	:	PUNCT
dpc-2137	370	5	10.1038	10.1038	NUM
dpc-2137	370	6	/	/	SYM
dpc-2137	370	7	s41416	s41416	NUM
dpc-2137	370	8	-	-	PUNCT
dpc-2137	370	9	020	020	NUM
dpc-2137	370	10	-	-	PUNCT
dpc-2137	370	11	01044	01044	NUM
dpc-2137	370	12	-	-	SYM
dpc-2137	370	13	8	8	NUM
dpc-2137	370	14	.	.	PUNCT
dpc-2137	371	1	pmid	pmid	NOUN
dpc-2137	371	2	:	:	PUNCT
dpc-2137	371	3	32868898	32868898	NUM
dpc-2137	371	4	.	.	PUNCT
dpc-2137	372	1	pmcid	pmcid	NOUN
dpc-2137	372	2	:	:	PUNCT
dpc-2137	372	3	pmc7653959	pmc7653959	VERB
dpc-2137	372	4	.	.	PUNCT
dpc-2137	373	1	47	47	NUM
dpc-2137	373	2	.	.	PUNCT
dpc-2137	374	1	valentin	valentin	PROPN
dpc-2137	374	2	j	j	PROPN
dpc-2137	374	3	,	,	PUNCT
dpc-2137	374	4	gérard	gérard	PROPN
dpc-2137	374	5	e	e	PROPN
dpc-2137	374	6	,	,	PUNCT
dpc-2137	374	7	ferte	ferte	PROPN
dpc-2137	374	8	t	t	PROPN
dpc-2137	374	9	,	,	PUNCT
dpc-2137	374	10	prey	prey	PROPN
dpc-2137	374	11	s	s	PROPN
dpc-2137	374	12	,	,	PUNCT
dpc-2137	374	13	dousset	dousset	ADJ
dpc-2137	374	14	l	l	NOUN
dpc-2137	374	15	,	,	PUNCT
dpc-2137	374	16	dutriaux	dutriaux	PROPN
dpc-2137	374	17	c	c	NOUN
dpc-2137	374	18	,	,	PUNCT
dpc-2137	374	19	et	et	PROPN
dpc-2137	374	20	al	al	PROPN
dpc-2137	374	21	.	.	PUNCT
dpc-2137	375	1	real	real	ADJ
dpc-2137	375	2	world	world	NOUN
dpc-2137	375	3	safety	safety	NOUN
dpc-2137	375	4	outcomes	outcome	NOUN
dpc-2137	375	5	using	use	VERB
dpc-2137	375	6	cemiplimab	cemiplimab	NOUN
dpc-2137	375	7	for	for	ADP
dpc-2137	375	8	cutaneous	cutaneous	ADJ
dpc-2137	375	9	squamous	squamous	ADJ
dpc-2137	375	10	cell	cell	NOUN
dpc-2137	375	11	carcinoma	carcinoma	NOUN
dpc-2137	375	12	.	.	PUNCT
dpc-2137	376	1	journal	journal	NOUN
dpc-2137	376	2	of	of	ADP
dpc-2137	376	3	geriatric	geriatric	ADJ
dpc-2137	376	4	oncology	oncology	NOUN
dpc-2137	376	5	.	.	PUNCT
dpc-2137	377	1	2021;s1879406821000527	2021;s1879406821000527	NUM
dpc-2137	377	2	.	.	PUNCT
dpc-2137	378	1	doi	doi	NOUN
dpc-2137	378	2	:	:	PUNCT
dpc-2137	378	3	10.1016	10.1016	NUM
dpc-2137	378	4	/	/	SYM
dpc-2137	378	5	j.jgo.2021.02.026	j.jgo.2021.02.026	PROPN
dpc-2137	378	6	.	.	PUNCT
dpc-2137	379	1	pmid	pmid	NOUN
dpc-2137	379	2	:	:	PUNCT
dpc-2137	379	3	33736973	33736973	NUM
dpc-2137	379	4	.	.	PUNCT
dpc-2137	380	1	48	48	NUM
dpc-2137	380	2	.	.	PUNCT
dpc-2137	381	1	rabinowits	rabinowit	NOUN
dpc-2137	381	2	g	g	PROPN
dpc-2137	381	3	,	,	PUNCT
dpc-2137	381	4	park	park	NOUN
dpc-2137	381	5	sj	sj	PROPN
dpc-2137	381	6	,	,	PUNCT
dpc-2137	381	7	ellison	ellison	PROPN
dpc-2137	381	8	dm	dm	PROPN
dpc-2137	381	9	,	,	PUNCT
dpc-2137	381	10	et	et	PROPN
dpc-2137	381	11	al	al	PROPN
dpc-2137	381	12	.	.	PUNCT
dpc-2137	382	1	checkpoint	checkpoint	NOUN
dpc-2137	382	2	inhibition	inhibition	NOUN
dpc-2137	382	3	in	in	ADP
dpc-2137	382	4	immunosuppressed	immunosuppressed	ADJ
dpc-2137	382	5	or	or	CCONJ
dpc-2137	382	6	immunocompromised	immunocompromise	VERB
dpc-2137	382	7	patients	patient	NOUN
dpc-2137	382	8	with	with	ADP
dpc-2137	382	9	advanced	advanced	ADJ
dpc-2137	382	10	cutaneous	cutaneous	ADJ
dpc-2137	382	11	squamous	squamous	ADJ
dpc-2137	382	12	cell	cell	NOUN
dpc-2137	382	13	carcinoma	carcinoma	NOUN
dpc-2137	382	14	(	(	PUNCT
dpc-2137	382	15	cscc	cscc	ADJ
dpc-2137	382	16	):	):	PUNCT
dpc-2137	382	17	data	datum	NOUN
dpc-2137	382	18	from	from	ADP
dpc-2137	382	19	prospective	prospective	ADJ
dpc-2137	382	20	cemiplimab	cemiplimab	NOUN
dpc-2137	382	21	-	-	PUNCT
dpc-2137	382	22	rwlc	rwlc	NOUN
dpc-2137	382	23	survivorship	survivorship	NOUN
dpc-2137	382	24	and	and	CCONJ
dpc-2137	382	25	epidemiology	epidemiology	NOUN
dpc-2137	382	26	(	(	PUNCT
dpc-2137	382	27	c.a.s.e	c.a.s.e	PROPN
dpc-2137	382	28	.	.	PUNCT
dpc-2137	382	29	)	)	PUNCT
dpc-2137	383	1	study	study	NOUN
dpc-2137	383	2	.	.	PUNCT
dpc-2137	384	1	jco	jco	PROPN
dpc-2137	384	2	.	.	PUNCT
dpc-2137	384	3	2021;39(15_suppl):9547–9547	2021;39(15_suppl):9547–9547	NUM
dpc-2137	384	4	.	.	PUNCT
dpc-2137	385	1	doi	doi	NOUN
dpc-2137	385	2	:	:	PUNCT
dpc-2137	385	3	10.1200	10.1200	NUM
dpc-2137	385	4	/	/	SYM
dpc-2137	385	5	jco.2021.39.15_suppl.9547	jco.2021.39.15_suppl.9547	NOUN
dpc-2137	385	6	.	.	PUNCT